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Abstract
The primary aim of the work presented in this thesis was to investigate the 
neurotensin transmission system of the mouse CNS by employing a reverse 
genetic approach. The neurotensin peptide and receptor distribution within the 
CNS has been extensively mapped, implicating a role of neurotensin in many 
brain functions but little is known of the exact functional relationship of 
neurotensin transmission with respect to other neuronal pathways. However, 
increasing biochemical, electrophysiological and neuropharmacological data 
have highlighted a neuromodulatory role of neurotensin over the dopaminergic 
mesolimbic and nigrostriatal pathways. These pathways are involved in the 
regulation of movement and motivational behaviour, which are believed to 
underlie the mechanism of reward reinforcement for such drugs as cocaine, as 
well as being important to the pathophysiology of schizophrenia.
Two gene targeting approaches were undertaken to create 
a null mutation of the neurotensin high affinity receptor. The first strategy was 
based on the 'Hit and Run' procedure of Hasty et al., 1992a. An integrative 
vector was designed based on a 2.8 kb Bam  HI DNA fragment of the 
neurotensin receptor gene subcloned from a X EMBL3 Balb/c mouse genomic 
library. Sequence analysis of the BamHI fragment revealed a large open 
reading frame encoding sequence encompassing the first four transmembrane 
domains of the receptor. Subsequent vector construction involved the 
introduction of a mutagenic linker which introduced a stop codon within the 
sequence encoding the first transmembrane domain of the receptor. PCR 
analysis of ES cell clones transfected with the integrative vector, (pKLF), 
indicated the targeted integration of pKLF at the neurotensin receptor gene 
locus. However, selection of these ES clones for the desired reversion event 
did not result in the identification of any ES cell clones containing the linker 
mutation within the NTR gene. Re-evaluation of the 'Hit and Run' technique, 
in light of the increased understanding of the factors governing gene targeting 
in ES cells, led to a change in approach.
The second strategy utilised a replacement type vector in 
combination with the 'positive negative selection' regime, (Thomas and 
Capecchi, 1987), to target the neurotensin receptor gene. The replacement 
vector used was constructed from a 5' 9.2 kb E c o R l  fragment of the 
neurotensin receptor gene subcloned from the X Dash 129J mouse genomic 
library. The targeting construct introduced a deletion and a disrupting 
neomycin cassette into the receptor gene within the sequence encoding the
xx
fourth transmembrane domain. This targeting construct was successfully used 
to target a number of ES cell lines; E14, R l, CGR8 and CGR8.8. Of the 4 
targeted R l ES sublines, 2 produced weakly chimaeric mice, (10-15% ES cell 
derived). No germline transmission of the null NTR allele was obtained from 
repeated matings of these chimaeric mice. A targeted CGR8 ES cell subline 
was used to generate 3 highly chimaeric male mice, (80-90% ES cell derived). 
However these mice were apparently sterile, with no progeny being produced 
from repeated matings. Two other targeted sublines were produced from the 
CGR8.8 ES cell line, and are to be tested for germline transmission. In 
addition, an in situ hybridisation analysis of the neurotensin receptor 
expression within the developing mouse embryo, revealed specific localisation 
of the probe to an unidentified structure of the developing forebrain.
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1.1 Overview of objectives
Neurotensin was accidentally isolated over 20 years ago during the course of 
work intended to isolate substance P from bovine hypothalamus tissue, 
(Carraway and Leeman, 1973). Since then a wealth of data has accumulated 
on the possible biological function of neurotensin, (NT), as a hormone of the 
intestinal tract and as a neurotransmitter or neuromodulator of the central 
nervous system, (CNS). Increasingly over the years, the focus of endeavour 
has moved from the possible trophic functions of NT to its functions within the 
CNS. This is principally because of its occurrence within particular brain 
structures involved in the mediation of pain, the regulation of body 
temperature, the regulation of sleep, the processing of movement and 
motivational behaviour. The majority of this research has detailed the 
distribution and roles of NT and its binding sites with particular neuronal 
pathways, particularly the role of NT within the nigrostriatal and mesolimbic 
dopaminergic pathways, for a number of reasons. The control of movement is 
mediated through the nigrostriatal pathway as demonstrated by the progressive 
lack of ability to execute movement in Parkinson's sufferers; as a consequence 
of the progressive loss of dopaminergic neurons from this pathway. The 
mechanism underling the rewarding and reinforcing effects of drugs such as 
cocaine and amphetamines is also thought to be mediated through these 
dopaminergic pathways. Furthermore, the development of dopamine D2 
receptor antagonists led to their clinical use as antipsychotics and the 
implication that a defective DA transmission underlying the pathophysiology 
of schizophrenia. Interestingly, the action of neurotensin when administered 
centrally mimics the profile of antipsychotic drugs, where the beneficial effects 
are thought to be mediated through the mesolimbic system. For these principal 
reasons, the background data on neurotensin and its receptor in the first part of 
this introductory chapter will concentrate on briefly reviewing the data 
concerning dopamine-neurotensin interactions and the accumulating evidence 
implicating neurotensin as an endogenous neuroleptic that may be involved in 
the pathology of schizophrenia.
Considerable insight into the CNS functions of NT has 
been gained using traditional neuroscience approaches, of neuroanatomy, 
neuropharmacology and neurophysiology. However, these approaches do not 
offer the same analytical power for the delineation of a neuropeptide's function 
compared to the modern reverse genetic technology of the mouse, (Davies et
2
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al., 1994). The classical neuroscience tools of intervention have been chemical 
agonists and antagonists, which have been used to obtain a functional 
understanding of particular neuronal transm ission systems. These 
pharmacological methods can be of great use when investigating a particular 
molecules function, and when that function can be assayed. However, there 
are a number of limitations. In the case of neuropeptides, there is a lack of 
chemical antagonists due to the time and cost in synthesising such inhibitors. 
The non-peptide antagonists also tend not to be exclusively specific for their 
intended target. Often a range of receptor types will bind these antagonists 
with varying affinities, which complicates the analysis of a specific 
peptide/receptor function(s). Moreover, this type of analysis, typically 
performed in the adult CNS, does not allow for the lack of function to be 
assessed with respect to the significance that lack of function may have as a 
result of ontogeny. Furthermore, the reverse genetic approach now has the 
flexibility to create a conditional gene specific defect which can be analysed 
within the adult CNS. This can be a genetic defect that can be investigated in 
the adult in light of its developmental background or conditionally induced to 
allow adult function to be analysed separately. It is also now possible, in 
principle, to disrupt NT transmission in any tissue specific, (neuronal specific), 
and developmental manner desired. Furthermore, precise mutations can be 
introduced into the receptor or the neuropeptide encoding precursor gene to 
address specific functional questions of the protein molecule. Induction and 
repression of the expression of a precisely mutated gene in a temporal and 
spatial manner is now possible. However, with respect to this introduction 
only those gene targeting approaches that were available for the disruption of 
the receptor within the time frame of this project will be discussed in the 
second part of this introduction.
1.2 Dopamine and neurotensin interactions
1.2.1 Introduction
There is substantial inform ation from anatom ical, neurochem ical, 
electrophysiological, behavioural, and pharm acological studies that 
demonstrates NT interaction with dopamine systems of the CNS, (reviewed in 
Kasckow and Nemeroff, 1991). A brief overview of such studies follows, and
3
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Figure 1.1 presents a sim p le diagram  o f  the major projections o f  dopam inergic  
neurons o f  the m eso lim b ic  and nigrostriatal pathways.
CPU (Dorsal striatum )
A10 A9
N.Acc OT
VTA
SN pc
AMY
B) NigrostriatalA) Mesolimbic
Figure 1.1 The dopaminergic neurons of the nigrostriatal and mesolimbic 
pathways. The shaded areas indicated the major regions of innervation of the 
dopaminergic neurons; it should be noted that there is considerable overlap 
and some collateralization of these pathways. The caudate and putamen 
(CPU) form one structure in rodents, but are separate in primates. A 
distinction is usually drawn between the dorsal striatum (the major portion of 
the caudate-putamen) and the ventral striatum (incorporating the nucleus 
accumbens, olfactory tubercle and the ventro-medial parts of the caudate- 
putamen). Abbreviations: A9, cell group of dopamine neurons in the 
substantia nigra, pars compacta (SNpc); A10, cell group of dopamine 
neurons in the ventral tegmental area (VTA). The A8 cell group and the 
A10 neurons of the mesocortical pathway are not shown. N. Acc., nucleus 
accumbens; OT, olfactory tubercle; AMY, central amygdaloid nucleus; LS, 
lateral striatum This Figure was adapted from Robbins, 1992.
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1.2.2 Anatomical studies
Many studies have documented the association of NT and its receptor with 
dopaminergic neurons. Principally, this association is with the mesolimbic and 
nigrostriatal dopaminergic systems. Double labelling studies using 1251- 
neurotensin and TH-immunocytochemistry, (specific for catecholamine 
neurons), have localised binding sites, (putative NTRs), to the dopamine 
neurones of the rat substantia nigra and ventral tegmental area, (Szigethy and 
Beaudet, 1989). These studies have been confirmed more recently by in situ 
hybridisation of rat brain slices using oligonucleotides derived from the rat 
cDNA, (Nicot et al., 1994). Neurotensin-immunoreactivity has also been 
demonstrated in the rat striatum, the nucleus accumbens and the olfactory 
tubercle. The close association of NTRs with the dopaminergic neurons was 
emphasised by in situ studies on brains from patients who had suffered from 
Parkinson's disease, (Yamada et a l , 1995). The authors observed a reduction 
in NTR mRNA levels that paralleled the loss of the melanised (most likely 
dopaminergic) neurons from the substantia nigra and the nucleus paranigralis, 
(the VTA of the rat brain). Confirmation that the neurotensin is localised to the 
dopaminergic neurons was obtained indirectly by chemical means, (see below).
1.2.3 Neurochemical studies
A number of chemical lesion studies have been performed on dopaminergic 
neurons of the CNS which localise NT and its receptor to these neurons. 6- 
hydroxydopamine can selectively destroy the dopaminergic neurons of the 
nigrostriatal and mesolimbic systems. These lesions not only remove the 
dopaminergic terminals, but a large percentage of the NT receptors are lost 
from the striatum, the nucleus accumbens and the olfactory tubercle, thus 
indicating the presence of presynaptic NTRs on dopaminergic neurons, (Fuxe 
et al., 1986). Furthermore, NT has also been shown to be co-localised in the 
dopamine neurons of the mesolimbic system, (Bean et al., 1989). 6-OHDA 
lesion studies also demonstrated the depletion of these co-localised 
neurotransmitters.
A number of biochemical studies have documented a 
marked increase in striatal NT concentrations in response to DA D2 receptor
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antagonists such as haloperidol, (Govoni, et al., 1980, Bean et al., 1989). 
Evidence also exists for the increase in NT-immunoreactive neurons in the 
striatal complex following DA D2 antagonist administration, (Zahm, 1992). 
Furthermore, haloperidol has been shown to increase the levels of NTR mRNA 
in the rat substantia nigra. This increase in NTR density could lead to 
increased excitability of DA cells as a compensatory mechanism to the effects 
of DA receptor blockade since the primary action of NT on dopaminergic 
neurons is to increase dopamine turnover, as has been demonstrated by many 
studies. For example, the microinjection of NT into the VTA increases the 
extracellular level of dopamine and its metabolites in the nucleus accumbens, a 
major terminal field of these dopaminergic neurons, (Laitinen et al., 1990).
1.2.4 Electrophysiological studies
From the biochemical data, NT administered centrally has a stimulant effect on 
dopaminergic systems in that it increases DA turnover. Therefore, it was 
surprising to observe that in vivo NT generally had no effect on the basal firing 
rate or the firing pattern of the DA neurons of the midbrain, (Shi et al., 1990). 
However, in the VTA injection of NT was shown to attenuate the action of 
D2/D3 DA agonists, suggesting that NT has an indirect neuromodulatory role 
on DA neurons. Analysis of the effects of microionotophoretically applied NT 
and DA revealed that for almost all cells treated, NT attenuated DA induced 
inhibition presumably mediated by an antagonistic action of the NTRs on the 
DA D2 receptors. This neuromodulatory effect could also be demonstrated 
when DA was replaced with D2/D3 agonists, (Shi, 1991). However, some DA 
cells did register an increased firing rate on the application of NT. This 
observation is typically made of midbrain DA neurons analysed in vitro, 
(Seutin et al., 1989, Pinnock, 1985). These type of experiments have indicated 
that the excitatory effect produced by NT occur at higher concentrations of NT, 
(>10 nM), than those needed for the neuromodulatory action of NT. The 
increased firing rate exhibited a linear dose response up to a concentration of 
300 nM, (Seutin et al., 1989); above this a cessation of neuronal firing was 
observed. In conclusion the stimulation of DA neurons occurs by two 
pathways, an unknown indirect neuromodulatory mechanism, (discussed in 
section 1.2.6), and directly by increasing the firing rates of DA neurons.
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1.2.5 Behavioural studies
The central administration of NT can produce a number of distinct 
physiological and behavioural effects: NT produces hypothermia, muscle 
relaxation, antinociception, reduced food consumption , catalepsy and 
alterations in locomotor activity, (see Bissette et al., 1991, for a review). The 
majority of these effects are similar to the action of neuroleptic drugs and are 
mediated through the dopaminergic mesolimbic and nigrostriatal pathways, 
(discussed in section 1. 4). The decrease in body temperature is mediated by 
the effects of NT on the DA neurons of the hypothalamus, (Kalivas et al., 
1982). The analgesic quality of NT is elicited by its injection into the 
periaqueductal gray (PAG) and is discussed in section 1.5.3.
1.2.6 Intramembrane interaction between neurotensin and dopamine 
receptors
The m echanism(s) by which NT exerts its predominantly stimulatory 
neuromodulatory effects upon dopaminergic neurons is not known. However, 
an increasing amount of data suggests that this regulation occurs by a NTR- 
mediated antagonistic action on D2 receptors. This neuromodulatory 
mechanism is thought to involve the stimulation of the G-protein linked 
neurotensin receptor secondary m essengers, (probably cGM P and 
inositoltriphosphate), which act directly or indirectly to alter the state of DA 
receptors. It has been proposed that activation of the NTR is antagonistic to D2 
mediated transduction, therefore increasing the Dj receptor-mediated DA 
transmission by removing the D2 receptor-mediated inhibition. Figure 1.2 
presents the possible pre- and post-synaptic organisation of D j, D2 and NT 
receptors within the terminal field of the nigrostriatal pathway.
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Figure 1.2 Possible pre- and post-synaptic interaction between neurotensin receptors 
and dopamine Dj and D2 receptors within the neurons of the striatum. Activation of 
neurotensin receptors causes a reduced affinity in D2 agonist binding sites and 
enhanced effects of Dj agonists. The broken arrow illustrates the reduced D2- 
mediated DA signal and the two uninterrupted arrows the increased transmission of 
the Dj mediated signal.
The diagram presented, (Figure 1.2), predicts that the selective regulation of 
DA receptors mediated by the NTR exerts an antagonistic effect on signal 
transduction via the D2 receptor subtype, favouring signal transduction via the 
Di receptor subtype and thus postsynaptic excitation. Similarly presynaptic 
NTR-mediated antagonism of D2 autoreceptors is thought to lead to increased 
DA release and enhanced dopaminergic neuronal activity. In vitro 
microdialysis studies have provided support for the intramembrane interaction 
of presynaptic NTRs and D2 receptors of the striatum by measuring DA release 
from the nigrostriatal DA neurons, (Tanganelli et al., 1989). The inhibition of 
DA release by D2 agonists was antagonised by the action of NT, presumably 
mediated by NTRs to counteract the transduction of the D2 autoreceptors. 
Evidence for the antagonistic action of NT/NTR action on postsynaptic D2
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receptors of the nigrostriatal pathway was also provided by microdialysis 
studies, (Fuxe, et al., 1992). The inhibitory action of D2 agonists was 
attenuated by NT application, as measured by the increase in extracellular 
levels of GABA released from the GABA neurons of the striatum. The 
increase in GABA release is also thought to be a result of selective action of Dj 
transmission in response to antagonism of D2 transduction.
Further, microdialysis studies on the effects of NT on DA 
transmission in the rat nucleus accumbens have documented an interaction with 
D2 autoreceptors different from that observed in the striatum. The perfusion 
of NT into the N. Acc. produced a long lasting GABA out flow from the 
GABAergic neurons. This is thought to be by a mechanism similar to that 
proposed for the action of NT on postsynaptic D2 receptors of the GABAergic 
neurons of the striatum. However, the presynaptic action of NT, (at 
subthreshold levels of 10 nM), was to elicit an inhibition of DA release from 
the DA neuronal terminals of the N. Acc. This effect of NT inhibition is 
thought to be mediated by a local increase of GABA outflow. This local 
GABA release could either directly inhibit DA release or indirectly reduce the 
excitatory input of the DA neurons of the N. Acc. In summary, the 
postsynaptic inhibition of D2 receptors mediated by NTR on application of NT 
is observed in the striatum and the N. Acc. However, the presynaptic 
antagonism of D2 receptor transduction is only observed in the striatum and 
not in the N. Acc when subthreshold levels of 10 nM NT are administered.
The previous studies have demonstrated the complexity 
of interaction between the NT and DA transmission. However, other factors 
can influence the action of the NT transmission system such as the type and 
density of receptors on the particular synaptic membranes. In particular, the 
interaction of the NT-NTR transmission with the full complement of DA 
receptor subtypes remains to be determined. This is particularly important in 
view of the observation that NTR action resembles that of atypical neuroleptics 
such as clozapine, (section 1.4), which are thought to act preferentially on the 
dopamine D4 and not the D2 receptor subtype. Furthermore, the input of other 
neuropeptide systems must be considered. This has been demonstrated for the 
neuropeptide cholecystokinin, (CCK). An inhibitory neuromodulatory action 
of CCK on D2 receptor-mediated transduction has also been observed within 
the presynaptic dopaminergic terminals of the striatum. CCK perfused into the 
striatum by a microdialysis probe was able, in a concentration related manner, 
to counteract the inhibitory action of the DA agonist apomorphine, (Tanganelli 
et al., 1993). This antagonism is mediated by the presynaptic CCKB receptor
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on the D2 autoreceptors, and produces an increased DA release. Furthermore, 
CCK and NT were observed to synergistically antagonise the DA agonist 
apomorphine induced inhibition of DA release NT at subthreshold 
concentrations of 0.1-1 nM in the presence of 1 nM CCK-8, counteracts the 
inhibitory action of apomorphine on DA release by 70%. However, these low 
concentrations of NT have no effect on apomorphine inhibition when applied 
in the absence of CCK-8.
In summary, the previous discussion has highlighted the 
complexity of interaction the NT transmission system has over DA 
transmission. In particular its neuromodulatory role mediated by an 
antagonistic action on D2 receptor signal transduction. However, this does not 
take in to account the influence of DA transmission on neurotensinergic 
systems. The effect of DA administration into the SNc is to upregulate NT and 
NTR density in the striatum, (Deutch and Zahm et al. , 1992). The current data 
suggests that this effect is mediated via DA-D1 receptor transmission. In 
support of this, the application of D2 receptor antagonists also upregulates NT 
concentrations and NTR density, (see section 1.4.). Therefore, the DA-Dj 
receptor action leads to an activation of the NTR mechanism, which in turn 
may operate as an inhibitory feedback loop on D2 receptor-mediated DA 
transmission.
1.3 The NT precursor gene, the NTR genes, possible receptor subtypes and
transduction pathways
1.3.1 The neurotensin and neuromedin N precursor gene
The neurotensin cDNA was first cloned from a canine cDNA library using a 
degenerate oligonucleotide designed from the 13 aa NT sequence of purified 
bovine neurotensin, (Dobner et a l , 1987). Sequence analysis of the isolated 
cDNAs revealed an open reading frame encoding a 170 aa protein. This 
precursor protein not only encoded the sequence for the 13 aa neurotensin but 
also the 6 aa neurotensin-like peptide known as neuromedin N. There is also 
another neuromedin N-like sequence encoded within the gene. In fact, there is 
the possibility that a number of undefined biologically active peptides may be 
present within this precursor protein. The amino terminal portion of the
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protein contains aa residues typical of signal peptides that precede most 
secreted proteins.
Subsequently the bovine cDNA was isolated, revealing a 
95% sequence identity to the cloned rat cDNA, (Dobner et al., 1992). 
Furthermore, genomic sequences were obtained for the rat and human 
neurotensin gene, (Kislauskis et a l , 1988). The identity at the aa level was 
73% in all four species. The NT/NM gene spans 10.2 kb of rat DNA and the 
coding sequence is divided into 4 exons as revealed by the rat genomic 
sequence. Exon 1 encodes the putative signal peptide sequence, exon 4 
encodes the NT and NM coding sequence with exons 2 and 3 encoding the 
remainder of the precursor protein. The fact that exon 4 contains the coding 
domain for NT and NM precludes the possibility that these peptides are 
differentially regulated at the level of alternative mRNA splicing. Although, 2 
major RNA species are produced by this gene, approximately 1.0 kb and 1.5 kb 
in length, they are the result of utilising 2 alternative consensus poly (A) 
addition signals as revealed by northern blot experiments. The different 
mRNA species are present at equal concentrations throughout the NT 
expressing brain areas. However, the 1.0 kb species was predominant in the 
gastrointestinal tract. Not all species displayed this pattern of expression. The 
bovine hypothalamus tissue exclusively expressed the 1.5 kb mRNA whereas, 
the canine intestine only expressed the 1.0 kb mRNA form, (Dobner et al., 
1987).
Further characterisation of the neurotensin/ neuromedin 
N gene was undertaken at the promoter level. Mutation and expression studies 
of the putative NT/NM gene promoter has defined a number cis regulatory 
elements that can influence the gene expression in PC 12 cells, (Kislauskis et 
al., 1990). The rat NT/NM promoter would appear to consist of a number of 
c/s-regulatory elements defined within sequences from -216 to +56, that are 
responsible for the complete synergistic regulation of the gene. These elements 
include a consensus cAMP response element (CRE) site, two AP-1 like sites, a 
glucocorticoid response element (GRE) related sequence and a sequence 
identical to the human c-jun site (JARE). Nerve growth factor acts 
cooperatively with glucocorticoids and adenylate cyclase to increase NT/NM 
gene expression in PC 12 cells, (Dobner et al., 1992). This induction of gene 
expression requires the simultaneous use of inducers in combination. 
Individual exposure of PC 12 cells to inducers has no or little effect on NT/NM 
gene expression. Lithium is an inducer molecule that can potentiate the 
expression of NT/N in combination with other inducers, (Dobner et a l , 1988).
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This is particularly interesting since lithium is used in the treatment of manic 
depression, yet the mechanism of its physiological action is not understood. 
Sequence alterations of the CRE or the GRE elements results in the selective 
reduction of gene expression. However, mutational analysis of the AP-1 site 
severely reduces gene expression in response to all combinations of inducer 
molecules, (Dobner et al., 1992). Therefore, the action of the various AP-1 
transactivator complexes would appear to play a crucial role in regulating the 
synergistic actions of the various stimuli that influence the expression of the 
NT/NM gene expression. More recently Harrison et al., 1995, have shown by 
transient transfection of c-Jun and c-Fos expressing plasmids in PC 12 cells that 
the various activator complexes potently activate the NT/NM promoter in a 
cooperative manner by an average of 50 to 100-fold.
The previous studies have all analysed the expression of 
the NT/NM gene expression in PC 12 cells. However, there is accumulating 
evidence that regulation of the NT/NM gene in the CNS may be governed by 
similar factors. The administration of pertussis toxin to striatal neurons, which 
increases the levels of adenylate cyclase, results in an increased expression of 
NT/NM in striatal neurons, (Augood et al., 1992). This suggests that cAMP 
may also up regulate the NT/NM gene. Expression of the NT/NM mRNA has 
been observed to be at high levels in the striatum in the new bom rat, (Kiyama 
et al., 1992). This expression declines after postnatal day 10 which coincides 
with a  drop in c-jun expression, (Pennypacker et al., 1993). A more direct link 
between the expression of c-fos and NT mRNA on the administration of the 
neuroleptic haloperidol, has been established. Both genes show a direct 
increase in mRNA levels in the striatum as a result of haloperidol 
administration. However, this response can be attenuated by antisense 
oligonucleotides directed against the c-fos mRNA. The subsequent decline in 
c-fos gene expression is paralleled by a reduction in NT mRNA, (Robertson et 
al., 1995).
1.3.2 Introduction to the super family of G-protein linked receptors
Communication between almost all cells in an organism is mediated by 
extracellular signals such as neurotransmitters, neuromodulators, hormones etc. 
These signals are transduced to the interior of the cell via diffferent classes of 
receptor. The vast majority of receptors belong to the super family of G- 
protein coupled receptors. On binding their native ligand these receptors
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undergo a conformational change resulting in the activation of distinct G- 
proteins that are attached to the surface of the plasma membrane. Ligand 
binding catalyses the exchange of guanosine 5'-triphosphate (GTP) to from 
guanosine 5'-diphosphate (GDP) on the G-protein causing it to dissociate from 
the G-protein receptor complex. The released G-protein subunits, the a subunit 
bearing GTP and the py dimer, can then act on effector systems that produce an 
intracellular signal within the cell such as cAMP, cyclic guanosine 5'- 
monophosphatec (GMP) calcium and inositol phosphates. In this way G- 
protein coupled receptors not only transmit the signal, but also amplify and 
integrate other extracellular signals to coordinate the cellular response.
1.3.3 Molecular structure of G-protein linked receptors
A large number (> 200) G-protein coupled receptors have been cloned and 
share a large degree of structural homology. They are characterised by 7 
transmembrane domains, predicted to form a helices, connected by altering 
extracellular and intracellular loops. Figure 1.3 depicts the 2-dimensional 
topology of the NTR high affinity receptor, Le et al., 1997. There are currently 
no high resolution X-ray crystallography images to accurately predict the 
structure of G-protein coupled receptors. However, a number of G-protein 
coupled receptor models have been proposed based on the structure of the non- 
G-protein coupled receptor bacterorhadopsin, (Henderson et al., 1990), and to 
the rhadopsin receptor model, proposed by Findlay and Pappin, 1986. Theses 
models predict that all G-protein linked receptors form a transmembrane 
helices that are arranged in a ring like fashion to form a tightly packed helical 
bundle.
The G-protein coupled superfamily of receptors have been 
classified into 3 groups. The rhadopsin like group which includes NTR and the 
majority of G-protein coupled receptors ; secondly the glucagon like group 
which includes the receptor for glucagon, secretin, calcitonin, growth hormone- 
releasing hormone and thirdly the group of metabotropic glutamate and 
calcium sensor receptors. There is no significant homology between these sub­
families and relatively little is known about the 2nd and 3rd groups. The 
primary amino acid sequence identity within the rhadopsin G-protein coupled 
receptor family is observed over the transmembrane domains. The receptors 
can be classified by the sequence homology between the transmembrane 
domains. For species homologues of a receptor this can be in the range of 80- 
90%: to 60-80% for subtypes of the same receptor to 35-45% for unrelated
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receptors, Strader et al., 1994. A similar trend has been predicted for species 
homologues of the NT receptor see Chapter 3 Figure 3.11.
Extracellular
Intron 3
LOJ&4?) I(o'o;o;o3 * h
Intron 1 © Intron 2
Intracellular
Figure 1.3 The primary structure of the NTR with the proposed topology of the 
seven transmembrane domains. The amino acid sequence was derived from the 
the human NTR gene. The sites at which the genomic coding sequences are 
interupted by introns are indicated by arrows at the relevant amino acid sites. 
i-1, i-2 and i-3 are intracellular loops 1, 2 and 3 respectively; o-l, o-2 and o-3 
are extracellular loops, 2 and 3 respectively, the Figure was adapted from Le et 
a l, 1997.
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1.3.4 Structure function relationships of G-protein linked receptors
A number of mutational type studies have been performed 
to delineate functional domains of G-protein linked receptors. Some 
investigators have taken a chimaeric receptor approach, whereby various 
domains of one receptor have been interchanged with another receptor, or even 
whole domains deleted to dissect functional domains. Alternatively, individual 
amino acid residues can be mutated to assess their individual impact on a 
receptors function, reviewed by Strader et al., 1994.
For receptors that bind small molecule neurotransmitters 
like dopamine, the binding site is within the transmembrane domains. Several 
studies have indicated that portions of the extracellular and intracellular loops 
have little or no effect on ligand binding, reviewed by Ostrowski et a l., 1992. 
In general m utational analysis has pinpointed a small num ber of 
transmembrane residues that are important for ligand binding, and tend to be 
conserved between homologues. In contrast, receptors that bind neuropeptide 
ligands have a number of extracellular residues that are also critical for ligand 
binding as well as transmembrane residues. The high affinity NT receptor 
primary binding site is proposed to consist of 8 residues within the 3rd 
extracellular loop, Pang et al., 1996. Although, replacement of residue Aspl39 
or Argl43 (1st extracellular loop) and Arg327-Arg328 (transmembrane domain 
VI) abolishes binding. Apparently residues 139 and 149 are directly involved 
with neurotensin interaction with its receptor. Where as the mutation of 
Arg327-Arg328 results in a gross conformational change of the protein 
preventing its activation. Other residues have been reported that have a lesser 
impact on the receptors ability to bind NT and elicit a response. Mutation off 
A sp ll3  of transmembrane I, and Argl49 or A spl50 of transmembrane III 
lower the binding affinity by 2-3 fold but do not abolish function, Botto et a/., 
1997. In general, receptors of this type have conserved amino acid residues 
which are critical for receptor binding and a second set of residues which are 
involved but to a lesser extent. Furthermore, mutational analysis of the 
neurokinin receptor has revealed that some residues affect the binding of one 
agonist type but not another. Implying that several different combinations of 
residues interacting with the respective ligand can bind and elicit a receptor 
response.
On binding the respective ligand, a conformational change 
of the receptor is produced resulting in a conformational change in the G- 
protein and its activation. The mechanism(s) by which the receptor induces a
15
Chapter 1
signal to the G-protein is still unknown. It may be that the conformational 
change involves an opening of the intracellular receptor surface, to allow G- 
proteins to interact with amino acid residues that could not previously be 
accessed. This view is supported by studies on the a factor pheromone receptor 
of yeast. The intracellular domains of the receptor become more sensitive to 
the action of trypsin cleavage when the receptor is activated, Bukusogulu and 
Jenness, 1996.
Many studies have also implicated transmembrane loops V and VI to be 
critical in the mechanism of conformational change. Receptor proteins have 
been produced that bind the appropriate ligand but do not activate the receptor. 
Such defective receptors can be produced by disulphide cross-linking of 
transmembrane domains VI and III. These results support the view that 
relative movement between the two domains is essential to produce a 
conformational change and thus activate the receptor. Conversely, rhodopsin 
constitutively active mutant receptors have been isolated that implicate 
transmembranes VII and III, (Robinson et al., 1992). It has been suggested 
that a salt bridge between these transmembrane domains holds the receptor in 
an inactive state. Further studies have begun to unravel domains that are 
apparently critical for the coupling and selectivity of the receptor to its G- 
protein. In general residues within the 1st and 3rd intracellular loops and to a 
lesser extent the 4th intracellular loop, Dohlman et al., 1991. Further evidence 
for the G-protein/receptor interface derives from a series of experiments using 
short synthetic peptides that mimic the receptor. The synthetic peptides 
derived from he 1st and 3rd intracellular loops can mimic or inhibit receptor 
interaction with G-proteins, Okamoto and Nishimoto, 1992. This is further 
evidence that a conformational change of the receptor reveals amino acid 
residues that were not previously exposed to the G-protein. Further studies 
have defined conserved residues that are critical to the receptor G-protein 
interaction, such as the charged residues of the intracellular loop 3 at the 
COOH-terminal domain and the Asp-Arg pairing commonly found at the 
junction of transmembrane III and intracellular loop 2. In a similar manner a 
limited number of primarily hydrophobic residues at the NH2 terminus of 
intracellular loop 3 are crucial for G-protein recognition, Hill-Eubanks et al., 
1996. In addition residues of intracellular loop 2 have been implicated, Blin et 
a l ,1995.
In summary the majority of receptor function studies 
suggest that much of the cytoplasmic facing surface of the receptor is involved 
in G-protein interaction. Inparticular, residues at the cytoplasmic loops close
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to the plasma membrane and the residues at the ends of all the transmembrane 
domains are implicated in G-protein /receptor interaction and specificity. The 
extracellular domains specify a receptors ligand specificity and transduce this 
signal to the G-protein by a conformational change that permits the necessary 
intracellular residues to interact. Although G-protein linked receptors display a 
common architecture it could have been thought that a receptors primary 
sequence would be sufficient to predict the critical residues for its action, 
however, further conformational studies are required to define functionality.
1.3.5 The neurotensin receptor genes
A functional clone of the rat neurotensin receptor cDNA was first isolated 
using an electrophysiological assay in Xenopus oocytes, (Tanaka et a l , 1990). 
Sib-selection from a pool of cDNAs, eliciting an electrophysiological response 
to the application of NT, resulted in the isolation of a single 3.6 kb cDNA 
encoding the NTR. Sequence comparisons revealed that the cDNA encoded an 
open reading frame for a 424 amino acid protein that belonged to the G-protein 
coupled superfamily of receptors with seven transmembrane domains. 
Subsequently a human NTR was cloned from a cDNA expression library 
derived from the HT29 cell line, (Vita et a l , 1993). The human cDNA 
encodes a 418 aa receptor with 84% sequence identity to the cloned rat cDNA 
and 92% homology at the amino acid level. These receptors exhibit similar 
binding profiles and affinities for NT and its analogues. These data suggest that 
these receptors are species variants of the same receptor. Furthermore, binding 
studies and biological assays using NT and its analogues in a variety of tissue 
types display similar profiles for these cloned receptors. Until recently there 
was no molecular data for the existence of NTR subtypes, a number of 
pharmacological and biochemical reports indicated the existence of other 
receptor subtypes; these data will be presented in the next section. 
Interestingly, Mazella et a l , have recently cloned the first low affinity 
neurotensin receptor from mouse brain, (Mazella et a l , 1996). The 417 amino 
acid peptide is 39% homologous to the cloned rat receptor of neurotensin. It 
displays a distinct pharmacological profile similar to that presented, in the 
following section, for the proposed levocabastine sensitive low affinity NTR.
17
Chapter 1
1.3.6 Evidence for NT receptor subtypes
The theoretical molecular mass of the rat and human 
receptors is approximately 47 kDa. However, a report on the photoaffinity 
labelling of mouse NTRs on neuronal cells indicates the presence 3 different 
binding sites for NT, (Charby et al., 1993). The authors reported 50 kDa, 60 
kDa and 100 kDa receptor species that were able to bind and internalise NT. 
However, treatment with phenylarsine oxide, an internalisation blocker, results 
in the 100 kDa protein no longer being detectable on cell membranes. 
Furthermore, the 100 kDa species can not be detected in the absence of NT. 
This apparent 100 kDa receptor has been purified from mouse, (Mazella et al., 
1989), and human brains, (Zsiirger et a l , 1994). Binding studies using NT 
analogues reported the affinity profile of the 100 kDa protein to be 
indistinguishable from the cloned receptor. Therefore this 100 kDa protein 
may be the result of dimerisation of the authentic NTR on binding to NT.
Levocabastine, the histamine antagonist, has been used to 
classify the NTR into two binding sites; site 1 and site 2, (high affinity and low 
affinity respectively). Sites 2 are sensitive to levacobastine and will not bind 
NT in its presence, whereas sites 1 are unaltered by the presence of the 
antagonist. Sites 1 also display a greater affinity for NT, (Kd = 0.13 nM), as 
opposed to sites 2, (Kd = 2.4 nM). Sites 1 display a lower binding capacity for 
NT, (66 fmol/mg), compared to sites 2, (160 fmol/mg), as reported by Mazella 
et al., 1983. It has also been observed that GTP increases the binding capacity 
of the high affinity sites but not the low affinity sites. The non-peptide 
antagonist of NT, SR48692, has a higher affinity for site 1 than site 2 receptors, 
(Gully et al., 1993). Furthermore, a number of studies have reported a greater 
proportion of the high affinity receptors in new-born rat and mouse brains than 
adult, (Schotte and Laduron, 1987). The high affinity receptor was reported at 
a 10-fold higher density in the adult human brain than the new-born, (Zsiirger 
et al., 1992).
Evidence for NT receptor heterogeneity has been 
suggested by a number of electrophysiological studies. Behbehani et al. , 1984, 
have observed two types of excitatory response elicited by NT action on the 
periaqueductal gray, (PAG), brain structure. The slow and fast acting 
responses are believed to be mediated by two receptor subtypes. Similarly the 
effects of NT on the evoked and spontaneous release of DA from cat striatal 
slices was suggestive of the existence of two types of NT receptor, (Markstein 
and Emson, 1988).
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Perhaps the most convincing evidence for the existence 
of two receptor subtypes is provided by studies using the SR48692 NT 
antagonist. Dubuc et a l , 1994, demonstrated that this antagonist could not 
attenuate the antinociceptive actions of NT administered into the PAG brain 
region. Furthermore, the same investigators showed that the hypothermia 
induced by centrally administered NT could not be suppressed by the use of the 
SR48692 NT antagonist. This was in contrast to the antagonism produced by 
SR48692 of the hypokinetic effect normally observed on central administration 
of NT, (Gully et al., 1993). Therefore it may be that the neurotensin induced 
analgesia and hypothermia are mediated through a NT receptor subtype that is 
distinct from the receptor mediating the DA response. It has been reported that 
SR48692 did not antagonise the increase of DA metabolism in the VTA after 
NT injection, (Steinberg et a l , 1994). This was surprising in light of SR48692 
ability to antagonise the potassium evoked DA release from striatal slices 
produced by NT, (Gully et al., 1993). These type of studies have led 
investigators to propose the existence of at least two types of NT receptor.
1.3.7 Signal transduction mechanisms of the NT receptor
A number of signal transduction mechanisms have been implicated in 
mediating the intracellular effects of NT binding to its receptor. Various cell 
lines, both neuronal and non neuronal that express NTR, have been used to 
demonstrate alterations in the cellular content of inositol phosphates, cyclic 
AMP, cyclic GMP and calcium produced by the action of NT, (reviewed by 
Vincent, 1995). Studies involving rat brain slices have demonstrated an 
increase of inositol phospholipid metabolism and calcium mobilisation on NT 
binding to many different cell types, (e.g. Sato et a l , 1991). Deletion studies 
have located the functional active domain of the receptor for inositol 
phospholipid metabolism to the third intracellular loop, (Yamada et a l, 1994). 
The effect on intracellular cGMP levels depends upon the cell type under 
investigation. Rat brain slices and the N IE -155 cell line show an increase in 
cGMP, (Pugsley et a l., 1995), whereas fibroblast cells transfected with the rat 
NTR cDNA show no change. The most confusing results concern the actions 
of NT relative to cellular cAMP levels. The N IE -155 neuroblastoma cell line 
exhibits an inhibition of cAMP formation on binding NT, (Bouzou et a l , 
1989). However, in the case of the CHO cell line, NT stimulates an increase in 
cAMP formation, (Yamada et al., 1993). The vast majority of these studies 
have been performed in vitro. Therefore, the association of the NTR with any
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of these secondary messenger systems still has to be accurately established as 
functional mechanisms of transmembrane signalling in neurons.
1.3.8 Retrograde axonal transport of NT
Another mechanism of cellular communication is by the internalisation of NT 
on binding to its receptor and the subsequent axonal transport to the cell body, 
where after a time it becomes predominantly associated with the nucleus, 
(Chabry et al., 1993). Furthermore, this retrograde transport of NT has been 
demonstrated within the nigrostriatal dopaminergic neurons of the rat brain, 
(Catsel et al., 1994). Iodinated NT was injected into the striatum, where NT 
receptors are located presynaptically on dopaminergic neurons. Two hours 
after injection the iodinated NT started to accumulate in the neuronal cell 
bodies of the substantia nigra pars compacta. After four hours the labelled NT 
was predominantly associated with the nucleus. Similarly, the binding, 
internalisation and perinuclear association of NT was demonstrated in the 
cholinergic neurons of the rat basal forebrain, (Faure et al., 1995). One 
proposed explanation for the internalisation of NT was that it is part of the 
mechanism for down regulation of the NT receptor. Indeed, rapid 
disappearance of the receptor was observed from rat embryonic neurons in 
culture on binding NT, (Vanisberg et al., 1991). However, this does not 
account for the axonal retrograde transport of the neurotensin/receptor complex 
to the nucleus. Castel et al., 1994, have observed a 39% increase in tyrosine 
hydroxylase mRNA expression in dopaminergic cells that exhibit retrograde 
axonal transport of NT. The same investigators reported that the increase of 
mRNA expression coincided with the arrival of labelled NT at the nucleus 4 
hours after injection. It has also been observed that chronic treatment of rats 
with the NT antagonist SR48692 decreases the tyrosine hydroxylase mRNA 
expression by 40%, (Laduron, 1995). Therefore, this mechanism may be a 
means by which NT can exert long lasting effects over neurons by influencing 
gene expression. Indeed, the presynaptic action of NT on the nigrostriatal 
neurons may be a mechanism by which NT acts as a feedback signal on these 
neuron cell bodies to increase the production and replemish the stores of DA. 
NT action on the presynaptic dopaminergic terminals is to stimulate the release 
of DA, but at the same time NT, via retrograde axonal, may increase the 
biosynthesis of TH which in turn increases the production of DA. In support of 
this hypothesis the NT receptor is believed to encode a sequence with
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similarity to a nuclear localisation signal, (Laduron, 1995). Whether NT or 
part of the NT/NTR complex interacts specifically at the genomic level or via 
another messenger molecule is not known.
Castel et al. , 1994, also reported that the quantity of 
retrogradely transported NT was reduced in aged rats. The rate at which NT 
was transported from the striatum to the SNc remained unchanged only the 
quantity diminished. This result may be due to fewer numbers of NTR in aged 
rats. Govoni et al., 1980 have documented a 20% reduction in NTRs of older 
rats. Nevertheless, the down regulation of this signalling system may have 
important consequences in ageing or in the pathology of degenerative diseases 
such as Parkinson's or in the pathology of illnesses such as schizophrenia, 
(discussed in next section). Lastly, mutational analysis of the rat cDNA 
receptor and expression in COS7 cells revealed that the carboxy terminus is 
critical to the ability of the receptor to internalise. Point mutation of aa 
residues Thr-422 and Tyr-424 almost completely abolished receptor 
internalisation.
1.4 Neurotensin as an endogenous neuroleptic
There is a considerable amount of data accumulating that implicates NT in the 
pathophysiology of schizophrenia. Analysis of the NT levels in the 
cerebrospinal fluid of a group of 21 drug free schizophrenic patients identified 
a subset of 9 patients who had lower levels of NT than control patients. 
However, when these patients were treated with antipsychotic drugs, the 9 
patients who had below normal levels of NT experienced a 5 to 8-fold increase 
of NT concentration in their cerebrospinal fluid. These were the first clinical 
data to suggest that NT may function as an endogenous neuroleptic in the CNS, 
(W inderlov et al., 1982). The neuroleptic drugs used in the treatment of 
schizophrenia are DA antagonists that preferentially bind to dopamine D2 
receptors, (Nemeroff et al., 1992). The beneficial effects of these drugs are 
thought to be mediated by the blockade of the D2 receptors in the dopaminergic 
mesolimbic system. However, these drugs take weeks before they work, which 
implies a complex readjustment within the dopaminergic neurons at the 
molecular level. Furthermore, neuroleptics also antagonise D2 receptors of the 
nigro-striatal pathway causing a number of detrimental side effects such as 
catalepsy, akathisia, dystonia and Parkinsonian like symptoms. Similarly, 
blockade of D2 receptors associated with the hypothalamus results in
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neuroendocrine effects such as prolactin secretion. Furthermore, due to the 
non specific nature of some neuroleptics, blockade of various different 
receptors can result in neurovegetative disturbances, (Liegeois et al., 1995).
The physiological effects of centrally administered NT 
demonstrates a pharmacological profile that is similar to that produced by 
neuroleptic drugs. NT produces catalepsy, poteniates barbiturate and ethanol 
induced sedation, induces hypothermia, inhibits the amphetamine induced 
hyperactivity, decreases locomotor activity and increases DA turnover in the 
nucleus accumbens, (Bissette et al., 1991). Furthermore, injection of NT into 
the nucleus accumbens antagonises amphetamine induced hyperactivity. 
However injection of NT into the striatum did not block this hyperactivity, 
(Jolicoeur et al., 1993). This is further evidence that NT neuroleptic like 
qualities are mediated via the mesolimbic system. In addition the ability of 
neurotensin to cause the efflux of dopamine from the nucleus accumbens in 
vivo was similar to the effect caused by the neuroleptic haloperidol, (Blaha et 
al., 1992). This effect may in part be mediated by the ability of NT, (at 
concentrations >10 nM but <300 nM), to increase the firing rate of 
dopaminergic neurons from the VTA, (Seutin et al., 1989).
Even more compelling evidence for NT acting as an 
endogenous neuroleptic comes from the observation that all clinically effective 
antipsychotic drugs have been shown to selectively alter the neurotensin 
system, (Myers et al., 1992). However, not all antipsychotic drugs have the 
same effect on the NT system. Neuroleptic drugs can be classified into two 
groups, namely typical and atypical. The atypical drugs display less side 
effects than the typical drugs. These two groups of drugs can be differentiated 
by their consequent action on NT expression, (Gygi et al., 1994). The atypical 
neuroleptics only increase NT concentrations in the N. Acc., (a terminal field 
of the DA neurons of the mesolimbic system). The typical neuroleptics 
increase NT levels in the N. Acc. and the caudate nucleus of the striatum, (a 
terminal field of the nigrostriatal pathway). It has been postulated that the 
extrapyramidal side effects associated with typical neuroleptics are mediated 
by their action on the nigrostriatal pathway, hence the increase in NT within 
the caudate nucleus. The beneficial effects of atypical neuroleptics are 
mediated via the mesolimbic system, hence the increase of NT expression 
preferentially in the N. Acc. and not in the caudate nucleus.
More recently it was demonstrated that the increase in 
NT expression was mediated by the c-fos gene, (Robertson et al., 1995). The 
expression of c-fos was increased within the striatum, on administration of the
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neuroleptic haloperidol. Furthermore, the authors demonstrated that 80% of 
the cells displaying Fos-like immunoreactivity also expressed the NT mRNA. 
The connection between c-fos gene expression and the upregulation of NT was 
demonstrated using antisense oligonucleotides for the c-fos gene. These 
oligonucleotides bind to c-fos mRNA preventing expression which in turn 
attenuates NT mRNA expression. This result was somewhat expected in light 
of the expression studies performed on the NT/NM promoter in PC 12 cells, 
(described in section 1.3.1).
In summary, there is growing evidence implicating NT in 
the pathophysiology of schizophrenia. Central administration of NT displays a 
profile similar to neuroleptic drugs. A subset of drug free schizophrenic 
patients were observed to have below normal levels of NT prior to neuroleptic 
treatment. All clinically effective neuroleptics increase NT levels in the 
dopaminergic mesolimbic system, (particularly the atypical neuroleptics). It is 
also interesting to observe that a rare allele of the tyrosine hydroxylase, (TH), 
gene is associated with the occurrence of schizophrenia, (Mallet, 1996). Two 
separate populations, of unrelated chronic schizophrenics, displayed the variant 
allele at a frequency of 5% and 9% compared to 0% within the control 
samples. The functional significance of this allele is unknown but, the 
implication is that it alters or disrupts TH gene expression in a manner that is 
important to the development of schizophrenia. As mentioned in the previous 
section, NT was demonstrated to undergo retrograde axonal transport in the 
nigrostriatal pathway of rats. The transported NT becomes targeted to the 
nucleus whereupon an increase in TH mRNA was observed. If indeed TH is a 
downstream target for NT, then the existence of a variant allele of the TH gene 
being associated with schizophrenia, is interesting in light of the evidence 
implicating NT transmission in the pathology of schizophrenia.
1.5 Other important functions of NT transmission
1.5.1 Neurotensin as a regulatory hormone
Neurotensin is a regulatory hormone of the gut that mediates several 
physiological responses and is secreted from endocrine N cells on luminal 
ingestion of nutrients, (Read et a l., 1984). Bom besin and other 
neurotransmitters are also capable of stimulating the secretion of neurotensin 
into the circulatory system from endocrine N cells, (Rokaeus, 1984). The
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neuromedin N peptide which has similar properties to NT and is encoded 
within the same gene is also co-localised with neurotensin in the cells of the 
rat ileum. However, neuromedin N is not co-released on administration of the 
usual stimulants, (Cuber et a l , 1990). The exact physiological role(s) of 
neurotensin in the intestinal tract is uncertain but many observations of its 
action suggest it may coordinate the digestive processes. For example, 
neurotensin is released from the N-cells of the ileum upon the ingestion of fat, 
but glucose and amino acids have negligible effects upon the secretion of NT, 
(Rosell and Rokaeus, 1979). Moreover, neurotensin has been shown to 
stimulate (3H) oleic acid translocation across the rat small intestine, 
(Armstrong et al., 1986). Furthermore, circulating neurotensin plays a role in 
the stimulation of pancreatic exocrine secretion, (Sakamoto et al., 1984). In 
addition, neurotensin can inhibit gastric acid secretion, (Anderson et al., 1980). 
A number of studies have shown that the infusion of neurotensin into the 
gastrointestinal tract increases colonic motility and defaecation, (Thor and 
Rosell, 1986). Trophic effects of neurotensin have been observed on the 
mucosa of the colon in young and aged rats, (Evers et a l , 1992). In young rats 
the increased weight/growth of the colon was associated with an increase in 
mucosal cellularity. However, in aged rats this growth of colon tissue was not 
accompanied by an increase in DNA content, suggesting the growth was the 
result of hypertrophy.
More recently the expression of neurotensin has been 
associated with 1 in 4 human colon cancers, (Evers et al., 1996). Furthermore, 
the developmentally regulated transient expression of neurotensin has been 
recorded in the human and rat foetal colon, (Evers et a l , 1993). Interestingly, 
this is when the developing colon has a morphological structure similar to the 
small intestine. The authors suggest that the neoplastic transformation of the 
colon cells could be the result of the reversion of neurotensin expression to a 
foetal like profile, in certain types of colon cancer. Another study by Sehgal et 
a l , 1994, provides evidence for neurotensin functioning as an autocrine trophic 
factor in human prostate cancer. In this investigation they postulated that the 
expression of endocrine peptides, such as neurotensin, may be responsible for 
the proliferation of androgen independent prostrate cancer. Normal growth of 
these cancers is stimulated by androgen and does not require neurotensin 
expression. Therefore, hormone depletion is the normal clinical treatment for 
these types of cancer. However, if this treatment fails progression of the 
cancer is thought to be through an alternative growth regulatory pathway 
distinct from that mediated by androgen. Analysis of an androgen dependent
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prostrate cancer cell line, registered an up regulation of neurotensin expression 
on withdrawal of androgen. Administration of neurotensin stimulated the 
growth of androgen deprived cells in culture, but did not have an affect on cells 
supplemented with androgen. Therefore, neurotensin may provide an 
alternative autocrine trophic factor for the proliferation of androgen 
independent prostate cancer.
1.5.2 Neurotensin and the cholinergic neurons of the basal forebrain
NT immunoreactive neurons have been shown to innervate the cholinergic 
neurons of the nucleus basalis of Meynert (NBM), (Zahm et al., 1987). 
Furthermore, NTRs are located on the perikarya and dendritic terminals of the 
NBM cholinergic neurons, (Szigethy et a l., 1990). M oreover,
intracerebroventricular administration of NT has been shown to produce an 
awakening effect and an increase in limbic theta rhythm activity, (Castel et al., 
1989). In vivo stimulation of the nucleus basalis leads to cortical arousal; 
therefore NT may play a role in the mechanism of cortical arousal. This brain 
region is also thought to be important to the learning and memory processes. 
These neurons provide the major cholinergic innervation of neocortex and the 
amygdala and are prone to degeneration in Alzheimer's disease and other 
dementias, (Whitehouse e ta l., 1991). However, this degeneration is secondary 
to the loss of neurons from the hippocampus which provide the cholinergic 
neurons with nerve growth factor. Cholinergic neurons from the NBM were 
grown in culture and the effects of NT analysed by the patch clamp technique, 
(Farkas et al., 1994). It was shown that NT acting via a pertussis toxin 
insensitive G protein produces a long lasting excitation of nucleus basalis
cholinergic neurons by reducing inwardly rectifying K+ conductance. NT is 
also thought to briefly excite these neurons by inducing an inward current, 
mediated in part by Na+ ions. Furthermore, Alonso et al., 1994, demonstrated 
that NT promotes oscillatory bursting behaviour within the cholinergic neurons 
of the basal forebrain magnocellular complex. In conclusion these results 
provide strong evidence that NT has an excitatory neuromodulatory action on 
cholinergic neurons.
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1.5.3 The antinociceptive effects of neurotensin
The central administration of NT and its inferred involvement in pain 
inhibition was first demonstrated by Clineschmidt et al., 1979. Subsequently a 
number of behavioural and electrophysiological studies have substantiated 
these initial observations. Injection of NT into the periaqueductal gray (PAG) 
brain structure produced a dose dependent analgesia which was not blocked by 
the opioid antagonist naloxone. These effects of NT on PAG are mediated 
through the nucleus raphe magnus (NRM). This was demonstrated by the 
lesioning of NRM which abolished the analgesic effects of NT, (Behbehani and 
Pert, 1984). The same study showed that the electrophysiological effect of NT 
treatments on PAG neurons was excitatory, which in turn activated the pain 
inhibitory pathway of the NRM that innervates the spinal cord. Furthermore, 
studies have documented the innervation of the rostral ventral medulla (RVM), 
an area of the brain that contains the NRM, by neurotensinergic neurons 
originating from the PAG, (Beitz, 1982), and the presence of NTRs in the 
PAG, (Behbehani, 1992). However, the source of NT-mediated response 
within the PAG has not been totally identified. One possible source is from the 
neurotensinergic cells of the lateral hypothalamus (LH) that innervate the PAG, 
(Kahn et al., 1980). Studies have shown that electrical stimulation of the LH 
neurons and chemical stimulation of PAG with exogenous NT elicited similar 
responses.
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1.6.1 Introduction to gene targeting and embryonic stem cell technology
The ability of classical genetical research to yield information on the function 
of complex organs such as the mammalian CNS, becomes increasingly more 
difficult the more complex the organism of study. In the case of the mouse, 
limitations are imposed by the attainable mutation rate, and the ability to 
isolate mutations relevant to the particular phenotype of study. Until recently, 
investigators were dependent on random mutagenesis to generate 'interesting' 
mutations by chance. It is now possible via gene targeting and ES technology 
to create a mouse of any desired genotype. In principle, it is possible to take 
any cloned murine gene and modify it in any required manner. A mutation is 
first engineered into a cloned fragment of the gene of interest. The mutated 
gene construct is used to transfer the specific alteration to the genome of mouse 
by first modifying the gene of interest within ES cells by a process known as 
gene targeting.
ES cells are pluripotent stem cells derived from the 
epiblast of mouse blastocysts, Brook and Gardner 1997. Under defined culture 
conditions they retain their ability to colonise the somatic tissues of a host 
embryo to form a chimaeric mouse, following their re-introduction into host 
blastocysts. Frequently the introduced ES cells colonise the germ cell lineage 
of the chimaeric mouse. Thus allowing the modified genotype to be 
transmitted to subsequent generations. This totipotent potential, combined 
with the stable growth in vitro of ES cells permits the introduction of specific 
modifications into the murine germline. A number of cell culture selection 
regimes allows the relative rare event of homologous recombination between 
the incoming modified gene construct and the target locus to be enriched 
allowing easier detection.
Breeding of chimaeras produced from the modified ES cells and 
subsequent breeding of their progeny can result in the production of 
homozygote mice for the desired genetic modification. Therefore, the effect of 
a specific modification on the phenotype of an animal can be analysed. This 
back to front method of genetic analysis, from genotype to phenotype, has 
become known as the 'reverse genetic' approach to studying gene function. 
Thus reverse genetics gives the neurobiologist the tools to dissect the 
functional role of any particular brain molecule in a precise manner never 
possible by traditional pharmacological methods. Figure 1.4 overviews the 
general principles of gene targeting and ES cell technology.
27
Chapter 1
iooiate
blastocyst
arrive ES cell 
line /
gene targeting
1 inject into blastocyst
Host blastocyst-derived progeny ES cell-derived progeny
Figure 1.4 Strategy for germ line m odification using ES cells. B lastocysts derived 
from  an inbred m ouse strain with a light coat colour, (usually 129/sv), are used to 
derive ES cells. ES cells are then modified by techniques known as gene targeting to 
specifically  alter the genome. The altered ES cells are introduced into host blastocyst 
o f a dark  coat-colour genotype. The host blastocysts are introduced into a surrogate 
m other w here they develop to term. The resulting chim aeric offspring are derived 
from  the 2 genotypes i.e. the ES cell and the host blastocyst, light and dark  coat- 
co lour respectively. Chim aeras are tested for germ line transm ission by m ating to the 
genotype from  which the ES cell line was derived, (light coat-colour). Progeny 
resulting from  ES cell colonisation of the germ line are of a light coat-colour, and half 
w ill statistically  carry the specific genetic m odification introduced into the ES cells. 
Recom binant DNA techniques are used to identify such individuals and conventional 
breeding used to derive mutant stocks. Adapted from Hooper 1992.
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The remainder of this introduction focuses on vector design and the parameters 
that are known to govern the frequency of gene targeting. Only those vector 
designs that were available for this study will be considered within this 
introduction. Since the strategy presented in Chapter 4 for targeting the 
receptor was designed in respect of the available technology at the beginning of 
1992. The second strategy of Chapter 5 was undertaken in light of the 
advances made in gene targeting up until the end of 1994. However, some 
consideration will be given to more recent advances within Chapter 9. There 
were essentially two basic types of vector that could be used for gene targeting; 
replacement vectors and insertion vectors, (Thomas and Capecchi, 1987). 
However variations on these vector types exist, some of which will be 
considered in due course. Firstly, the general features of replacement vectors 
and the positive negative selection system will be presented.
1.6.2 Replacement vectors and the positive negative selection strategy
The most widely used approach to creating a null mutation via gene targeting 
has been to create a replacement vector for the desired gene and employ the 
positive negative selection strategy; see Figure 1.5. A replacement vector 
consists of a portion of gene homology interrupted within its exonic sequence 
with a selectable marker, such as a neomycin cassette. This cassette typically 
includes promoter and polyadenylation sequences to create a functional 
neomycin phosphotransferase gene. The cassette, as well as being mutagenic, 
provides positive selection for the genomic integration of the vector into ES 
cell chromosomal DNA using G418 selection. In addition, one arm of the gene 
homology, sometimes both (Chauhan and Gottesman, 1992), is flanked by a 
thymidine kinase cassette derived from the herpes simplex virus. The gene 
replacement vector is believed to homologously integrate via 2 reciprocal 
crossover events between the 2 arms of homology and the endogenous gene, 
although integration may infact proceed through a single strand exchange 
within one region of homology, followed by branch migration and resolution 
within the second arm of homology, (Ellis and Bernstein, 1989). The result is 
that homologous integration of the vector does not extend to the integration of 
the thymidine kinase cassette. However, the mechanism of non-homologous, 
(random), integration is independent of homology, thus gene sequence and 
marker gene sequence can not be distinguished. Thus, random integration of 
the vector, generally results in the genomic integration of the thymidine kinase 
cassette. This allows ES cells that have randomly integrated the vector to be
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selected against using a toxic nucleotide analogue such as gancyclovir or 
FIAU, (l-(2-deoxy-2-fluro-b-D-arabinofuranosyl)-5-iodouracil, which are 
substrates for the vector but not the cellular thymidine kinase. This system of 
sim ultaneously selecting for integration and against non-homologous 
integration is known as the positive negative selection strategy (PNS). The 
enrichment for targeted clones using this technique was originally reported to 
be up to 2000-fold, (Mansour et al., 1988). However more typically 
enrichments of 2 to 20-fold are normally observed. It is also possible to use the 
diphtheria toxin A fragment gene for negative selection instead of the herpes 
thymidine kinase gene. Since the product of the diphtheria toxin A fragment 
gene is toxic to ES cells, then there is the added advantage of not having to 
select the cells with toxic nucleosides such as gancyclovir. An enrichment 
factor of about 10-fold was obtained when targeting the c-fyn locus in the 
original study, (Yagi et al., 1990).
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Figure 1.5 Gene targeting with a replacement vector used in the positive and 
negative selection strategy. The 4 exons of the gene are represented by black 
boxes. The thin black lines represent introns; NEO, the neomycin cassette; 
TK, the thymidine kinase cassette and the striped boxes represent exons of 
another gene. The targeting vector consists of exons 2 and 3 flanked by a 
thymidine kinase cassette with exon 2 interrupted by a neomycin cassette.
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Homologous recombination results in the integration of the neomycin cassette 
within exon 2 of the endogenous gene, but the thymidine kinase cassette does 
not integrate. However, non-homologous recombination generally results in 
both selectable markers being integrated.
Enrichment for targeted clones can also be achieved by 
using engineered neomycin cassettes, i.e. the use of enhancerless type 
cassettes, (Jasin and Berg, 1988), or neomycin cassettes devoid of a 
polyadenylation signal, (Donehower et al., 1992), or promoterless neomycin 
cassettes, (Jeannotte et al., 1991). Such vector constructs require the 
chromosomal integration site to provide the necessary sequences for the 
creation of a functional neomycin gene and for the target gene to be 
transcriptionally active in ES cells. The Donehowe study reported a 50-fold 
increase in targeting frequency for the p53 tumour suppresser gene targeted 
with a neomycin gene lacking a polyadenylation signal. For a promoterless 
neomycin construct, approximately only 1% of random integrants will provide 
promoter sequences for neomycin activation. Therefore, this approach 
potentially provides a 100-fold enrichment for homologous integrations. The 
Jeannotte et al. , 1991 study, further demonstrated that high levels of the target 
gene transcription are not necessary to provide adequate levels of G418 
resistance. In this case the Hox 1.3 gene RNA expression could only be 
detected in ES cells after PCR amplification of poly (A)+ selected RNA, and 
not by northern blotting. However this approach can be prone to failure if the 
fusion protein o f the target gene produces non-functional neomycin 
phosphotransferase. This problem can be alleviated by not relying on the 
translation start signal of the target gene but, incorporating a viral internal 
ribosomal entry site within the 5' end of the neomycin cassette, (Mountford and 
Smith, 1995). However it must be noted that low transcription levels at a gene 
locus in ES cells may not result in effective levels of drug resistance for a 
selectable marker. Te Riele et al., 1992, observed that the use of a mutated 
version of the neomycin gene reduced the recovery of hom ologous 
recombinants more than the recovery of random integrants. They concluded 
that the expression of their neomycin gene at the retinoblastoma susceptibility 
gene locus is around or even below the threshold required for drug resistance.
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1.6.3 Insertion type vectors
This vector is constructed from a region of gene homology with a neomycin 
cassette. However, unlike the replacement vector, the neomycin cassette is 
placed outwith the region of homology in the plasmid backbone and the vector 
is linearised within the region of homology prior to ES cell transfection. The 
result is that homologous recombination results in the complete insertion of the 
vector into the target locus creating a duplication of the region of homology, as 
presented in Figure 1.6. This disruption of a gene normally produces a null 
allele. However, if read through occurs at the neomycin polyadenylation site 
then a transcript may result that could be spliced to produce a product, 
functionally similar to that of the wild type gene, as demonstrated by Moens et 
aU  1992.
Targeting Vector
X
Genomic Locus
1 2 3 2 3 4
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Figure 1.6 Gene targeting with an insertion type vector. The 4 exons of the gene 
are represented by the black boxes; introns by thin lines; and the plasmid back 
bone by thick black lines. The vector consists of exons 2 and 3 with a neomycin 
cassette, (Neo), inserted within exon 2, and is linearised within the region of 
homology. Homologous recombination results in the insertion of the entire 
vector creating a duplication of exons 2 and 3.
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1.6.4 Creation of subtle mutations using insertional vectors.
The majority of gene targeting studies have been concerned with the disruption 
of the gene using the neomycin selectable marker stably integrated into the 
gene locus of interest. However, it may not be desirable to introduce 
enhancer/promoter elements into a gene locus as these elements may 
deregulate the transcription of neighbouring genes, thus producing a difficult 
phenotype to analyse. The introduction of specific subtle mutations can be 
engineered using insertional type vectors like those used in the 'Hit and Run' or 
'In-Out' procedures, (Hasty et a l ,  1991a; Valancius and Smithies, 1991). This 
method uses a two step recombinational approach to introduce subtle mutations 
within the target gene locus, see Figure 1.7. An insertion type vector is 
constructed with a region of gene homology bearing the desired mutation, with 
the neomycin and thymidine kinase selectable markers positioned within the 
plasmid back bone of the vector. In the first step, selection is applied for those 
cells that have integrated the vector by selecting for neomycin gene expression. 
If homologous integration occurs then a duplication of the gene homology 
separated by the plasmid backbone and the selectable markers will normally be 
created with the desired mutation present. The second step of the procedure 
applies negative selection against the thymidine kinase selectable marker. This 
can result in the excision of the vector and one copy of the duplicated 
sequences such that the mutation is retained within the gene locus, due to 
intrachromosomal recombination between the duplication. The frequency at 
which the mutation is retained within the genome during this reversion event 
depends upon the location of mutation relative to the vector linearisation site. 
Hasty et al., 1991a, observed that 2 of the 15 colonies from the study of the 
Hprt locus contained the BamHl mutation after selection. Further discussion of 
this strategy is presented in Chapter 4.
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Figure 1.7 The 'Hit and Run' procedure. The diagram shows an insertional 
vector containing a neomycin cassette (NEO), a phosphoglyceratekinase 
promoter (PGK), a thymidine kinase cassette (TK) and the plasmid b- 
lactamase gene conferring ampicillin resistance (Amp). The mutated gene 
site is indicated by an *, and the open and filled boxes represent the gene 
homology. The method is a two step recombination process; homologous 
recombination of the vector at the gene locus results in a duplication that can 
be subsequently resolved by intrachromosomal recombination. In the 
example shown the reversion event has resulted in the mutated sequence 
being retained within the endogenous gene. Refer to the text for a more 
detailed explanation, (section 1.6.4).
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1.6.5 Creation of subtle mutations using replacement type vectors
Replacement type vectors have been used to create subtle mutations using a 
gene targeting approach known as 'Tag-and-Exchange', (Askew et al., 1993). 
This technique employs a strategy of sequential gene targeting. The first step 
is to tag the gene of interest with selectable markers, and secondly to replace 
the tagged sequence with sequence carrying the desired mutation(s). In the 
original study a neomycin phosphotransferase gene and the herpes simplex 
virus thymidine kinase gene were used as positive and negative selectable 
markers. These genes were fused into one cassette which was then flanked on 
either side with gene homology to construct a 'tagging vector'. G418 was used 
to select for homologous integrants which were detected at a targeting 
frequency of 1 in 40. The second step requires the use of an 'exchange vector'. 
This vector consists of gene homology with the engineered mutation(s). This 
vector is used to target the tagged locus by homologous recombination and 
negative selection against the thymidine kinase marker gene. Therefore, 
targeting the tagged locus results in the removal of the selection cassette and 
the introduction of the site specific mutation(s). This was achieved in the 
Askew et al., 1993 study, at a targeting frequency of 1 in 54 for the second 
replacement event. This system provides a method of introducing subtle 
mutations without introducing unwanted enhancer/promoter elements into the 
target locus, as outlined in Figure 1.8. There is also the added advantage that 
once a tagged cell line has been generated, then various exchange vectors can 
be designed to introduce a variety of different mutations.
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Figure 1.8 The 'Tag-and-Exchange' approach to gene targeting. The 4 exons of 
the gene are represented by black boxes, the intronic sequences by the thin lines. 
The tagging vector consists of exons 2 and 3 with the fused selection cassette, 
(Neo and TK), inserted between the two exons. The asterisk denotes the 
mutation in the exchange vector and the targeted locus.
1.7 Factors that influence gene targeting frequencies in ES cells
Early gene targeting experiments showed great variation in the number of 
homologous integrants versus the total number of integrations, ranging from 1 
in 20 to 1 in 40,000, (Hasty et a l , 1991b). Several factors are known to be 
critical to gene targeting frequencies such as the design of the vector, overall 
length homology and the use of isogenic as opposed to non-isogenic DNA. 
Each of these factors will be considered in the following sections.
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1.7.1 The effect of homology length on gene targeting frequencies
The influence the length of homology has on homologous recombination was 
known to be important for sometime, from studies by Rubnitz and Capecchi, 
1984. They observed the rates of extrachromosomal intram olecular 
recom bination in mammalian cells, and showed a linear increase in 
recombination frequency with increased length of homology from 0.25 kb to 
0.5 kb. However, such studies do not address the question of 
vector/chromosome relationships, which may not be governed by the same 
criterion. The first insights were gained from the Thomas and Capecchi, 1987 
study, who noticed that a 2-fold increase in homology length resulted in a 20- 
fold increase in homologous recombination at the hprt gene locus. A more 
detailed study by Hasty et al., 1991b, demonstrated even greater increases of 
gene targeting frequencies at the hprt locus with increasing targeting homology 
length. 9 replacement and 3 insertion vectors with gene homology ranging 
from 1.3 kb to 6.8 kb were used to target the gene. They observed an increase 
in gene targeting frequency, compared to random vector genome integration, of 
greater than 190-fold for replacement vectors and 250-fold greater for insertion 
vectors over this size range. Furthermore, their results suggest that there is no 
added advantage in using vectors containing gene homologies greater than 6 
kb. No increased targeting frequency accompanied vectors utilising greater 
than 6 kb homology, in their study. However, the relevance of targeting 
frequencies using such a small fragment of gene homology as 1.3 kb must be 
doubted especially when this homology is split in two for the construction of a 
replacement vector. The most informative study was performed by Deng and 
Capecchi, 1992. The targeting efficiency at the hprt locus was investigated 
using a total of 22 replacement and insertion vectors. They concluded that 
there was a strong dependency of the targeting frequency on the length of 
homology between the targeting vector and the target locus. The relationship 
between length of homology to targeting frequency between the range of 2 kb 
to 10 kb was exponential, in fact a 100-fold increase in targeting frequency was 
observed. Unlike the Hasty et al., 1991b study, these authors observed 
increasing gene targeting frequencies with constructs using 14 kb of gene 
homology as opposed to 6 kb in length.
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1.7.2 Isogenic and non-isogenic DNA influence on gene targeting efficiency
Observations such as the decrease in the sensitivity of the E.coli homologous 
recombination frequency due to base pair mismatches between the substrates of 
hom ologous recombination, (Shen and Huang, 1986), prom pted the 
investigation of this parameter in ES cells. Furthermore, in mammalian cells it 
has been shown that base pair mismatches strongly affect the efficiency of 
intrachromosomal recombination (Bollag et a l , 1989).
The first of these studies by Te Riele ,1992, analysed 
gene targeting at the retinoblastoma susceptibility gene. They used 2 identical 
replacement vectors containing 17 kb of gene homology. However, one vector 
consisted of DNA isogenic to the ES cell line, derived from the 129J mouse 
strain. The other vector was constructed of DNA derived from the BALB/c 
mouse strain. They achieved a 20-fold increase in gene targeting efficiency 
using the isogenic DNA derived vector, in fact they reported a targeting 
frequency of 78%. The total extent of sequence divergence between the two 17 
kb homologous fragments was not determined. However, a total of 1687 nt 
from each fragment was sequenced for comparison. 9 base pair substitutions, 
three small deletions, (1 ,4  and 6  nt), and a polymorphic CA repeat, (a 14 nt 
deletion), were detected in the BALB/c derived sequence relative to the 129 
sequence.
A similar study for the efficiency of isogenic versus non- 
isogenic DNA was undertaken using the creatine kinase M gene locus as a 
target, (van Deursen and Wieringa, 1992). This study involved the comparison 
of two replacement vectors consisting of 8 .1  kb of gene homology derived 
from the 129 and BALB/c mouse strains. The isogenic construct targeted at a 
frequency of 1 2 %, whereas, the non-isogenic construct produced no 
homologous recombinant clones for the 357 colonies analysed. The extent of 
sequence divergence at this locus was estimated at 2 %, based upon sequencing 
data generated from 4 regions of the gene.
It is now well accepted within the gene targeting field 
that the allelic differences observed between the vector and the endogenous 
gene can reduce targeting frequencies. However, this information was not 
published when the decision to construct the insertional vector, (pKLF), used 
in Chapter 4 was made.
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1.7.3 Vector design
There has been some confusion concerning the relative merits of using 
replacement vectors or insertion vectors for gene targeting with respect to their 
targeting frequencies. Thomas and Capecchi, 1987, reported no significant 
difference between insertion and replacement constructs on targeting 
frequencies containing gene homology of the same size. However, the Hasty et 
al., 1991b study, claims to observe a difference, in that they suggest insertion 
vectors to be more efficient at targeting the hprt locus than the replacement 
vectors. A 250-fold increase of gene targeting frequency compared to random 
genome integrations was observed with the insertion vectors, whereas 
replacement vectors produced a 190 fold increase in gene targeting frequency 
over the range assayed. The analysis was based on 3 insertion vectors; two 
with homology of 1.3 kb and one with 6 .8  kb, 9 replacement vectors; ranging 
from 1.3 kb to 6 .8  kb of gene homology. Therefore, major conclusions were 
based largely on vectors with small amounts of gene homology. In particular, 
doubts exist regarding data for gene targeting frequencies of replacement 
vectors with less than 1 kb of gene homology in an arm of the vector, for 
reasons discussed later.
A second study by Hasty et al., 1991c, suggests higher 
targeting frequencies for insertion vectors over replacement vectors. Again 
they target the hprt locus using 6 .8  kb of gene homology for the vector 
constructions. Overall they observed a 5 to 9 fold higher targeting frequency 
using insertion vectors. The proposed reasons for these differences were the 
advantage of presenting a substrate for homologous recombination with two 
ends of homology by creating a double strand break within the region of 
homology. Secondly the gene homology of the vector is not interrupted by a 
selectable marker gene and apparently requires only one cross-over to 
recombine at the target locus. Replacement vectors may require two cross-over 
events to homologously integrate.
At that point in time, the summer of 1991, insertion 
vectors appeared to undergo homologous recombination at greater frequencies 
than replacement vectors, based on the above data. The 'Hit and Run1 
procedure which allowed for the introduction of subtle site-specific mutations 
was developed using insertion vectors. These apparent advantages influenced 
my decision to generate an insertional targeting vector for the neurotensin 
receptor gene, with a view to using the 'Hit and Run' method of gene targeting. 
However, the publication of two particular papers the following year, shed
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considerable doubt on whether insertion vectprs were as a general rule more 
efficient at gene targeting than replacement vectors.
The first of these papers, by Thomas et a l., 1992, 
analysed the frequency of gene targeting for replacement vectors. More 
specifically the study directed attention towards the minimum length of gene 
homology within the short arm of the vector required for effective gene 
targeting. In conclusion, the results suggested a minimum size of 1 kb gene 
homology should be contained within the short arm of a replacement vector. 
Using less than 1 kb of homology severely decreases the ability of a 
replacement vector to homologously integrate. These results suggest that 1 kb 
of homology is the minimum length the mammalian recombinational system 
will recognise as a substrate for homologous recombination between 
extrachromosomal DNA and chromosomal DNA. Moreover, unpredictable 
patterns of integration and rearrangement are observed at the target locus if the 
vector has less than 1 kb of homology at the end. Therefore, if these results 
can be extrapolated as a general rule, the results of Hasty et al., 1991b and 
1991c have to be re-evaluated. A number of the replacement vectors in these 
studies had short arms of homology which were less than 1 kb in the length. 
Furthermore it became apparent as discussed in Chapter 1, (section 1.7.2), that 
mismatches between vector and target gene due to non-isogenic DNA decrease 
the efficiency of gene targeting. Together these observations may explain the 
higher targeting frequencies observed with insertional vectors as opposed to 
replacement vectors in the Hasty et al., studies.
The most comprehensive analysis of vector design and 
influence on gene targeting frequencies was performed by Deng and Capecchi, 
1992. 13 replacement and 9 insertion vectors consisting of isogenic and non- 
isogenic DNA were designed against two sites of the Hprt gene. The major 
observations for all vectors (except one replacement construct) were: i) no 
significant difference in targeting frequencies was observed between insertion 
and replacement vectors; ii) the overall length of homology, between 2  and 1 0  
kb, exhibited an exponential relationship, exhibiting a 1 0 0 -fold increase in 
gene targeting frequencies over this range; iii) constructs of isogenic DNA 
target at 4 to 5-fold more efficiently than non-isogenic DNA constructs of the 
same length; iv) no increase in gene targeting frequencies are oberved using > 
14 kb of homology. The one exception to this rule was a replacement vector 
constructed of non-isogenic DNA, which targeted at an approximately 10-fold 
lower frequency than expected. The explanation proposed was that an 
unfavourable distribution of heterology between the endogenous gene and the
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vector severely handicapped its ability to target the locus. It is also known that 
a significant degree of allelic variation exists at the hprt locus. The results of 
this paper combined with the enrichment advantages gained by using the 
positive negative selection strategy, greatly influenced the decision to create a 
replacement vector as a second strategy to targeting the neurotensin receptor 
gene.
1.8 Screening procedures for targeted ES clones
Many elements of good vector design can be used to enhance the frequency of 
homologous recombinant ES cell clones e.g. the use of isogenic DNA, large 
portions of gene homology up to about 14 kb, positive negative selection using 
replacement vectors, and the use of more than 1 kb of homology the short arm 
of a replacement vector. Nevertheless, a screening regime is required to detect 
the homologous recombinants relative to the background of random integrants. 
The most common procedure is to screen the clones by Southern blot analysis. 
Typically, a restriction site within the disrupting marker provides a new 
restriction pattern for a targeted locus. The probe in such an analysis is 
generally derived from a flanking fragment of the gene exclusive of the 
homology used in the targeting vector, see Chapter 6  (section 6.3) for an 
example. However, some investigators have been known to base the screening 
procedure on the difference in restriction fragment size caused by the insertion 
of the selectable marker at the target locus, e.g. Endelman, et al., 1996.
Another common approach is to use a PCR screen to 
detect homologous recombinants. This strategy was first outlined by Kim and 
Smithies 1988, and involved screening pools of colonies with a pair of PCR 
primers specific for the targeted event. Positive pools subsequently undergo a 
PCR/sib-selection protocol until individual targeted colonies can be identified. 
A variation of the original protocol is outlined in Chapter 4.
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1.9 Future directions for increasing gene targeting frequencies in ES cells
1.9.1 Introduction
The frequency of non-homologous integration of targeting vectors is generally 
accepted to be 3 to 5 orders of magnitude more frequent than integration by 
homologous recombination. Improvements in gene targeting frequency maybe 
achieved by incorporating sequences, that stim ulate hom ologous 
recombination, into the targeting vector. Furthermore, the identification of the 
enzymes that promote homologous recombination should provide methods for 
increasing gene targeting frequencies in ES cells.
1.9.2 Double strand breaks and homologous recombination
Current models of homologous recombination in eukaryotes, are primarily 
deduced from experiments in Saccharomyces cerevisae, and involve double 
strand breaks (DSBs) at the site of recombination, (Petes et a l., 1989). A 
natural example of homologous recombination being initiated by DSBs is 
observed at the M A T  locus of Saccharomyces cerevisae. This reaction is 
initiated by DSBs initiated by the mating type Endonuclease HO at the M AT  
locus, (Strathem et al., 1982). Therefore, by extrapolation the introduction of a 
DSB at a target gene should increase the frequency of homologous 
recombinants generated during a gene targeting experiment. This has been 
demonstrated by Smith et al., 1995. Their study involved, placing a I-Sc el 
restriction site at the target locus. This locus was then re-targeted in the 
presence of transient expression of the I-Seel restriction enzyme. They found 
that the introduction of DSBs at the target locus by l-Scel stimulated the gene 
targeting frequency about 50-fold. Those two step strategies for gene targeting 
that involve a second replacement or exchange event would benefit from the 
incorporation of a l-Scel site within the first targeting vector. The second 
targeting event would then be more efficient due to DSBs created within the 
target sequence. The feasibility of this approach is supported by the 
observations of Brenneman et al., 1996. They studied the frequency of 
homologous recombination on a duplicated portion of the hprt gene with 
enzymes that cut within and outwith the duplicated region of the gene. 
Homologous recombination was increased 10-fold for enzymes that cut within 
the region of homology but not outwith. Therefore in conclusion, the
42
Chapter 1
introduction of DSBs at the target locus is a method by which the frequency of 
homologous recombination may be increased.
1.9.3 Cis-acting elements that influence the frequency of homologous 
recombination
In a number of distantly related organisms, certain cis-acting elements have 
been identified that influence the frequency of recombination. For example, 
the M26 sequence of Schizosaccharomyces pombe increases homologous 
recombination by introducing DSBs, (Schar et a/., 1994). Analysis of the 
recombinicity of the IgH locus indicates that an element(s) within the VH-Cm 
intron influences the rate of recombination by 10-fold. However, the 
investigators were unable to define further the genetic element(s) that was 
specifically responsible for this influence on recombination. Nevertheless, 
progress is being made towards identifying cis like elements that may be used 
in the construction of more efficient gene targeting strategies. Inclusion of 
such elements within a targeting construct may not increase initial targeting 
frequencies. However, once integrated into the chromosome their benefits may 
be realised for two step targeting systems.
1.9.4 Possible approaches to altering gene targeting frequencies
The continuing elucidation of the eukaryotic mechanism of homologous 
recombination will create opportunities for the improvement of gene targeting 
frequencies. In particular, the enzymes which mediate this process, may be 
used to increase the frequency of gene targeting. One such enzyme is the 
product of the Rad51 gene, (Plug et a l , 1996). This gene is believed to be the 
mouse homologue of the E. coli RecA gene. This enzyme has been 
demonstrated to play a central role in recombination both as a structural protein 
and as reaction catalyst, (reviewed by West, 1992). The mouse RecA 
homologue could possibly be used to increase gene targeting frequencies. The 
gene could be either transiently expressed in ES cells or its protein 
electroporated with the targeting vector into ES cells, which would hopefully 
increase the frequency of homologous integration of the targeting vector .
In addition, it may also be advantageous to introduce the targeting 
vector as ssDNA. The double strand break repair model, (Orrweaver and 
Szostak, 1983), predicts that ssDNA is essential to the homologous 
recombination process, as the reaction is initiated by the invasion of single
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strand 3' DNA end into the region of homology of the reciprocal duplex. The 
ability of single stranded DNA to participate in gene targeting in mammalian 
cells has been investigated by Fujioka et a l , 1993. They targeted the A P R T  
gene with ssDNA vectors and dsDNA vectors in CHO cells. Their results 
suggested that both types of vector target with equal efficiency. Unfortunately, 
the selection regime employed did not allow for comparison of random 
integrants to homologous integrants. Therefore, it is possible that ssDNA 
vectors target the locus with a greater efficiency than dsDNA vectors, since 
ssDNA may be more prone to cleavage and degradation by nucleases. 
Nonetheless, these results demonstrate the feasibility of using ssDNA vectors 
for gene targeting. In combination with cis and trans  components of the 
mammalian recombination machinery they may provide methods for more 
efficient gene targeting procedures in ES cells. Moreover, the elucidation of 
the critical factors for homologous recombination may alleviate the need to use 
laborious selection procedures for ES cells altogether. Further development of 
cell transfection methods combined with more efficient gene targeting 
procedures, could possibly create systems whereby gene targeting would be 
achievable at the mouse embryo stage, therefore circumventing the need to use 
ES cells at all.
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2.1 Introduction
The chapter is divided into four main sections for convenience: general 
information, (2.2); Growth, M aintenance, and Storage of E .co li and 
bacteriophage X, (2.3); DNA molecular biological techniques, (2.4); and 
general ES cell culture methods, (2.5).
2.2 General Information
2.2.1 Chemicals and biochemicals
It is not practical to list every supplier of every chemical or reagent used in this 
thesis. However, an attempt has been made to list all those most commonly 
used. Furthermore, when a particular reagent is deemed to be crucial to the 
success of an experiment the supplier will be indicated within the text.
Antibiotics were obtained from Sigma Chemical Co. (Poole, UK). 
Bactotryptone, yeast extract and Bactotryptone (agar) were obtained from 
Difco (Oxford, England).
General chemicals of analytical grade, biochemicals, and organic solvents were 
obtained from one of the following suppliers: BDH Chemicals Ltd., (Poole 
UK); Formachem Ltd., (Strathaven, Scotland); FSA Laboratory Supplies, 
(Loughborough, UK); Koch-Light Ltd., (Haverhill, UK); Sigma Chemical Co., 
(Poole UK).
Oligonucleotides were synthesised on an Applied Biosystems Model 280A 
DNA synthesiser at the Institute of Genetics, University of Glasgow, using 
reagents from Cruachem, (Science Park, Glasgow).
All restriction enzymes, T4 DNA ligase, and T4 Polynucleotide kinase were 
obtained from BRL and Promega Corporation.
The sequencing kit used was the Sequenase™  sequencing kit (USB 
Biochemicals, La Jolla, Ca., USA).
Cuvettes for electroporation were supplied by Bio-Rad
Nucleon I DNA extraction kit: Scotlab, Kirkshaws Road, Coatbridge,
Strathclyde, Scotland, ML5 8 AD.
QIAEX Gel Extraction Kit: Qiagen Inc., 9259 Eton Avenue, Chatsworth, CA 
91311, USA.
Plastic pipettes 1 ml, 5 ml, 10 ml, 25 ml, for ES cell culture, (Bibby Sterilin Ltd, 
Staffordshire, England.
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Plastic flasks for ES cell culture: Coming Inc. Coming, NY 14831, USA.
The various constituents for ES cell medium were obtained from BRL (Gibco 
Ltd. Paisely, Scotland), with the exception of foetal calf serum for CGR8  and 
CGR8 .8 , (selected batches from Globerpharm Surrey).
2.2 .2  Bacterial strains
Strain Genoype Reference/Source
Escherichia coli strains
LE392 Lsdr514(r k">mk+) supE44 supF58 
LacY galKZ galT22 metBl trp55 
mcrA.
Borck et al., 
1976.
DH5a F"> supE44 lacU169 (f801acZ M15) 
hsdR17 (r k",rnk+) recAl endAl 
gyrA96 thi-1 relAl D(lacZYA-arg¥), X~
Hanahan et al., 
1983.
DH1 OB F~ mcrA D(mcr-hsd RMS-mcrBC) B io-Rad
f80d lacZDM15 Dlac X74 deo RecAl 
end A l ara D139 D (ara, leu) 7697 
gal U gal K At rpsh hupG
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2.2.3 Plasmid and bacteriophage vectors
Plasmid Description Reference/Source
pBluescript 
H SK+/“
TM Cloning vectors Mead et a l , 
1985
Stratagene USA
pGem 3 ,5Zf(+), 
+llZf(-),9Zf(-)
Cloning vectors Promega
Corporation
prNTR2
p2.8B
p4.5B
pN T
The rat NTR cDNA cloned into 
pBluescript II KS(+).
A 2.8 kb BamHl fragment of the 
NTR gene subcloned from the X 
cedi clone into pBluescript II SK_.
A 4.5 kb BamHl fragment of the 
NTR gene subcloned from the X 
ced5 clone into pBluescript II SK‘.
Insertion vector used for the 'Hit 
and Run' procedure. It contains 
a thymidine kinase and a neomycin 
cassettes.
Tanaka, et al., 
1990
Chapter 3
Chapter 3
Hasty et al., 
1991a
pKLF A mutated 2.8 kb BamHl fragment 
of the NTR gene inserted into pNT.
Chapter 4
pNeo A neomycin cassette (XhoUXbal Chapter 5
fragment from pNT) cloned into the 
HincU site of pBS™ B SK"-
4 8
Chapter
pTK A thymidine kinase cassette, (Hindlll
/EcoRl fragment from pNT), cloned 
into pGem 9Zf(-) plasmid.
p9.2EiG7 A 9.2 kb EcoRl fragment of NTR
gene subcloned from the 1 T 1 2  
clone into the pGem 7Zf(-) plasmid.
p4.8EiG7 A 4.8 kb EcoRl fragment of NTR
gene subcloned from the 1 T 1 2  
clone into the pGem 7Zf(-) plasmid.
p9.2EiL A deletion of the 1.5 kb Ncol
fragment from p9.2EiG7 plasmid 
and insertion of a Sail linker.
p9.2EiNeo A neomycin cassette from pNeo
subcloned into the Sail linker site
of the p9.2EiL plasmid.
p9.2EiNeoTK The EcoRl fragment of p9.2EiNeo
subcloned into the EcoRl site of 
pTK to generate a replacement vector.
pX650 A 650 bp Xhol 5' fragment of the
NTR gene, subcloned into the 
pBS SKH-.
p9.2EiNeoC The EcoRl fragment of p9.2EiNeo 
subcloned into the pTK plasmid to 
generate a control replacement 
type vector.
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Bacteriophage Description Reference/Source
X DASH mouse 
genomic library
Genomic DNA derived 
from E14 ES cells
Dr. J. Rossant
X EMBL3 Mouse Genomic DNA derived
genomic library from adult liver of the
Balb/c mouse line. Average 
insert size of 15 kb.
Clontech
laboratories
Inc.
2.3 Growth, maintenance and storage of E.coli and bacteriophage X
2.3.1 Media for propagation of E.coli
The most common suppliers for the following media were BDH Chemicals 
Ltd.; Sigma Chemical Co. Ltd. and Difco Laboratories, (Detroit, Michigan, 
USA).
L-broth
1% (w/v) tryptone, 0-5% (w/v) yeast extract, 0*5% (w/v) NaCl, 0-1% (w/v) 
glucose, 0*002% (w/v) thymine, made up in distilled water and adjusted to pH 
7*0 with NaOH.
L-agar
As L-broth, but without glucose and with the addition of 1*5% (w/v) bacto- 
agar.
2X YT medium
1*6% (w/v) bacto-tryptone, 1% (w/v) bacto-yeast extract, 0*5% (w/v) NaCl, 
made up in distilled water and adjusted to pH 7*0 with NaOH.
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SOC medium
2% bacto tryptone, 0.5% Bacto yeast extract, 10 mM NaCl, 2.5 mM KC1, 10 
mM MgCl, 10 mM MgSC>4 , 20 mM glucose
Top agar
As L-agar, but with only 1 % (w/v) bacto agar.
Top agarose
As L-Agar, but with 0-65% agarose.
NZCYM medium
To 950 ml of dH2 0  add 10 g of NZ amine, 5 g of NaCl, 1 g casamino acids, 2 g 
MgS0 4 -7 H2 0 , adjust to pH 7.0 with 5 M NaOH and finally adjust volume to 1 
litre with dH2 0 .
2.3.2 Growth of E.coli
Liquid cultures of E. coli strains from which plasmids were to be isolated 
were grown in L broth with the appropriate antibiotic selection, (typically 
ampicillin at 100 mg/ml). For the preparation of electro-competent cells, liquid 
cultures of E. coli DH5a or DH10B were grown in L-broth with no antibiotic 
selection. The volume of broth inoculated depended on the quantity of 
plasmid required. Routinely, 3 ml and 100 ml cultures were used for small and 
large scale plasmid preparations, (sections 2.3.8 and 2.3.9 respectively). All 
cultures were incubated at 37°C in an orbital shaker at 250 rpm.
2.3.3 Storage of E.coli
E.coli strains were stored in glycerol at -70°C. A 1 ml aliquot of an overnight 
culture was mixed with an equal volume of 1 0 0 % glycerol, and snap frozen in 
liquid N2 . The strains were revived by scraping the surface of the frozen 
suspension with a sterile inoculating loop and streaking onto a L-agar plate to 
isolate single colonies.
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2.3.4 Antibiotic selection and indicators
When necessary ampicillin, the only antibiotic used for bacterial work in this 
study, was used at a final concentration of 1 0 0  (Xg/ml, (the stock was stored at 
-20°C at a concentration of 20 mg/ml in sterile water). Where possible the 
selection of recombinant clones was aided by the use of X-gal and IPTG to 
indicate the disruption of the lacZ gene present in many of the plasmids used 
in this study. Typically when the lacZ  gene is disrupted the resulting 
recombinant clones appear as white colonies as opposed to the blue non 
recombinant colonies. X-gal was dissolved in dimethylformamide and IPTG 
was dissolved in sterile water. Both solutions were stored -20°C at a stock 
concentration of 2 0  mg/ml and used at a final concentration of 2 0  pg/ml.
2.3.5 Sterilisation
All growth media and glassware were sterilised by autoclaving at 121 °C for 15 
minutes. Buffer solutions were autoclaved at 108°C for 8 minutes. Plastic 
ware was autoclaved at 121°C for 9 minutes. Heat sensitive reagents were 
sterilised by filtration using membrane filters of 0.45 Jim pore size, (Millipore).
2.3.6 Preparation of electro-competent E.coli
The preparation of these cells was essentially as described by Dower D. J.. 
(Bio-Rad Laboratories), with the exception of centrifuge times being reduced 
to 7 minutes. Furthermore, all plasticware was washed thoroughly by steeping 
in sterile distilled water overnight to remove any traces of detergent and pre­
chilled on ice prior to use. The E.coli strains DH5a and latterly DH10B were 
used for this procedure.
2.3.7 Transformation of E.coli by electroporation
This was performed according to the manufacturers instructions using a Bio- 
Rad Gene Pulser® with the following alterations. The electroporation cuvette 
size used was 0.1 cm, (Bio-Rad), and the apparatus was set at 25 jiF 
capacitance, 1800 V and the pulse controller unit set at 200 £2. If SOC
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medium was not available for the re-suspension of cells then 2X YT medium 
was used supplemented with glucose to a final concentration of 20 mM.
2.3.8 Small scale plasmid preparation
Small plasmid preparations or 'mini-preps' were performed according to the 
'Wizard mini-prep1 procedure, (Promega). The procedure is similar to the 
alkaline lysis method, (Sambrook et al., 1989). The primary difference is that 
no phenol-chloroform or ethanol precipitation steps are required. Instead the 
'Wizard mini-prep' procedure employs a silica-based binder to selectively 
remove the plasmid DNA from solution as an alternative. The solutions used 
were that of the alkaline lysis method i.e. solutions BDI, BDII, and BDIII, 
(section 2.4.1). The yields for a high copy number plasmid were typically 3-5 
jug per ml of culture.
2.3.9 Large scale plasmid preparation
Large plasmid preparations were performed according to the 'Wizard midi- 
prep' procedure, (Promega). This is similar to the procedure outlined above; 
however, volumes of 1 0 0 - 2 0 0  ml of bacterial culture can be processed as 
opposed to 3 ml.
2.3.10 'One Step' plasmid preparation
1 ml of culture was pelleted by centrifugation at 1 2 0 0 0  rpm for 2  min and 
resuspended in 200 p i of FSB solution, (1 ml 10% SDS and 2 ml of 10X 
loading buffer in 8 ml of distilled water). The cell pellet was resuspended by 1 
min of vigorous vortexing and allowed to stand on the bench for a further 15 
min. Samples were then centrifuged at 12000 rpm for 20 min. After which 10- 
2 0  pi of the supernatant was carefully removed for further analysis by agarose 
gel electrophoresis,, (section 2.4.6).
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2.3.11 Storage of bacteriophage lambda
High titre bacteriophage lambda library stocks and single clone isolates were 
maintained in phage buffer at 4°C. Lambda plugs from primary secondary or 
tertiary rounds of library screening were also stored at 4°C in 1 ml phage 
buffer with 50 jil of chloroform. Long term storage of lambda at -70°C was 
achieved by supplementing the phage buffer with 7% DMSO prior to storage. 
Lambda library plates, sealed in plastic bags, were also stored at -70°C after 
the plaque lawn had been overlaid with Whatman 3 MM paper impregnated 
with 60% glycerol in phage buffer.
2.3.12 Preparation of lambda plating cells
An overnight culture of the E.coli strain LE392 was grown from a single 
colony. A 1:100 dilution of the culture was made with LB-broth and grown 
for approximately 3 hours to an OD6 oonm of 0.5. The culture was then 
centrifuged at 4000 rpm. for 10 min at room temperature. The cells were then 
resuspended in 10 mM MgSC>4 to an OD600 = 2. These cells can be stored at 
4°C for up to 1 week with little loss of viability.
2.3.13 Plating bacteriophage lambda to determine titre
The method used was that detailed in Ausbel et al., 1990, with minor 
modifications. It was necessary to make serial dilutions of phage lysates to 
determine the titre of the stock phage. Typically 10-fold dilutions were made, 
of which 10 (il were added to 200 jil of LE392 plating cells, (section 2.3.12), 
and incubated at 37°C for 20 min. The cell phage mix was then added to 3 ml 
of top agar pre-melted to 48°C and spread onto LB bottom agar plates, (82 
mm in diameter), pre-warmed to 37°C. After 6  to 8  hours of incubation at 
37°C visible plaques formed, thus allowing the viable number of phage in the 
starting stock to be calculated.
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2.3.14 Liquid lysates
Liquid lysates were performed by infection of bacteria at high multiplicity of 
infection. Typically, 5 j l l I  of a high titre stock, (section 2.3.15), was incubated 
with 200 |il of plating cells, (section 2.3.12), at 37°C for 20 min. The phage 
cell mix was then added to 50 ml of pre warmed NZCYM medium in a 250 ml 
flask, and incubated with vigorous shaking at 37°C for up to 6  hours. 1 ml of 
chloroform was added to the resulting lysed culture and incubated for a 
further 1 0  min.
2.3.15 Plate lysates and high titre stocks
Prior to making plate lysates it was necessary to determine the titre o f the 
phage stock, (section 2.3.13). Approximately 1 X 105 p.f.u are mixed with 
500 pi of plating cells, (section 2.3.12), and incubated at 37°C for 20 min. The 
phage cell mix was added to 5 ml of top agar pre melted to 48°C, and spread 
onto bottom LB-agar plates, (10 cm x 10 cm), pre warmed to 37°C. Plaques 
will be visible after 6 - 8  hours but were typically left to grow for 1 0  hours until 
they reached confluence. Then 5 ml of phage buffer was added and the 
phage allowed to elute overnight. The remaining phage buffer, (1-2 ml), was 
collected and stored as a high titre stock, (section 2.3.11).
2.3.16 Plating bacteriophage lambda libraries and transferring to filter 
membranes
The methods used were essentially those detailed in Ausbel et al., 1990, with 
minor modifications. Bacteriophage were plated at high density on to LB- 
agar plates and replica copies of the plates were transferred on to nylon 
membranes. The filter membranes were processed to fix the lambda DNA and 
subsequently screened by nucleic acid hybridisation to identify homologous 
clones.
Prior to plating the library it was necessary to determine the 
titre of the library by serial dilution as described in section 2.3.13. The library 
was plated on to large 245 mm X 245 mm plates (Nunc), containing 400 ml of 
bottom LB agar, dried in a 37°C incubator and pre incubated to 37°C. The 
phage were then mixed with 2 ml of plating cells, (section 2.3.12), allowed to
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adhere at 37°C for 20 min, mixed with 30 ml of top agar/agarose 0.65% (w/v) 
and plated to give 100,000 p.f.u./plate. A total of 10 plates were used to allow 
1 X 106 p.f.u. to be screened. The plates were then incubated at 37°C for 8 - 
1 2  hours in an inverted position until plaques were visible but not confluent. 
The plates are then incubated at 4°C for at least 1 hour prior to making filter 
lifts.
Bacteriophage were then transferred onto Hybond-N 
nylon filters, (Amersham), by placing the filter directly on to the surface of the 
cold plate and allowing the phage to absorb for 1 min. During this time the 
orientation of the filters was recorded by piercing the filters/LB-agar at several 
asymmetrical points with a 20-G needle that had been dipped in Indian ink. 
The second filter was applied to the phage for 2 minutes and pierced with a 
needle at exactly the same positions. The resulting filters were then allowed 
to dry at room temperature for 10 min and placed phage side up onto 3 MM 
paper saturated with 0.2 M denaturing solution for 7 min. The filters were 
then transferred sequentially to 3 MM paper soaked with neutralising 
solution, (twice), and 2X SSC for 3 min each. The filters are then baked in a 
oven at 80°C for 2 hours and stored in a dry environment at room 
temperature.
2.3.17 Small scale preparation of lambda DNA
Liquid lysates were prepared as described in section 2.3.14. 1.6 pi of liquid 
lysate was centrifuged at 10000 rpm for 5 min. The supernatant was removed 
to a fresh tube and treated with 3 p i of DNase/RNase, (20 mg/ml each), at 
37°C for 30 min. Precipitation of the phage particles was achieved by adding 
400 pi of PEG solution (30% PEG, 3 M NaCl), mixed by inversion and placed 
on ice for 1 hour. The phage particles were pelleted by centrifuging at 12000 
rpm for 20 min. The supernatant was removed and the remaining pellet was 
resuspended in 340 p i of reagent B, (400 mM Tris-HCl pH to 8.0 using 2M 
NaOH, 60 mM EDTA, 150 mM NaCl, 1% SDS). 2 m l of 10 mg/ml RNase A 
was added and incubated at 37°C for 15-20 min. A 100 p i of 3M sodium 
perchlorate was added to each tube and incubated at 37°C for 20 min with 
occasional inversion. Samples were then incubated for a further 20 min. at 
65 °C with occasional inversion. 580 pi of chloroform chilled on dry ice was 
added, and the samples rotary mixed at room temperature for 2 0  min. 
Centrifugation at 12000 rpm for 20 min was followed by the removal of the
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supernatant to a fresh microfuge tube and the above chloroform step was 
repeated. 2 volumes of 100% ethanol, about 750 pi, were added to the 
supernatant to precipitate the DNA. Samples were subsequently centrifuged 
at 12000 rpm for 10 min. Supernatants were removed and 500 p i of 70% 
ethanol was used to wash each pellet followed by a 12000 rpm. spin for 5 min. 
Again supernatants were removed and the DNA pellets allowed to dry at room 
temperature. The DNA's were resuspended in 60 p i of H2 O. 5 pi of each 
sample was used to check the integrity and estimate the concentration of 
DNA by agarose gel electrophoresis, (section 2.4.6).
2.3.18 Large scale preparation of lambda DNA
The large scale preparation of lambda DNA was achieved by adapting the 
method detailed above, (section 2.3.17). 16 ml of liquid lysate was centrifuged 
at 10,000 rpm for 5 min. The supernatant was removed to a fresh tube and 
treated with 50 m l of DNase/RNase, (20 mg/ml each), at 37°C for 30 min. 
Precipitation of the phage particles was achieved by adding 400 p i of PEG 
solution, (30% PEG, 3 M NaCl), mixed by inversion and placed on ice for 1 
hour. The phage particles were pelleted by centrifuging at 12000 rpm for 20 
min. The supernatant was removed and the remaining pellet was resuspended 
in 680 ml of reagent B, (400 mM Tris-HCl pH to 8.0 using 2 M NaOH, 60 mM 
EDTA, 150 mM NaCl, 1% SDS). 5 pi of 10 mg/ml RNase A was added and 
incubated at 37°C for 15-20 min. A 200 pi of 3 M sodium perchlorate was 
added to each tube and incubated at 37°C for 20 min with occasional 
inversion. Samples were then incubated for a further 20 min at 65°C with 
occasional inversion. 650 ml of chloroform chilled on dry ice was added, and 
samples rotary mixed at room temperature for 20 min. Centrifugation at 12000 
rpm for 2 0  min was followed by the removal of the supernatant to a fresh 
microfuge tube and the above chloroform step was repeated until no debris 
was observed at the interface. 2 volumes of 100% ethanol, about 1.5 ml, were 
added to the supernatant to precipitate the DNA. Samples were subsequently 
centrifuged at 12000 rpm for 10 min. Supernatants were removed and 500 m l 
of 70% ethanol was used to wash each pellet followed by a 12000 rpm spin 
for 5 min. Again supernatants were removed and the DNA pellets allowed to 
dry at room temperature. The DNAs were re-suspended in 100 pi of H2 O. 2 
ml of each sample was used to check the integrity and estimate the 
concentration of DNA by agarose gel electrophoresis, (section 2.4.6).
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2.3.19 Picking and processing of phage plugs
Positively identified plaques were picked for further processing using cut 
sterile 1 ml micropipette tips. Firstly, 1.5 cm of the tip was removed using a 
heated scalpel blade. The wide bored tip was accurately forced into the 
library plate at the point indicated by the positive signals on the replica filters, 
(the filters were aligned by their asymmetric ink marks to the phage plates 
with the aid of a light box). The phage agar plug was recovered and placed in 
a 1 .6  ml microfuge tube with 1 ml of phage buffer and 60 |il of chloroform. 
The phage were allowed to elute from the plugs at room temperature for at 
least 4 hours.
2 .3 .4  D N A  m olecu lar  b io log ica l techn iqu es
2.4.1 Commonly used Buffers 
TE buffer (lOx)
100 mM Tris-HCl pH 8  0,10 mM EDTA.
TAE buffer (50x)
242g Tris-HCl, 57.1 ml glacial acetic acid, 37.2g of Na2EDTA-2 H2 0 , in 1 litre 
distilled water, pH adjusted to 8-5 with glacial acetic acid.
T B E  b u ffer  (lO x)
10*9% (w/v) Tris, 5*5% (w/v) boric acid, 0-93% (w/v) Na2EDTA.2H20  pH 
adjusted to 8 .0 , in distilled water.
Agarose gel loading buffer (lOx) pH 7*4
0*5% (w/v) bromophenol blue, 0-05% (w/v) xylene cyanol, 50% (w/v) Ficoll, 
1% (w/v) SDS, 100 mM EDTA.
1 Hind  HI DNA markers
1 DNA cleaved with H ind lll generating 8  fragments, 23.1 kb to 125 bp, 
(Boehringer Manheim).
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1 kb DNA Marker
Mixture of 1018 bp fragment, its multimeres and pBR322 fragments. A total of 
23 fragments, from 12216 bp to 756 bp. (Boehringer Manheim).
Denaturing solution
1-5 M NaCl, 0-5 M NaOH.
Neutralising solution
1-5 M NaCl, 0-5 M Tris-HCl pH 7.4.
Birnboim Doly I (BDI) solution
50 mM glucose, 25 mM Tris-HCl pH 8  0,10 mM EDTA.
Birnboim Doly II (BDII) solution
0-2 M NaOH, 1% (w/v) SDS which was stored in a plastic container.
Birnboim Doly m  (BDIII) solution
5 M KOAc pH 4*8; prepared by mixing equal volumes of 3 M CH3COOK and
2 M CH3COOH.
SSC (20X)
3 M NaCl, 0*3 M tri-sodium citrate, pH 7-0.
SSPE (20X)
175.3 g NaCl, 27.6 g NaH2P0 4 , 7.4 g EDTA, in 800 ml H2O, pH adjusted to 7.4 
with 10 M NaOH, final volume adjusted to 1 litre.
Denhardt's solution (100X)
2% (w/v) Ficoll 400, 2% (w/v) polyvinylpyrrolidone, 2% (w/v) bovine serum 
albumin, (Pentax Fraction V), filtered and stored at -20°C.
Phage Buffer
20 mM Tris-HCl pH 7.4,100 mM NaCl, 10 mM M gS04.
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2.4.2 Quantification of DNA
DNA concentrations were calculated by spectrophoretically measuring the 
OD at 260 nm. At this wavelength an OD = 1 corresponds to a concentration 
of 50 pg/m l for double stranded DNA and approximately 33 pg/m l for 
oligonucleotides. However, when necessary a more accurate estimation of 
oligonucleotide concentration can be calculated using extinction coefficients 
as described by Sambrook et al.. 1989. When samples had limiting quantities 
of DNA< 200 ng, then a small portion of the sample was run on a 1% (w/v) 
agarose gel containing EtBr, (0.5 mg/ml), with known DNA concentration 
standards. The gel was then photographed, (section 2.4.8), and by comparing 
the intensity of fluorescence of the sample to the known standards, an 
estimation of DNA concentration was made.
2.4.3 Preparation of genomic DNA from ES cells
Genomic DNA was prepared by a method similar to the 'Nucleon I' DNA 
extraction kit method of Scotlab. The following method is optimised for the 
extraction of DNA from the confluent wells of a 24 well tissue culture plate. 
Each well of the 24 well plate was washed twice with IX  PBS. Cells were 
then trypsinised with 100 pi TVP (section 2.5.2) for 3 minutes. 1 ml of ES cell 
growth medium (section 2.5.2) was added to each well. The cell suspension 
was placed in a 1.6 ml microfuge tube and centrifuged at 2000 rpm. for 5 min. 
The cell pellets were resuspended by gentle vortexing in 340 j l l I  of reagent B 
(400 mM Tris-HCl pH to 8.0 using 2 M NaOH. 60 mM EDTA. 150 mM NaCl. 
1% SDS). 2 pi of 10 mg/ml RNase A was added and incubated at 37°C for 15- 
20 min. A 100 p i of 5 M sodium perchlorate was added to each tube and 
incubated at 37°C for 20 min with occasional inversion. Samples were then 
incubated for a further 20 min at 65°C with occasional inversion. 580 p i of 
chloroform chilled on dry ice, was added and samples rotary mixed at room 
temperature for 20 min. Centrifugation at 12000 rpm. for 20 min was followed 
by the careful removal of the supernatant to a fresh microfuge tube and the 
above chloroform step was repeated. This time 2 volumes of 100% ethanol, 
(750 pi), were added to precipitate the DNA which was obvious upon 
inversion of the tubes. Samples were subsequently centrifuged at 12000 rpm. 
for 10 min. Supernatants were carefully removed and 500 pi of 70% ethanol 
was used to wash each pellet followed by a 12000 rpm. for 5 min spin. Again,
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supernatants were removed and the DNA pellets allowed to dry at room 
temperature. The DNAs were resuspended in 60 jil of H2 O; to help 
resuspension, samples were placed at 65°C for 10 min or alternatively placed 
at 4°C overnight. Subsequently, 20 |il of each sample was used for restriction 
digestion as this volume typically contained approximately 10 (ig of DNA.
2.4.4 Preparation of genomic DNA from tissue
It was necessary to isolate genomic DNA from rat and mouse livers. The 
method used was essentially that detailed in Sambrook et al., 1989, ’Protocol 
I'. This procedure is based on a method first reported by Blin and Stafford, 
1976.
2.4.5 Restriction enzyme digestion
Restriction enzymes were used according to the manufacturers instructions 
with the appropriate buffer unless otherwise specified in the text. For 
restriction digests, a 2-3 fold excess of enzyme was used i.e. 2-3 units/|Hg of 
DNA with the enzyme concentration not exceeding 1/20 of the total reaction 
volume. Digestions were incubated at 37°C for 1 hour in the case of plasmid 
or lambda DNA, however for genomic DNA incubation times were increased 
to 3 hours.
2.4.6 Agarose gel electrophoresis
DNA was electrophoresed on agarose gels of a concentration range of 0.5% 
to 2%, depending on the size of the fragments to be resolved using a IX  TBE 
buffer, (Sambrook et al., 1989). The applied voltages depended on fragment 
sizes being analysed and duration of running time, however they did not 
exceed 10 V/cm. It was necessary to use low melting point agarose gels for 
DNA band isolation. Therefore IX TAE buffer was used and the gels were 
electrophoresed at 4°C in the cold room. All agarose gels contained 0.5 |Lig/ml 
EtBr for the visualisation of DNA, (section 2.4.8).
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2.4.7 Polyacrylamide gel electrophoresis for sequencing
Sequencing reactions were prepared as detailed in section 2.4.16. The 
products were separated on denaturing polyacrylamide gels; 6 % (w/v) 
acrylamide (N, N'-methyleneisacrylamide, 19:1), 7 M urea, in IX TBE. 
Acrylamide polymerisation was achieved by the addition of 1 ml of 10% (w/v) 
am m onium  persu lphate  and 25 jll 1 o f TEM ED ( N ,N ,N 'N ', 
-tetramethylenediamine) to 100 ml of acrylamide/urea mix. The gels were 
poured and run on the IBI 'Base Runner' sequencing apparatus according to 
the manufacturers specifications. Gels were pre-run at 60 watts for 30 min. 
prior to the addition of the samples and subsequently run at 60 watts for the 
required length of time. Gels were finally transferred to 3 MM Whatman 
paper and dried at 80°C under vacuum for 1 hour prior to autoradiography, 
(section 2.4.25).
2.4.8 Gel visualisation and photography
All agarose gels contained 0.5 |Lig/ml of EtBr for visualisation of double 
stranded DNA. However, if further staining of gels was required then they 
were placed in IX TBE containing 0.5 pg/ml of EtBr for 15 min after which 
they were washed in IX TBE for 10 min. The DNA bands could then be 
visualised by fluorescence under a 254 nm or 302 nm transilluminator. Gels 
were photographed using a Polaroid camera loaded with type 667 land film 
fitted with a Kodak Wratten filter No. 23A. Alternatively a picture image 
could be made using a Mitsubishi video copy processor attached to a UVP 
video camera, fitted with a Kodak Wratten filter No. 23A.
2.4.9 Purification of DNA from LMP gels
Purification of DNA from LMP gels was achieved using the 'QIAEX Gel 
Extraction Kit' from Qiagen, based on principles first reported by Vogelstein et 
a l., 1979. Typically, DNA fragments were separated on 1% LMP gels and 
processed as described in sections 2.4.6 and 2.4.8. The DNA bands were then 
excised from the gels using sterile scalpel blades and placed in 1 .6  ml 
microfuge tubes. The gel slices were then processed according to the 
manufacturer's instructions. Briefly the gel slices were placed in solubilisation
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buffer at 50°C with 10 |il  of DNA binder. This buffer contains a high 
concentration of sodium perchlorate which not only facilitates solubilisation 
but binding of DNA molecules to the silica particles due to the high salt 
concentration. The bound DNA is then washed in a high salt, ethanol 
containing buffer. The pellet is then allowed to dry and the DNA eluted from 
the silica gel particles using H2O.
2.4.10 Ligation of double-stranded DNA
The ligation of double-stranded DNA molecules was performed as described in 
the Promega Protocols and Application Guide, (Promega). Typically about 
200 ng of vector and a vector to insert molar ratios of 1:1 and 1:3 were used 
for ligations. Most ligations in this study also used vectors which had been 
dephosphorylated as selection of recombinant clones using X-gal/IPTG 
selection, (section 2.3.4), was often not an option. Unlike the Promega 
protocols, Shrimp Alkaline Phosphatase, (SAP, (USB Biochemicals)), was used 
as opposed to Calf Intestinal Alkaline Phosphatase (CIAP), as detailed by the 
supplier. SAP is reliably inactivated at 65°C for 15 min unlike CIAP. The only 
other major modification was that the transformation of E. coli was achieved 
by electroporation, (section 2.3.7). The ligations were performed overnight at 
16 °C, unless otherwise stated.
2.4.11 Exonuclease III deletion library
This procedure was performed essentially as detailed in Promega Protocols 
and Application Guide, (Promega), with minor modifications. The method is 
based on the procedure developed by Henikoff et al., 1984. The Exonuclease 
III enzyme is used to digest double stranded DNA from a 5' protruding or 
blunt end, while leaving a 4 base or larger 3' overhang intact. Alternatively, 5’ 
protruding overhangs can be protected from digestion by incorporating a -  
phosphorothioate deoxynucleotide derivatives onto the overhang. The 
doubly cut linear molecule can now be subjected to progressive Exo III 
digestion from the blunt or 5' overhang closest to insert while the 3f or 5' 
protected end will remain resistant to Exo III digestion. Samples of the 
digesting DNA of study are removed at convenient time points since digestion 
proceeds at a rate of 450 bp/min when incubated at 37°C. These samples are
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then subjected to SI nuclease digestion to remove the single-stranded DNA 
generated by Exo III digestion. Klenow DNA polymerase was added to 
generate blunt ends which are then ligated to circularise the plasmids. The 
resulting ligations are then transformed into E.coli. producing a variety of 
colonies containing different sized subclones.
2.4.12 Generation of template DNA for exonuclease m  digestion
10 mg of supercoiled plasmid was prepared as described in section 2.3.7. A 
S a il  restriction digest was performed as described in section 2.4.5. 
Completion of digestion was checked by agarose gel electrophoresis, (section 
2.4.6). The resulting 5' protruding end had to be protected using a -  
phosphorothioate, (thio), base derivatives. Therefore, thio base derivatives of 
dATP and dGTP along with normal dCTP and dTTP were added at a final 
concentration of 10 mM and incubated at 30°C for 30 min in the presence of 
10 U/ml Klenow DNA polymerase, (Boehringer), to fill in the 5' overhang. The 
completed digest and fill in reactions were subjected to phenol-chloroform 
extraction and isopropanol precipitation, (sections 2.4.30 and 2.4.29 
respectively). The DNA was then re-suspended in EcoRl restriction enzyme 
buffer and digested for 1 hour. However, an aliquot (200 ng) of single cut 
DNA was retained for a test Exo III digestion. The completed digest was 
subjected to phenol-chloroform extraction followed by ethanol precipitation, 
(sections 2.4.30 and 2.4.29 respectively). The DNA was resuspended in 60 pi 
of IX Exo m  buffer, (10X: 660 mM Tris-HCl pH 8.0,1 mM EDTA).
2.4.13 Exonuclease III test digestion
The single enzyme cut thio protected template DNA and the double enzyme 
cut template DNA were subjected to Exo III test digests. 200 ng of each DNA 
in 10 \iX IX  Exo m  buffer, (10X 660 mM Tris-HCl pH 8.0,1 mM EDTA), with 
50 units of Exo III were incubated for 15 min at 37°C. The reaction products 
were then checked by agarose gel electrophoresis, (section 2.4.6). The 
protected thio filled template should remain resistant to digestion but the 
double cut template appears as a smear as a result of digestion.
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2.4.14 Exonuclease III digestion and SI nuclease digestion
The DNA template in 60 pi of IX Exo III buffer was pre warmed to 37°C. The 
digestion was started by the addition of 750 units Exo III and allowed to 
incubate at 37°C. At 40 s intervals 2.5 p i samples of the reaction were 
removed and placed into 1 of the 17 microfuge tubes on ice containing 7.5 ml 
of SI mix, (45 mM KOAC pH 4.6, 350 mM NaCl, 1.3 mM ZnSC>4 and 7% 
glycerol), and 2 Units of SI nuclease. All the samples were then incubated at 
room temperature for 20 min. The reactions were stopped by adding 1 j l l I  SI 
stop buffer, (0.3 M Tris base 0.05 M EDTA), and incubated at 70°C for 10 
min.
2.4.15 Ligation and transformation of Exo III deletions
All time point samples received 1 pi of Klenow mix, (30 pi Klenow buffer (20 
mM Tris-HCl pH 8.0, 100 mM MgCl2 ) and 3-5 Units Klenow DNA 
polymerase), and were incubated at 37°C for 10 min in the presence of 1 pi of 
the dNTP mix, (0.125 mM each of dATP, dTTP, dCTP, and dGTP). The 
ligations were then performed using 4 pi of each Klenow reaction combined 
with 20 p i of ligation mix (IX  Promega ligase buffer, 5% PEG, 1 mM DTT 
5U/ml T4 ligase). Samples were then incubated at room temperature for 3 
hours and 2 p i of each reaction was used for transformation into D H 5a, 
(section 2.3.7).
2.4.16 Double-stranded DNA sequencing
DNA sequencing reactions were performed using the Sequenase version 2.0 
kit exactly as described by the manufacturers, (USB Biochemicals). 5 pg of 
double stranded plasmid was used as the template and was prepared as 
described in section 2.3.8.
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2.4.17 End-labelling of oligonucleotides using T4 kinase
The radioactive labelling of oligonucleotides was catalysed by bacteriophage 
T4 polynucleotide kinase using y32P ATP as a label. The reaction was 
performed in a total reaction volume of 1 0  p i containing 1 0  pmoles of 
oligonucleotide, 30 pCi of y32P ATP at 3000 Ci/mmole, 10 units T4 kinase in 
IX  T4 kinase buffer, (50 mM Tris-HCl pH 8.0,10 mM MgCl2 , 5 mM DTT, 0.1 
mM spermidine). The reaction was stopped by adding 1 pi of 0.5 M EDTA. 
Purification of labelled oligonucleotide from unincorporated label was 
achieved by gel filtration, (section 2.4.19).
2.4.18 Random priming DNA templates
The random priming method for DNA labelling was performed using a 
Random Primed DNA Labelling Kit, (Boehringer). The labelled DNA is 
synthesised with the klenow enzyme after the hybridisation of all possible 
combinations of random hexanucleotides to the denatured DNA template. 
Typically 25 ng of template was combined with 50 pCi of a 32P dCTP (3000 
Ci/mmole) to produce probes with a specific activity of 1-1.5x10^ dpm/pg. 
The labelled templates were purified from unincorporated a 32P dCTP by gel 
filtration section, (2.4.19).
2.4.19 Purification of radioactive probes
Sephadex G-50 and G-25 columns, (Pharmacia), were routinely used to purify 
radioactively labelled random primed and end-labelled oligonucleotide probes 
respectively. This method uses gel filtration chromatography to separate 
labelled molecules from unincorporated 32P label. The columns were 
equilibrated with 1 ml of IX  TE prior to use. The probe reactions with 50 pi of 
bromophenol blue, (0.05% w/v), were loaded directly onto the column and 
100 p i aliquots of IX  TE were added to run the sample in. A further 1.5 ml of 
IX  TE was added, allowing the column elutant to be collected in 3 drop 
samples. The labelled probe was present in the blue dye fraction with the 
unincorporated 32P being present in later fractions.
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2.4.20 Preparation of non-radioactive probes
Non-radioactive probes were also produced using the random priming method 
detailed in section, (2.4.18), except that dideoxygenin-ll-dUTP was used 
instead of a 32P dCTP. The probed filters were processed according to the 
manufacturer's protocols, (Boehringer).
2.4.21 Southern blotting by capillary transfer
Southern blotting was performed as described by Sambrook et al. 1989, this 
method was first reported by Southern et al., 1975. The gels were prepared 
for transfer by sequentially soaking for 1 hour in denaturing solution, 30 min 
in neutralising solution, 10 min in 20X SSC and then transferred to Hybond-N 
nylon membranes, (Amersham), by capillary action. Nylon membranes were 
pre-wetted in distilled water for 10 min and equilibrated in 20X SSC prior to 
DNA transfer. DNA was fixed to the membranes by UV cross-linking using a 
Stratalinker, (Stratagene), on the auto cross-link mode as instructed by the 
manufacturer or by baking at 80°C for 2 hours.
2.4.22 DNA transfer by electro-blotting
Gels for transfer to nylon membranes were prepared as described in section 
2.4.21, except that the gels and membranes were equilibrated in IX  TBE as 
opposed to 20X SSC prior to transfer. Electroblotting was performed with the 
'Electrophor' apparatus, (Hoefer Instruments), in IX TBE at 50 V, 1.5 milliAmps 
with constant agitation of the buffer using a magnetic stir bar for a minimum of 
4 hours or overnight. The DNA was then fixed to the membrane as described 
in section 2.4.21.
2.4.23 Pre-hybridisation and hybridisation of membrane fixed DNA
Nylon membranes were routinely pre-hybridised for 1 hour at 42°C with 
hybridisation buffer, (50% formamide, 6X SSPE, 5X Denhardt's solution, 1% 
SDS and 100 jug/ml sheared salmon sperm DNA), at a volume of 0.2 ml/cm2 of 
membrane. Pre-hybridisation was performed in a rotary oven, (Techne), or in
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plastic bags placed in a shaking water bath. Hybridisation was performed 
with at 42°C for 16 hours with denatured radioactive DNA probes at 1-3 X 
1 0 6  dpm/ml of hybridisation buffer.
2.4.24 Washing of membranes
Membranes were washed once with 2X SSPE, 0.1% SDS at room temperature, 
once with 2X SSPE, 0.1% SDS at 60°C and twice with 0.25X SSPE, 0.1% 
SDS at 60°C. Membranes were then sealed in plastic bags prior to 
autoradiography, (section 2.4.25).
2.4.25 Autoradiography
Auotoradiograph was performed at -70°C with intensifying screens when 
necessary. Fuji NIF RX X-ray film was exposed to the radioactive membranes 
for as long as required. Development of X-ray film was performed using the 
X-Ograph (Compact X2). Processed sequencing gels were treated as above 
except that intensifying screens were not used and autoradiography was 
performed at room temperature.
2.4.26 Re-use of DNA bound membrane filters
DNA bound membrane filters were 'stripped' of probe by immersion in a 
boiling solution of 0.1% SDS, which was allowed to cool to room temperature, 
where-upon the procedure was repeated. Removal of radioactive probes was 
verified by autoradiography, (section 2.4.25).
2.4.27 Oligonucleotide synthesis and deprotection
Oligonucleotides were synthesised using the automated PCR-MATE 391 
DNA synthesiser in accordance with the manufacturer's instructions, (Applied 
Biosystems). To separate the oligonucleotides from the glass bead synthesis 
matrix, the beads were treated with 1 ml of 30% NH4 OH and left at room 
temperature for 1 hour. The glass beads are then removed by centrifugation at
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12000 rpm for 10 min. A further 1 ml of 30% NH4 OH was added to the 
solution and incubated at 50°C for 16 hours. The oligonucleotide was 
subsequently ethanol precipitated by the addition of 0.11 vol of 3 M NaAc pH
5.2 and 3 vol of absolute ethanol at -20°C for 2 hours. The oligonucleotide 
was centrifuged at 1 2 0 0 0  rpm for 2 0  min, and the pelleted oligonucleotide 
was washed in 70% ethanol. The oligonucleotide was repelleted by 
centrifugation at 12000 rpm, the 70% ethanol was removed and the pellet was 
dried at room temperature. The oligonucleotide was now resuspended in 200 
|l l  of IX TE or sterile dH2 0 , of which 10 jil was sacrificed to accurately 
measure the optical density at 260nm, (section 2.4.2).
2.4.28 PCR reactions
The PCR reactions were performed as detailed in "PCR protocols: a guide to 
methods and applications, (Innis et al., 1990). Reactions were performed on a 
Perkin Elmer 9600 machine. A typical reaction mix contained the following 
reagents in a total volume of 1 0 0  (xl in thin walled microfuge tubes; typically 
100 ng of template DNA, 100 pmoles of each primer, IX reaction buffer ( 20 
mM Tris-HCl pH 8.3, 1.5 mM MgCl2 , 25 mM KC1), 0.2 jliM of each dNTP and
2 units of Taq DNA polymerase, (Promega). Reaction mixtures were heated to 
95°C for 5 min prior to the addition of Taq. The PCR reaction cycle 
conditions were specific to the target sequence to be amplified and are 
therefore detailed within the text. One tenth of the reaction products were 
analysed by agarose gel electrophoresis, (section 2.4.6).
2.4.29 Ethanol or isopropanol precipitation of DNA
The precipitation of DNA was generally achieved by the addition of 0.1 vol of
3 M NaAc pH 5.2 and 2 vol of absolute ethanol to the DNA sample and stored 
at -20°C for 30 min. Instead of using ethanol, 0.7 vol of isopropanol was 
added and incubated at room temperature for 15 min. The precipitated DNA 
was centrifuged at 12000 rpm for 20 min. The supernatant was discarded and 
70% ethanol was added; after brief vortexing the sample was centrifuged at 
12000 rpm for 5 min. The supernatant was again discarded, the pelleted DNA 
was dried at room temperature and resuspended in a suitable volume of IX TE 
or sterile dH2 0 .
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2.4.30 Phenol-chloroform extraction of DNA
Phenol-chloroform extractions were performed to deproteinise aqueous DNA 
solutions. For this purpose commercially supplied distilled phenol was used, 
(Aldrich). The phenol was melted at 55°C and buffered by sequentially 
adding fresh 0.1 M Tris-HCl pH 8.0 until the pH of the phenol reached 8.0. 
The phenol was saturated by mixing with an equal volume of IX  TE. The 
saturated phenol was added to an equal volume of chloroform and 0 .1 % 8 - 
hydroxyquinoline antioxidant, (w/v). The DNA solution was extracted with 
an equal volume of phenol-chloroform (v/v) and using gentle vortexing for 1 
min. The sample was centrifuged at 12000 rpm for 5 min to separate the 
phases and the upper aqueous phase was carefully removed leaving the 
interface undisturbed. The extraction was generally repeated until no 
interface was observed. The DNA was then recovered by ethanol 
precipitation of the supernatant as described in section 2.4.29.
2.4.31 In  situ hybridisation
Sections were fixed with 4 % paraformaldehyde in phosphate buffered saline 
(PBS), ph 7.4, for 10 mins, rinsed twice in PBS, and placed in 2X SSC for 10 
mins. at room temperature, dehydrated in ethanol, defatted in chloroform, 
rinsed in 95% ethanol and air dried. Radioactive probes were generated by end 
labelling of 45mer oligonucleotides: 15ng of oligonuleotide was labelled with 
20 jLtCi35S dATP using terminal transferase according to the manufacturers 
instrucions, (Pharmacia). Labeled probe was purified from unincorporated 
nucleotide by centrifugation of the reaction through a 1 ml G-50 sephadex 
column,(4 min 12000 rpm). All hybridizations were standardized such that 
each contained 2.0 xlO3 dpm/ml of probe in hybridization buffer (50% (v/v) 
formamide, 4 x SSC, 25 mM sodium phosphate (pH 7.0), 1 mM sodium 
pyrophosphate, 20 mM dithiothreitol, 5 x Denhardt's solution, 10% (w/v) 
dextran sulphate, 200 jig/ml acid-alkali hydrolyzed salmon sperm DNA, 100 
mg/ml poly adenylic acid, 120 mg/ml heparin). Sections were hybridized in 200 
j l l I  buffer, under parafilm coverslips, overnight at 42°C. Control sections were 
hybridized in the presence of a 50-fold molar excess of the appropriate 
unlabelled oligonucleotide. After hybridization, coverslips were removed in 1 
x SSC at room temperature, and the sections were washed in 0.3x SSC for 60
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min at 55°C. They were rinsed at room temperature in lx  SSC, followed by a 
rinse in 0.1 x SSC, dehydrated sequentially in 70% (v/v) and 95% (v/v) ethanol 
and air-dried. All wash solutions contained 10 mM dithiothreitol. Sections 
were exposed to Kodak X-Omat film at room temperature for 15 days before 
being dipped in Ilford K-5 emulsion. After exposure for 50 days at 4°C , 
sections were processed in Kodak D19 developer for 2 min at 17°C, briefly 
rinsed in distilled water, fixed in 30% (w/v) sodium thiosulphate for 4 min, and 
finally washed in distilled water for 10 min. Sections were dried overnight at 
room temperature before being counterstained with 0.05% (w/v) thionin, 
differentiated in an ascending ethanol series (70%, 95% and 100% (v/v)), 
cleared in Histo-clear (National Diagnostics), and mounted in DPX (BDH).
2.6.32 Photography for in situ hybridisation
Autoradiographic images generated on X-ray film were printed with an 
enlarger directly onto Kodak Kodabrome II RC photographic paper (grade F5 
M), giving reverse images. All sections were photographed onto Kodak Tech- 
Pan film using a Leitz microscope and 35mm camera with lightfield and 
darkfield condensers at 200 ASA and 1600 ASA settings respectively. 
Negatives were processed using Kodak HC-110 developer at 20°C for 4.5 
minutes. Both lightfield and darkfield negatives were printed onto Kodak 
Kodabrome II RC photographic paper (grade F5 M).
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2.5. ES cell tissue culture, media, maintenance and methods
2.5.1 ES cell lines
ES Cell Lines Source
EI4 Handy side et al., 1989.
RI Nagy et al., 1993.
CGR8  Mountford et al., 1994.
CGR8 .8  Skames W. C., CGR in Edinburgh,
(personal gift).
2.5.2 ES cell tissue culture media and materials 
E14 ES cell medium
E14 ES cells were grown on the Glasgow modification of Eagle's medium with 
the supplements detailed below after the medium had been conditioned on 
Buffalo Rat Liver, (BRL), cells as detailed by Handyside et al., 1989.
CMB medium;
Sterile Water
10X BHK21 medium, (Glasgow MEM;Gibco)
7.5% Sodium bicarbonate, (Gibco)
100X MEM non-essential aa, (Gibco)
100 mM Na pyruvate, (Gibco)
200 mM L-glutamax, (Gibco)
0.1 mM b-mercaptoethanol, (Gibco)
100X Penicillin-streptomycin, (Gibco)
Foetal calf serum, (selected batches; Gibco)
375 ml 
45 ml 
16.5 ml 
5 ml 
5 ml 
5 ml 
5 ml 
5 ml 
25 ml
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Newborn calf serum, (selected batches; Gibco) 25 ml
The CMB medium was conditioned by incubating in the presence of 
confluent BRL cells. 175 cm2 tissue culture flasks were seeded with BRL 
cells and grown to confluence using CMB medium. Upon reaching 
confluence, fresh CMB medium was added for conditioning at 60 ml/ 175 cm2 
flask and incubated at 37°C/5% CO2 for 1 week. Then the medium was 
passed through a membrane filter of pore size 0.8 mm or smaller. The filtered 
medium was stored at -20°C until required. This medium was designated 
'100% BRL-conditioned medium'. For growth of E14 ES cells, 60% BRL- 
conditioned medium was used. Therefore 6  volumes of 100% BRL- 
conditioned medium was mixed with 4 volumes of CMB medium.
R1 ES cell medium
R1 ES cells were grown on the Glasgow modification of Eagle's medium with 
the supplements detailed below:
Sterile Water
10X BHK21 medium, (Glasgow MEM Gibco)
7.5% Sodium bicarbonate, (Gibco)
100X MEM non-essential aa, (Gibco)
100 mM Na pyruvate, (Gibco)
200 mM L-glutamax, (Gibco)
0.1 mM b-mercaptoethanol, (Gibco)
100X Penicillin-streptomycin, (Gibco)
Foetal calf serum, (selected batches Gibco)
Murine leukaemia inhibitory factor, (Gibco)
(1 X 107 units/ml)
CGR8 and CGR8.8 ES Cell Medium
CGR8  and CGR8 .8  ES cells were grown on the Glasgow modification of 
Eagle's medium with the supplements detailed below:
267 ml 
40 ml 
13.2 ml 
4 ml 
4m l 
4 ml 
4 ml 
4 ml 
60 ml
40 ml
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Sterile Water
10X BHK21 medium, (Glasgow MEM Gibco) 
7.5% Sodium bicarbonate, (Gibco)
100X MEM non-essential aa, (Gibco)
100 mM Na pyruvate, (Gibco)
200 mM L-glutamax, (Gibco)
0.1 mM b-mercaptoethanol, (Gibco)
100X Penicillin-streptomycin, (Gibco)
Foetal calf serum, (selected batches from 
Globerpharm, Surrey)
Murine leukaemia inhibitory factor, (Gibco), 
(1 X 107 units/ml)
336 ml 
40 ml 
13.2 ml
4 ml 
4m l 
4 ml 
4 ml 
4 ml
40 ml
40 ml
TVP (cell disaggregating solution)
0.025% (w/v) trypsin, (Gibco);l mM Na2 EDTA, (Sigma); 1% (v/v) chick 
serum, (Flow Labs); in (Ca++, Mg++-free) IX PBS, (Gibco). The solution is 
sterilised by membrane filtration using filters of 0.4 mm pore size, (Millipore), 
and stored as -20°C aliquots.
1% Gelatin Stock Solution
Gelatin, (Sigma, swine skin), was dissolved in distilled water at 10 g/1 and 
autoclaved. The resulting solution was allowed to cool at room temperature 
and re-autoclaved. The stock was stored in 20 ml aliquots at 4°C.
Freezing Medium
ES cell growth medium supplemented with 10% (v/v) DMSO, (Sigma).
2.5.3 Maintenance of ES cells
The following procedures apply to the maintenance of E l4, R l, CGR8 and 
CGR8 .8  ES cell lines. All cells were grown on a feeder cell independent 
system. Medium was generally changed every day and cells were not allowed
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to grow to confluence. All ES cell manipulations were performed in a laminar 
flow hood. All ES cells were grown in humidified 37°C/5% CO2 incubators 
and all solutions were warmed to 37°C prior to use.
2.5.4 Growth and passage of ES cells
ES cells are grown on plastic tissue culture flasks, (Corning Inc.), precoated 
with 0.1% gelatin, (1% stock solution was warmed to 37°C to liquefy and 
further diluted to 0.1% with sterile water). Typically, 2 ml of 0.1% gelatin was 
added to a 25 cm2 flasks and allowed to sit for 5 min at room temperature. 
The gelatin solution was then aspirated off prior to the addition of medium on 
to cells. When growing cells from frozen, an aliquot of frozen cells (0.5 X 107) 
was quickly thawed at 37 °C and 10 ml of pre-warmed medium was added and 
pelleted by centrifugation at 1200 rpm for 5 min. The cell pellet was 
resuspended in 5 ml of medium and added to a 25 cm2 flask prepared as 
described above. The cells were then incubated at 37°C for no longer than 16 
hours prior to the change of medium.
ES cells were passed when the cells had neared 
confluence, typically about every 2-3 days. For a 25 cm2 flask the medium 
was aspirated off and 5-10 ml of IX  PBS was added and gently allowed to 
wash over the cells. The IX  PBS was aspirated off and the above wash step 
repeated. The cells are then covered with 1 ml of TVP and allowed to incubate 
at room temperature until a cell suspension forms, (approximately 3 min). 9 ml 
of medium was added to stop trypsinisation. One tenth of this cell suspension 
was removed and placed in a freshly gelatinised 25 cm2 flask with 4 ml fresh 
medium. Therefore, a 1:10 split ratio was typically used for the passage of ES 
cells. However, when expanding ES cells for an electroporatation experiment 
the same procedure was followed but with the cells being passed at twice the 
density, (a 1:5 split ratio), into larger flasks.
2.5.5 Freezing of ES cells for long term storage
Cells are washed twice in IX PBS and trypsinised as described above. 9 ml of 
medium was added to stop the reaction and the cell suspension centrifuged at 
1200 rpm for 5 min. The medium was aspirated off and resuspended in 1 ml of 
freezing medium and 0.5 ml aliquots were frozen down in cryotubes. When 
freezing ES cells it is desirable to freeze at l°C/min. This was achieved by
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placing the cell vials in a polystyrene box prior to overnight storage at -70°C 
The next day the cell vials were placed in the vapour phase of a liquid 
nitrogen storage vessel.
2.5.6 Short term storage and recovery of ES cells
This method was only used for the storage of ES cells grown on 24 well plates 
and is a modification of a procedure first presented by McPheat et al., 1991. 
Individual ES cell clones were grown in 24 well plates to near confluence. 
The medium was aspirated off and 250 pi of freezing medium was added to 
each well of the plates. The plates were then placed in polystyrene boxes and 
stored at -70°C for up to 3 months. The recovery of individual clones from 
these plates was achieved by transferring the plate to a 37°C incubator. 2 ml 
of medium was added to a thawed well. This 2 ml of medium was 
subsequently transferred to 1 well of a six well plate with 8  ml of fresh 
medium. The original well received 1 ml of fresh medium. Both parts of the 
sample were maintained in culture until the cells recovered, changing the 
medium daily.
2.5.7 Preparation of vector DNA for electroporation
Plasmid DNA was isolated using the large scale plasmid preparation method, 
(section 2.3.9). 25 pg  of the vector DNA was linearised by restriction 
digestion as described in section 2.4.5. The digest was checked for 
completion by running 200 ng of the digested vector on a 0.7% agarose gel, 
(section 2.4.6). The digested DNA was ethanol precipitated, (section 2.4.29), 
and washed with 1 ml of 70% ethanol and centrifuged at 12000 rpm for 5 min. 
The 70% ethanol was removed by aspiration in a laminar flow hood where the 
pelleted DNA was allowed to dry at room temperature. The DNA was then 
resuspended in 100 p i of IX PBS for several hours at room temperature or 
overnight at 4°C. Lastly, the vector DNA was heated to 65 °C for 5 minutes 
prior to its use in transfection.
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2.5.8 Transfection of E14 and R1 ES cells
It is important that cells are growing well prior to electroporation, therefore 
actively growing cells that required passage every 2-3 days were used. 
Typically 5 X 107 cells were used, (this approximates to a near confluent 175 
cm 2 flask), which were fed with fresh medium 3 hours prior to harvest. The 
cells were washed twice with IX  PBS, trypsinised with 2.5 ml of TVP, the 
reaction was stooped by adding 25 ml of growth medium and centrifuged at 
1200 rpm for 5 min. The supernatant was aspirated off and the pellet of cells 
resuspended in 10 ml IX  PBS. The cells were pelleted as described and 
resuspended in a further 10 ml of IX PBS and centrifuged. The pelleted cells 
were resuspended in 0.7 p i of IX PBS, added to the tube containing the 
linearised plasmid, (section 2.5.7.), and transferred to a 0.4 cm electroporation 
cuvette, (Bio-Rad). Electroporation was performed with a Bio-Rad Gene 
Pulser unit set at 500 pF and 250 volts. Cells were allowed to recover for 20 
min in the cuvette at room temperature prior to plating. The electroporation 
mix was plated onto 6  freshly gelatinised plates, ( 1 0  cm in diameter), with 1 0  
ml of fresh medium. Selection was not applied to the cells until 24 hours after 
electroporation. All plates received fresh medium daily, containing 200 pg/ml 
G418 and 1 X 10“6 M GANC except for the sixth plate, which received only 
200 pg/ml G418. This regime continued for 10-14 days, after which colonies 
of 1 mm and larger were ready to be processed as described in section 2.5.10. 
Colonies from the plate which were only selected with G418 were not picked. 
This plate provided a means by which to assess the efficiency of GANC 
enrichment of targeted clones.
2.5.9 Transfection of CGR8 and CGR8.8 ES cells
CGR8  and CGR8 .8  ES cells were electroporated and G418R GANCR cells 
selected as described above with the following exceptions. A cell 
concentration of 1 X 108 cells were electroporated with 150 pg of linearised 
vector DNA at 3 pF and 800 volts. The electroporation mix was plated onto 
20 X 10 cm diameter plates and selected as above with one of the plates not 
receiving GANC selection. However, these cells grow quicker and only 
require 9-12 days of selection.
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2.5.10 Processing G418/gancycIovir resistant ES colonies
G418-GANC resistant ES colonies were picked and grown on 24 well plates. 
The plates containing the resistant colonies were washed twice with IX  PBS 
and a final 10 ml of IX  PBS added. Colonies were picked with a P200 
Pipetteman set at 100 pi with sterile tips; colonies were dislodged, the cells 
pipetted in a volume of 100 ml IX  PBS and transferred to a 24 well plate. 
Once 24 colonies had been picked, 100 pi of TVP solution was added to each 
well and incubated at 37°C with frequent tapping until the colonies were 
dispersed. 2  ml of growth medium was added to each well to stop the 
trypsinisation. The colonies were expanded until near confluent. The cells 
were then trypsinised with 4/5 of the cells being harvested for Southern blot 
analysis and 1/5 of the cells used to re-seed a freshly gelatinised 24 well plate. 
The plates were then grown to near confluence and stored as described in 
section 2.5.6, until required.
2.5.11 Production of chimaeric mice by blastocyst injection
This work was performed by Dr. W. C. Skarnes of the Centre for Genome 
Research, University of Edinburgh, Scotland. The material and methods used, 
for the blastocyst injection approach to producing chimaeric mice, are well 
documented in a number of publications such as Papaioannou and Johnson, 
1993. Briefly, blastocysts were collected from 3.5 day post coitus C57BL/6J 
females on the morning of injection. 10-12 ES cells were microinjected into 
each b lastocyst using a hanging drop cham ber m ounted on a 
micromanipulator. Injected blastocysts were incubated at 37°C for a 1-2 hour 
recovery period. These embryos were then transferred into the lumen of the 
uterus of pseudopregnant foster mothers.
2.5.12 Preparation of metaphase spreads from ES cells
A culture of ES cells was set up in a 25 cm2 flask such that it was about 50% 
confluent on the day the cells were harvested. 24 hours prior to to harvest 
the cells were fed with fresh medium , (this causes partial synchronisation). 2  
hours prior to harvest colcemid was added to a final concentration of 0 .1  mg 
/ml. Cells were harvested as described in section 2.5.4. Cells were then gently 
resuspended in 10 ml of hypotonic solution, (0.075 M KC1), incubated at room
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temperture for 4min. Cells were spun at 500 rpm for 5 min, all but one drop of 
supernatent was removed, in which the pellet was resuspended by gently 
flicking the tube, and placed on ice. Cells are then fixed by drop wise 
addition of ice cold fixative, (methanol/glacial acetic acid 3:1 v/v, freshly 
prepared), to a final volume of 10 ml and left on ice for 30 min. Cells were 
pelleted by spining at 500 rpm for 5 min. The pellet was resuspended in 10 ml 
ice cold fixative and left on ice for 5 min. After which, it was re-pelleted as 
before and resuspended in 5 ml fixative. 2-3 drops of the cell suspension were 
then droped from a height of about 30 cm on to prepared microscope slides 
placed at a 45° angle. The slides were prepared in advance by washing 
thourghly in 70% ethanol and rinsing in cold tap water immediately prior to 
use. Chromosomes were stained by allowing the slides to air dry for at least 1 
hour prior to dipping in a 3% Giemsa solution for 12-15 min followed by 2 
washes in distilled H2O for 30 s.
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Chapter 3
Cloning and Characterisation of Lambda Clones Containing 
Genomic DNA Encompassing the Neurotensin Receptor Gene
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3.1 Introduction
A primary aim of this project was to clone suitable genomic mouse fragments 
encoding the mouse neurotensin receptor gene (NTR), for the construction of a 
gene targeting construct. Theoretically, a number of possible strategies could 
be used to clone the NTR gene. However, a functional cDNA clone of the rat 
NTR became available, (Tanaka, et al., 1990). Thus the most logical approach 
was to clone the NTR gene by homologous nucleic acid hybridisation using the 
rat cDNA to probe a X EMBL3 Balb/c mouse genomic DNA library.
The resulting positive X clones, from the mouse genomic 
EMBL3 library, were subjected to basic characterisation. The clones were 
restriction digested to release their genomic fragments and subsequent 
hybridisation with probes derived from the rat cDNA allowed the identification 
of suitable fragments for vector construction. Such fragments were subcloned 
and restriction enzyme mapped. The isolation of genomic DNA fragments 
containing exonic NTR sequences was confirmed by DNA sequencing. The 
sequencing of the gene fragments provided the necessary data for the 
construction of an insertional targeting vector, based on the 'Hit and Run' 
procedure presented in Chapter 4, and subsequently for the construction of a 
replacement type vector, (Chapter 5).
3.2 Hybridisation conditions of library screens
Suitable hybridisation conditions for screening the X EMBL3 Balb/c library 
were determined by Southern blot analysis of digested mouse and rat genomic 
DNA with a rat NTR cDNA derived probe. Typically in such an analysis the 
starting point would be hybridisation performed at relaxed stringency with low 
stringency washings. The specificity of the resulting hybridising bands can be 
increased by altering the stringency of the procedure. Either increase the 
stringency of hybridisation by raising the temperature or by adding formamide 
to the buffer. Alternatively the temperature of the washes could have been 
increased or the salt concentration lowered. However, for this particular 
experiment the Southern blot was probed at high stringency with formamide 
based buffer and subsequently washed at high temperature with washings at 
low salt concentrations. The strategy was one of starting at high stringency, 
followed by stepwise reduction in stringency, until Southern analysis resulted 
in a hybridisation profile indicative of a single copy gene.
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Rat and mouse DNAs were restriction digested with 
EcoRl and BamHl enzymes. The resulting digests were ethanol precipitated, 
resuspended in 10 p,l of dP^O and electrophoresed on a 0.7% agarose gel. The 
gel was stained, photographed and the DNAs transferred to a nylon membrane 
by Southern blotting. The membrane was pre-hybridised and hybridised in a 
50% formamide buffer at 42°C for 16 hours as described in section 2.4.23. 
The probe used was derived from the 3.6 kb rat cDNA (Tanaka et al., 1990). 
Only the 1.4 kb 5' portion of the cDNA was used as indicated in Figure 3.1. 
This terminal Smal portion of the gene was chosen as it contains the majority 
of the coding region of the NTR gene, from position 171 nt to position 1257 nt. 
The 3' non-coding sequence was discarded so as to reduce cross-hybridisation 
of the probe to spurious sequences.
Smal ATG Smal
I II III IV V VI VII 1---------- r
-171 +1 1257
1.4 kb Smal fragment
Figure 3.1 Diagram of the 1.4 kb Smal fragment of the rat cDNA. This 
fragment was used as a probe for Southern analysis and library screening. The 
nucleotide positions of the Smal sites are indicated relative to the ATG start 
codon, position +1. The sequence encoding the seven presumptive 
transmembrane domains are indicated as I-VII.
The 1.4 kb Smal NTR cDNA fragment was purified by 
first digesting 20 jig of the prNTR2 cDNA with the Smal enzyme in a total 
volume of 60 j u l I .  The digested DNA was then electrophoresed on a 1.5% LMP 
agarose gel at 50 volts for 3 hours. The 1.4 kb band was then cut from the gel 
and purified as described in section 2.4.9. 25 ng to 30 ng of this fragment was 
then labelled with 50 p,Ci a  32P dCTP by the random priming method. The 
resulting probe was then added to the hybridisation mix at 3 X 106 dpm/ml 
hybridisation buffer. The probed membrane was washed as described at a final
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w a sh  o f  0 .2  X  S S P E . 0 .1 %  S D S  at 6 0 °C  fo r  20  m in . T h e  re su ltin g  h y b rid is in g  
b a n d s  w ere  o b se rv e d  a fte r  3 d ay s  a u to ra d io g ra p h y  see F ig u re  3.2.
—  -25 kb
—  -20 kb
—  9.2 kb
—  7.5 kb
—  7 kb
—  4.5 kb
—  2.8 kb
Figure 3.2 Southern blot analysis o f m ouse and rat gD N A s with the rat N TR 
cD N A . 10 p g  o f each sam ple o f D N A  was digested  w ith 30 units o f either 
BamHl or F coR I for 3 hours at 37°C. The digested DN As were resolved on a 
0 .7%  agarose gel. The gel was transferred  to a nylon m em brane and probed 
w ith a 3 2 p  labelled  1.4 kb Smal derived  fragm ent o f the rat cD N A . The 
resulting blot was exposed to X-ray film  for 3 days. The approxim ate sizes of 
the visible hybridising bands are indicated on the right hand side of the Figure.
Lane 1; Rat gD N A  digested with EcoRl 
Lane 2; M ouse gDNA digested with FcoR I 
Lane 3; Rat gD N A  digested with BamHl 
Lane 4; M ouse gDN A digested with BamHl
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3.3 Results of Library Screen
The number of individual lambda clones from the EMBL3 Balb/c genomic 
library that had to be screened to give a 99% probability of cloning a single 
copy gene, was calculated using the formula shown below :
N = ln(l-P) 
ln[l-(I/G)]
where: N = the number of clones that must be screened
P = the probability of finding a particular sequence 
I = the average insert size of genomic DNA/clone which in this 
case was 1.5 X 10^ bp 
G = the haploid size of the genome which in this case is 2.7 X 
1 0 9 bp for the mouse genome
Thus the number of recombinant clones that had to be screened to give a 99% 
probability of cloning any single sequence was calculated to be approximately 
830,000. Therefore the following library screen was undertaken with a total 
number of about 1 ,0 0 0 ,0 0 0  clones being screened.
The library was plated onto 10 large plates, (245 mm X 
245 mm), as described in section 2.3.16. Replica filters were made and probed 
with a 32P labelled 1.4 kb Smal fragment of the rat cDNA (specific activity of 1 
X 109 dpm/jig) at a concentration of 1.5 X 106 dpm/ml of hybridisation buffer. 
The filters were washed as described in Material and Methods, (section 2.4.24), 
with a final wash concentration of 0.2 X SSPE, 0.1 % SDS at 60°C for 20 min. 
Autoradiography was performed overnight and a total of 10 putative positives 
were identified; an example of one is shown in Figure 3.3A and its replica filter 
in Figure 3.3B.
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F igure  3.3 Tw o putative positive plaques on rep lica filters from  the in itial 
library screening. The filters (24 cm  X 24 cm) were probed at high stringency 
in a 50 % form am ide based hybridisation buffer w ith a 32P labelled portion o f 
the rat cDNA, (see text for details). The blot was w ashed and exposed to X-ray 
film  overnight. The two potentially positive hybridising plaques are indicated 
by the arrows on filters A and B.
3.4 Secondary and tertiary  screening of putative positives clones
T h e  10 p u ta t iv e  p o s it iv e  c lo n e s  f ro m  th e  lib ra ry  s c re e n  w e re  p ic k e d  as 
d e s c r ib e d  in  se c tio n  2 .3 .1 9 . It w as th en  n e c e ssa ry  to  p u r ify  the  X c lo n e s  as 
e a ch  p lu g  can  co n ta in  up  to ab o u t 85 d iffe re n t p .f .u . T h e  titre  o f  e a ch  p lu g  w as 
d e te rm in e d  and  a p p ro x im a te ly  300  p .f .u . w e re  p la te d  o n to  10 cm  X  10 cm  
p la te s . R e p lic a  f ilte rs  w ere  m ad e  as p rev io u s ly  d e sc r ib e d , w ith  the  e x c e p tio n  
th a t o n e  se t o f  the  re p lic a  f ilte rs  w ere  p ro b ed  w ith  a d io x ig e n in  (D IG ) la b e lle d  
p ro b e , ( se c tio n  2 .4 .2 0 ) . A n  e x a m p le  o f  th e  r e s u l tin g  a u to ra d io g ra p h s  a re  
sh o w n  in  F ig u re  3 .4 . P o s itiv e  p la q u e s  w ere  a g a in  p ic k e d  an d  su b je c te d  to  a 
te r tia ry  ro u n d  o f  sc re e n in g . A fte r  su c ce ss fu l sc re e n in g , w e ll iso la te d  p o s itiv e  
p la q u e s  w ere  p ick ed  an d  h ig h  titre  s to ck s w ere  m ad e  by  the  p la te  ly s is  m e th o d  
d e sc r ib e d  in  sec tio n  2 .3 .15 . A  to ta l o f  8 p o s itiv e  X c lo n es  w ere  iso la te d .
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Figure 3.4 R eplica filters indicating six positive plaques from  a second round 
library screening o f a phage plug taken from the original library. F ilter A was 
prepared and probed as previously  described w ith the exception  that only 3 
hours autoradiography w as needed. R eplica filter B was probed w ith a DIG  
labelled probe, (M aterials and M ethods; section 2.4.20), and exposed to X-ray 
film  for only 3 m inutes.
3.5 Confirmation of positive lam bda clones
T h e  m a in  a im  o f  the  fo llo w in g  S o u th e rn  b lo t an a ly s is  w as to  c o n firm  th a t th e  8 
p o s it iv e  X c lo n es  c o n ta in e d  D N A  in se rts  th a t h y b rid ise d  at h ig h  s tr in g e n c y  to  
th e  ra t  cD N A . F u rth e rm o re , the  p rin c ip le  in te res t w as no t fu ll c h a ra c te r is a tio n  
o f  th e  1 in se rts , b u t th e  id e n tif ic a tio n  o f  su ita b le  g e n o m ic  D N A  fra g m e n ts  fo r  
th e  c o n s tru c tio n  o f  a ta rg e tin g  v ec to r. P re fe rab ly , a D N A  fra g m e n t c o n ta in in g  
5 ' c o d in g  seq u en c e  w as so u g h t, s in ce  it w as in ten d ed  to  m u ta te  the  N T R  c o d in g  
se q u e n c e  as su itab ly  n e a r  to  the  A T G  sta rt co d o n  as p o ss ib le .
D N A  w as p re p a re d  fro m  each  o f  the  8 p o s itiv e  X c lo n e s  
(ce d  1, 2, 4 , 5, 7, 8, 9, and  ced  10). E ach  w as d ig es ted  se p a ra te ly  w ith  £c<?RI, 
BamHl and  Sail re s tr ic tio n  en zy m e s . T h e  c o m p le ted  d ig es ts  w e re  re so lv e d  on  
an  0 .7  % a g a ro se  g e l. T h e  ge l w as  b lo tte d  an d  p ro b e d  w ith  a 1.4 k b  Smal 
f ra g m e n t  o f  the  ra t N T R  c D N A , (F ig u re  3 .1 ). T h e  re s u ltin g  a u to ra d io g ra p h , 
(F ig u re  3 .5 ), c o n firm s  the  p re se n c e  o f  d iffe re n t h y b rid is in g  in se r t  s iz e s  w ith in  
th e  8 c lo n e s . M o st in te re s tin g  w as  the  p re se n c e  o f  th e  2 .8  k b  BamHl  b a n d s
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( la n e s  1 an d  8), th e  4 .5  kb  BamHl b a n d  (lan e  4 ), an d  the  9 .2  kb  E co R I ban d  
(lan e  10), w h ich  a re  id en tica l in s ize  to those  o b se rv ed  in  the  g e n o m ic  S o u th e rn  
b lo t, (F ig u re  3 .2).
9.2 kb
4.5 kb
kb
Figure 3.5 Southern blot analysis o f the 8 purified X clones.
A bout 250 ng o f each  clone w as restric ted  w ith BamHl, EcoRl and  Sail 
enzym es, reso lved  on an 0.7%  agarose gel, b lo tted  and probed w ith the 32p 
labelled  1.4 kb Smal fragm ent o f the rat NTR cD N A  at high stringency. The 
blot was w ashed at high stringency (final wash 0.2 X SSPE, 0.1%  SDS at 60°C). 
The blot was then exposed to X-ray film  for 6 hours and the resulting exposure 
is show n above. The sizes o f some bands are indicated to the left o f the figure.
Lane 1; c e d i, lane 2; ced2, lane 3; ced4, lane 4; ced5, lane 5; ced7, 
lane 6; ced8, lane 7; ced9 and lane 8; cedlO , are all d igested with ZtomHI.Lane 
9; 1 Hindlll m arker. Lane 10; ced 1, lane 11; ced2, lane 12; ced4, lane 13; ced5, 
lane 14; ced7, lane 15; ced8, lane 16; ced9 and lane 17; cedlO ; are all d igested 
w ith EcoRl Lane 18; 1 kb m arkerLane 19; ced 1, lane 20; ced2, lane 21; ced4, 
lane 22; ced5, lane 23; ced7, lane 24; ced8, lane 25; ced9 and lane 26; cedlO ; 
are all digested w ith Sail.
U n fo r tu n a te ly  p a r t ia l  d ig e s t io n  in  la n e s  1 to  8 h as  m a d e  th e  r e s u l ts  a  b it 
c o n fu s in g . N o n e th e le s s , th e  b lo t w as  s tr ip p e d  an d  re -p ro b e d  w ith  a m o re  
d e fin e d  4 5 8  bp  Pstl  5 ' p o r tio n  o f  the  ra t cD N A , (-171 n t to  287  n t). T h is  w as 
d o n e  to  id e n t if y  a n y  D N A  f ra g m e n ts  w h ic h  m a y  c o n ta in  s e q u e n c e s
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c o r re s p o n d in g
a u to ra d io g ra p h
9.2 kb
4.5 kb  
2.8 kb
Figure 3.6 Southern analysis o f 8 purified X clones w ith a defined 5' rat cD N A  
derived probe. This is the same blot as Figure 3.5 that has been stripped and re ­
probed w ith the 458 bp Pst\ 5' portion o f the rat cD N A  (-171 nt to 287 nt). 
Therefore, refer to Figure 3.5 for lane d e ta ils  etc .
3.6 Subcloning of the 2.8 and 4.5 kb Bam H l fragm ent
T h e  in itia l  re s tr ic tio n  d ig e s t an d  5' p ro b in g  d a ta  re v e a le d  th e  p re s e n c e  o f  a 
n u m b e r  o f  d if fe re n t X c lo n es . O f  p a rtic u la r  in te re s t w as the  c lo n e s  c o n ta in in g  
h y b r id is in g  b a n d s  o f  s iz e s  s im ila r  to  th a t f ir s t  o b s e rv e d  in  th e  S o u th e rn  
a n a ly s is , see  F ig u re  3 .2 . T h e re fo re  the  BamHl  2 .8  k b  b a n d  fro m  c lo n e  c e d i  
an d  the  4 .5  k b  b an d  fro m  c lo n e  ced5  w ere  su b c lo n e d  in to  p B lu e sc r ip t II K S + > 
(p la s m id s  p 2 .8 B  an d  p 4 .5 B  re sp e c tiv e ly ) . T h is  w as d o n e  b e c a u se  i f  th e se  
b a n d s  p o te n tia l ly  c o rre sp o n d e d  to  c o d in g  fra g m e n ts  o f  th e  N T R  g e n e , th en  
th ey  w o u ld  p ro v id e  la rg e  e n o u g h  seg m en ts  o f  D N A  fo r  th e  c o n s tru c tio n  o f  an  
in se r tio n a l  ty p e  v e c to r  s im ila r  to  th a t u sed  in  the  'H it a n d  R u n ' a p p ro a c h  to  
g e n e  ta rg e tin g , (H asty  et a l ,  1991a)
C lo n e s  c e d i  a n d  ced 5  w e re  r e s t r ic t io n  d ig e s te d  w ith  
BamHl e n z y m e  an d  su b seq u e n tly  e le c tro p h o re se d  on  a 1% a g a ro se  L M P  gel. 
T h e  2 .8  k b  a n d  4 .5  kb  Bam H l  b a n d s  w e re  th en  p u r if ie d  fro m  th e  a g a ro se , 
(M a te ria ls  an d  M e th o d s , sec tio n  2 .4 .9 ). T h e  p u r if ie d  D N A s w ere  lig a te d  in to
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to th e  5 ' c o d in g  re g io n  o f  th e  N T R  g e n e . T h e  r e s u l t in g  
is sh o w n  in F igu re  3.6
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the pBluescript II SK" vector linearised at the BamHl site. The resulting 
ligations were transformed into electro-competent D H 5a cells. The resulting 
transformed white colonies were picked and grown overnight. The plasmids 
were purified and subjected to BamHl digestion to verify the presence of the
4.5 kb and 2.8 kb bands.
3.7 Restriction mapping of p2.8B and p4.5B plasmids
The plasmids p2.8B and p4.5B were subjected to basic restriction mapping, as 
such information would be essential to the design of a targeting construct. The 
strategy employed was to use 6  base cutter enzymes such as EcoRl that were 
unique to the parental plasmid, (pBluescript II SK"), in the hope of finding 
restriction sites that occured only once or twice within the insert DNA. The 
data generated from this initial analysis is summarised in Figures 3.7 and 3.8.
500 bp 
<  ►
I_______I_______ l_______ I_______l_______I_______ l_______ I_______ i
T7 promoter T3 promoter
<--------► BamHl BamHl
i-i 1 *---------1---------- 1— i------------------------------- 1-------- r  '
AccI Smal Sstl Accl Ncol Pvun Ncol Smal Sstl
Figure 3.7 Preliminary restriction map of the p2.8B plasmid. The 2.8 kb BamHl 
fragment was cloned into the BamHl site of the pBluescript SK II* vector. The 
known restriction sites within the fragment are shown with selected sites from 
the vector polylinker, (polylinker sites are not to scale).
T7 promoter 
 ^  Bam HI
—1---- 1—'-^Kpn I I Pvul
Hin dill
Bam HI
Pvul Hin dffl Kpn I S stl
I------------ 1------------1------------1------------1------------ 1------------1------------ 1------------1------------1------------1------------ 1
M ►
500 bp
Figure 3.8 Preliminary restriction map of the p4.5B plasmid. The 4.5 kb BamHl 
fragment was cloned into the BamHl site of the pBluescript SK IT vector. The
89
Chapter 3
known restriction sites within the fragment are shown with selected sites from 
the vector poly linker, (poly linker sites are not to scale).
3.8 Generation of a deletion library from plasmid p2.8B
The plasmid p2.8B containing the genomic BamHl 2.8 kb fragment was chosen 
for further characterisation for the following reasons. Initial double-stranded 
sequencing from the 5’ and 3’ ends of the insert revealed sequence homology to 
the 5' untranslated region of the rat NTR cDNA, (data not shown). Therefore, 
it was presumed that p2.8B plasmid potentially contained the start of the open 
reading frame of the mouse NTR gene. Furthermore, the 2.8 kb sized BamHl 
fragment provided sufficient homology for the design of an insertional vector 
similar to that used in the approach described by Hasty et al. 1991a The p2.8B 
plasmid was further characterised by sequencing the deletion library created by 
Exonuclease III digestion of the plasmid.
The procedure used for the generation of the deletion 
library was based on that of Henikoff et al. , 1984. The buffers used were 
optimised by Tomlinson, 1994, the recipes of which were essentially that 
detailed in Promega Protocols and Applications guide, (Promega). The 
complete method used is detailed fully in materials and methods, however a 
brief outline follows. It was necessary to generate a linear template of the 
p2.8B plasmid. Typically the DNA template is linearised with two different 
restriction enzymes; one of which provides 3’ protruding ends from which 
Exonuclease III digestion cannot proceed and the other provides 5' protruding 
or blunt ended molecules for digestion. A suitable restriction enzyme site 
leaving a 3' overhang was not available in the p2.8B plasmid . Therefore, the 
plasmid was linearised with the Sail enzyme which leaves 5f protruding ends. 
The protruding ends were then filled in using the klenow enzyme to 
incorporate the appropriate a-phosphorothioate deoxynucleotide derivatives 
into the overhang. A sample of this protected template DNA was then treated 
with Exo III enzyme to test the efficiency of the fill-in reaction. The linearised 
template was then digested with the EcoRl enzyme to produce 5' protruding 
ends. Exo III digestion was then allowed to proceed with the reaction sampled 
every 40 s. These samples were then subjected to SI nuclease digestion to 
remove the single stranded tails. The plasmid molecules were then ligated and 
transformed into DH 5a by electroporation. Plasmids were eventually isolated 
by the 'one step' plasmid prep procedure and resolved on a 1% agarose gel. A 
number of plasmids were selected on the basis of size and digested with
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BamHl enzyme to release the insert DNAs, the results are presented in Figure 
3.9.
1 2 3 4 5 6 7 8 9 10 12 14 16
—  2.8 kb
“  500 bp
Figure 3.9 The deletion series plasmids generated from the p2.8B plasmid. The 
deletion plasmids have been digested with BamHl enzyme to free the insert 
DNA; lanes 3 to 17. The insert DNA ranges in size from 2.8 kb to 500 bp. 
Lane 1 is X Hindlll marker.
3.9 Sequence analysis of the p2.8B plasmid deletion library
Creation of a deletion library from the p2.8B plasm id allowed the 
unidirectional sequencing of individual clones from the plasmids T7 promoter 
sites to positions progressively within the 2.8 kb BamHl fragment. Miniprep 
DNA was prepared from each of the differing sized plasmids isolated from the 
deletion library. The double stranded template DNA was subjected to dideoxy 
chain termination sequencing method as described in Material and Methods; 
section 2.4.16. The resulting sequence from the nested set of deleted clones 
was analysed using the Assembly Align software package from Mac Vector. 
This allowed the overlapping sequences to be assembled into a 3 contigs, 
(Figure 3.10). A nucleotide BLAST search was performed with the 3 contigs; 
only contig 1 revealed any significant sequence similarity to entries present in 
the GenBank and EMBL databases. Contig 1 contained sequence that aligned 
to the rat NTR cDNA, results of the aligned sequences as well as the 
sequences of contigs 2 and 3 are presented in Figure 3.11., contig 1 was
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aligned to the rat cDNA sequence using the GCG Gap Align software 
programme from GCG.
500 bp 
M ►
I_______ I_______ i_______ I_______ i_______i_______i_______ I_______ i
T7 promoter T3 promoterP♦   B am H l*
" t -----------------1------------------ 1------- 1-----------------------------------------------------------1-----
Sma I' S m a l  ''' I I 1 I 1
Accl Sst I Acc I Nco I Pvu I Ncol Smal Sstl
E x o n  1
C o n t i g  1 
C o n t i g  2  
C o n t i g  3
1 2 5 0  b p
4 5 0  b p
4 0 0  b p
Figure 3.10 The relative position of the 3 contigs derived from the p2.8B 
plasmid. The sequencing of the subclones derived from the exonuclease 
deletion library produced 3 non-overlapping clones. There is a gap of 
approximately 300 nucleotides between contig 1 and contig 2, and a gap of 
about 200 nucleotides between contigs 2 and 3.
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Rat c DNA 
Mouse p2.8B
- 1 7 1  ..................................... GTCGTGAGCCCCAGAGCTACCAGGCAGGATCCCCTGG
l l l l l l l l l l l l l l  I I I I I I M  M i l l
- 1 8 4  CTGAGCCGGCACGTCTCTGAGCCCCAGAGCTCC. . . . CAGGATCTCCTGG 
- 1 3  3 ATAACGCGCTTACCCGCTGGACGGCACGCCCCCCTTAGCTTCTGCACCCT
I I I  I I N I  I I I I  M i l l  l l l l l l l l l l l l l l l l l  M I N I
ATAGCTGGCTT. CGCGCCGGACGCGACGCCCCCCTTAGCTTCCACACCCT 
- 8  3 CTCCTCTGGGCGCCTCCTCATCTGCCCCTGGAGGGACTTTCACCTGCAAA
M I N I M  1111111I I 1111111I I 111111111111111111 1111
CTCCTCTGAGCGCCTCCTCATCTGCCCCTGGAGGGACTTTCACCTTCAAA
+1
- 3  3 GGTGCAGGACAAAGCAGCATACCCGGCACCCACCATGCACCTCAACAGCT
I I I I I I I I I I I I I I I M i l l  I I I I  I I I I I ITT I I I I I I I I I I I I I I
GGTGCAGGACAAAGCCGCATATCTGGCGCCCACCATGCACCTCAACAGCT 
1 7  CCGTGCCGCAGGGCACCCCTGGTGAACCCGATGCCCAGCCCTTTT
l l l l l l  I I  I I I I I  I I  I I  I M i l l
CCGTGCAGCTCCGTGCAGCAGGGAGCCCAAGTGTGCCAGCCTTTC 
6 3 CGGGACCACAGTCCGAAATGGAAGCGACGTTCCTGGCGC . TCAGTTTGAG
I l l l l l l  I I  I 1111 I I  I I I I I  I I I  I I
CACATGCACAGTTCGGACTGGAGACGTCTCTGCGCTCACTTGAGCATGGT 
1 1 3  CAATGGTTCTGGCAATACCTCGGAATCCGACACGGCAGGGCCCAACAGCG
I I I I  I I I I I I I  I I I I I I I I I I I
TCTGGCATCTCAGATCATGTGAGCAGAATCCATCCTGGAGCCCAACAGCA 
1 6 3  ACCTGGACGTGAACACTGACATTTATTCCAAGGTGCTGGTGACTGCTATA
I I  I I  I I I I I I I I I I I I I I I I I I I I I  I I I I I I I I I I I I I I  I I I I I I I  I I
ACCTGGACGTGAACACTGACATTTATTCCAAGGTGCTGGTGACCGCTGTA
_________________________  TM I ____________________________
2 1 3  TACCTGGCACTCTTCGTGGTGGGCACTGTGGGCAACTCCGTGACAGCCTT
I I I I I  I I I I I I  I I  I I I I I I I I I I I I  I I I I I I I I I I I I I I I I I I I I I I
TACCTGGCACTTTTTGTGGTGGGCACTGTGGGCAACTCGGTGACAGCCTT 
2 6 3  CACTCTAGCGCGGAAGAAGTCACTGCAGAGCCTGCAGAGCACTGTGCATT
I I I  I I I I I I I I I  I I I I  I I I I I  I I I I I I I I I I I I I I I  I I I I I I I I I I I I ICACTCTAGCGCGGAAGAAGTCGCTGCAGAGCCTGCAGAGCACTGTGCATT
_________________________ TM I I __________________________
3 1 3  ACCACCTGGGCAGCCTGGCACTGTCTGACCTGCTTATCCTTCTGCTGGCC
I I I I I I I I I I I I I I I I I I I I I I I I I I I  I I  I I I I M i l l  I I I I I I I I I
ACCACCTGGGTAGCCTGGCACTGTCTGACCTGCTCATCCTGCTGCTGGCC 
3 6 3  ATGCCCGTGGAGCTATACAACTTCATCTGGGTACACCATCCCTGGGCCTT
I I I I I  I I  I I  I I I  I I I I I I I I I I I I I I I  I I I I I I I I I I I I I I I I I I I I I
ATGCCCGTGGAGCTGTACAACTTCATCTGGGTGCACCATCCCTGGGCCTT 
4 1 3  TGGGGACGCTGGCTGCCGTGGCTACTATTTCCTGCGTGATGCCTGCACCT
l l l l l l  I I I I I I I I I  I I I I  I I I I  I I I I I I I I I I I I I I I I  I I I I I
TGGGGATGCTGGCTGCCGTGGCTACTATTTCTGCGGAGATGCCTGCACCT
---------------------- -  TM III  .----------------------- .-------------
4 6 3  ATGCCACAGCCCTCAATGTAGCCAGCCTGAGTGTGGAGCGCTACTTGGCC
I I I I I I  I I I I I I  I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I  I I I I I
ATGCCACAGCCCTCAATGTAGCCAGCCTGAGTGTGGAGCGCTACTTGGCC
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612 ATCTGCCATCCCTTCAAGGCCAAGACCCTCATGTGCCGCAGCCGCACCAA
MINIUM! I M M M I M 11 M M M 11 111111111111111ATCTGCCATCCCGGCAAGGCCAAGACCCTCATGTCCCGCAGCCGCACCAA
|-------- :---------------:--------------- . TM I V ----- :--------------- .
662 GAAATTCATCAGTGCCATATGGCTAGCTTCGGCGCTGCTGGCTATACCCA
11111 M 11 M 11111II11 l l l l l l  MMIIMIIMMI IMMI
GAAATTCATCAGTGCCATATCGCTAGCCTCGGCGCTGCTGGCTGTACCCA 
712 TGCTTTTCACCATGGGCCT&. . . CAGAACCGCAGTGGTGACGACACGCAC
1111111II1111II11111 Il l l l l l l l l l l  M I I INI
TGCTTTTCACCATGGGCCTGACAGAGAACCGCAGTGCCGATGGCCAGCAC 
759 CCTGGCGGCCTGGTGTG. . . CACACCCATTGTGGACACAGCCACTGTCAA
M M I I M I Ml MINIM 11111111111111 1111762 CCTGGTGACCGGTGGTGTGCCACACCCACGGTGGACACAGCCACCGTCA. 
806 GGTCGTCATCCAG
I I I I I I I I I II I
812 .GTCGTCATCCAGgtaagaac a tc ta a a a g g  g g a c t c t c t g
a g c tg tn g c a  c a tta g a a g g  g ca ca cca n g  g g c a g c tg g g  
t t t c c c g t c t  g g g c t g t t t c  t t t c t a t t g g  a rcca ca ca g  
a a a c t t t t a g  c a g tg tc a c c  tc a g a a a ty c  c g g tn g a ttc  
n aggcaccac  ctggggan aa  a c a c a g c c g t  g t t g c c t t g t  
tggaaagaac tg tn c c tc a a  a a n c a c t t ta  t t c t t c n c c n  
n tg tc c c a a a  g tn g g cccn n  tnacnnannt nnnnannnan 
nnantcnnnn ancnnrgncn c t t a g a g t t g  gaanggnggg  
g g g ca tn a cc  a t c a c t c t c t  c a c t t t t c a t  c c a t t t g c a t  
g c c c t c c t n .................................................................................
................gap o f  about 300 n u c le o t id e s .................
............................................................................... g g a a t tg tc c
c c n t t t g a g t  ta c a c tn g c c  c tg n c tg tg a  agggan gtgg  
a tc n g n a c tt  ggtcn n gagg  gcncanagag g g g t t tg n c n  
g c n ccca tn c  ta a g tc g g tc  caggn cn tn g  n t g t t g t t a n  
t t c a g n t t c t  n ca ta a cn n t c t g a a c t g t c  tg g g g n c tg a  
c ta g g tg c c c  a g g t ta c n a t  t g g g a t t a tn  n a c n c c a t tc  
c n c tg n g g tc  tg a n c tta g n  tg ca ccg g a n  ca n a tg g g a t  
ccca ccn cg g  t a a g t t c c c n  n c a ta c ta a c  ncgacanggn  
c ta c tn c n c n  tc a g g a g c tg  a c c t t g a t g t  gngaaggggg  
c a tc g g c g g g  g tcccn a n a g  c a t a t t c c a c  n tc n c a a c c t  
c a tg c a tg g t  tn a a n g g tg c  c g n ta c tc n a  aaan gctn ac  
g ca tg ca n g a  t t a a c c a g t t  n tg a a .....................................
gap of about 200 nucleotides
cctgccatgt
catctgtctg
actcccagat
atgtccaggc
ttgtaaccca
tctctgaggt
gtcccccctg
tgcccaatgt
gtgcacattc
tagagggtcc
t t t c t t t c t t
cctcacagtg
aacacccaga
cattccgatg
gggccatggg
agctgccact
ttctaacaag
gttgggtgtt
tccagggaag
caccaagcc
agattctgtg
caccagaaat
ccaggcaact
gataagtgtc
cctcaggggg
gtcctctgca
ccacgtgaca
gaggtcgact
ctggctgtgc
atctatag
gtcacatggt
gctgggtcag
caacagtgca
cctgtgtgag
actgagtcag
tttaggcaa
agcagta
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Figure 3.11 Sequence alignment of the rat NTR cDNA with 5' sequence of the 
mouse 2.8 kb BamHl fragment. The sequence on the top line represents the 
rat cDNA, with the lower line sequence being derived from mouse genomic 
DNA. The sequences are numbered relative to the predicted underlined ATG 
start codons, i.e. +1. The putative transmembrane domains are indicated, I-IV, 
on the basis of the hydropathic profile predicted from the rat cDNA sequence. 
The 3' sequence of contig 1 and all of contigs 2 and 3 are presented in lowercase 
and do not reveal significant similarity to the cloned neurotensin receptors or 
any other sequences present in the GenBank or EMBL databases.
Comparison of the rat cDNA sequence to the mouse genomic sequence, 
revealed a similarity of 84% over the first 890 nucleotides of rat sequence. 
However, the majority of sequence divergence occurred in the region of the 
gene encoding the putative N-terminal portion of the receptor. Generally this 
is a highly variable region of G-protein linked receptors, (Burbach and Meijer, 
1992). When the sequence encoding the putative transmembrane domains I to 
IV, the first two intracellular domains and the first extracellular domain are 
considered separately from the N-terminal sequence, then the sequence 
similarity between the 2 species rises to 97%.
The mouse sequence was translated using GCG software 
to provide the predicted amino acid sequence. The peptide sequence was used 
to search the EMBL and GenBank databases with the GCG BLAST 
programme. The closest matches are presented as a table of amino acid 
identities at the foot of Figure 3.12. which also provides an alignment of the 4 
receptor sequences. The derived amino acid sequence shares a high level of 
identity with the human and rat high affinity neurotensin receptors 84% and 
79% respectively. The next highest significant identity was to the low affinity 
mouse receptor (41%). The database search also revealed lower identities 
(<25%) to other members of the G-protein linked family of receptors.
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Rat NTR-1 High affinity neurotensin receptor 73.2% 78.2% 41.0%
H um an NTR-1 High affinity neurotensin receptor _ 79.0% 40.0%
M ouse N TR-X Putative high affinity neurotensin receptor 79.0% _ 41.0%
M ouse NTR-2 Low affinity neurotensin receptor 40.0% 41.0% _
Figure 3.12 Sequence alignm ent o f the putative m ouse N TR  to other m em bers 
o f the N TR fam ily. The am ino acid sequences o f the hum an, rat and mouse 
neurotensin receptors were aligned w ith the putative m ouse receptor sequence 
using the G C G  m ultiple alignm ent program m e PILEUP. A table o f identitites 
was also produced using the GCG program m e D ISTA N C ES. The predicted 
transm em brane dom ains o f the receptors are underlined, based on the rat
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receptor cDNA sequence (Tanaka et al. 1990). Those amino acid residues that 
have been identified as critical for the ligand binding are highlighted with *, and 
those that lower binding activity by 2-3 fold with +, Botto et al., 1997.
NTR-1, high affinity neurotensin receptor; NTR-2, low affinity neurotensin 
receptor; NTR-X, putative high affinity mouse neurotensin receptor (sequence 
derived from clone p2.8B).
Primary sequence identity of G-protein linked receptors typically display 
sequence identity across the transmembrane domains of 85-95% for species 
homologues, to 60-80% for related receptor subtypes, down to 35-45% for 
related family members and down to 20-25% for unrelated G-protein linked 
receptors, (Strader et al., 1994). Similarly, when the sequence identity of the 
putative mouse NT receptor was compared to the rat and human high affinity 
receptors, for the amino acid sequence across the first 4 transmembrane 
domains, then a sequence identity of 96% and 94% respectively was recorded. 
These data suggests that the sequence encoded within clone p2.8B is an 
orthologue of the high affinity neurotensin receptor or at the very least a 
subtype of the receptor.
In general, most of the variability between G-protein 
linked receptors is in the N-terminal extracellular domain, the third 
intracellular loop and the C-terminal domain. It is also apparent from Figure 
3.11, for the portion of the neurotensin receptor depicted, that the most variable 
part of the protein is the N-terminal domain as highlighted by the lack of 
consensus between all 4 sequences. However, this region of G-protein linked 
receptors has been shown to be critical, as in the case of neurokinin receptors 
for the binding of the respective ligand, (Fong et al., 1992). A number of 
residues namely N23, Q24 and F25 have been shown to be necessary for high 
affinity binding. In contrast, the lutropin receptor has a long N-terminal 
domain (338 amino acids), and when expressed in the absence of this domain 
the mutant receptor still possess high affinity and specificity for its ligand 
luteinizing hormone, (Tsai-Morris et al., 1990). In general peptide binding G- 
protein linked receptors do not have stretches of conserved amino acids that are 
critical for ligand binding but rather specific amino acids within domains. 
Binding affinity studies of neurotensin to its receptor have also identified a 
number of residues which are essential for high affinity binding. Eight 
residues located within transmembrane domain III have been demonstrated by 
mutation studies to be important for neurotensin binding, (Pang et al., 1996). 
A more recent study, Botto et al. 1997, has extended this work to identify two 
residues Asp 139 and A rgl43 that when mutated abolish the ability of
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neurotensin to bind to the receptor. These residues are conserved within the 
predicted coding sequence derived from the p2.8B clone, Figure 3.12. 
Therefore, the lack of overall sequence conservation between the species may 
reflect the involvement of only a small number of amino acid residues in the 
receptors specificity for neurotensin.
Examination of the peptide sequence derived from the 
mouse clone p2.8B predicts that the coding sequence terminates within 
transmembrane IV at residue Q242, (—VIQ.). This termination of coding 
sequence is in agreement with the defined intron /exon structure of the human 
high affinity neurotensin receptor, see Figure 1.3. Furthermore, the mouse 
genomic sequence observes the AG-GT consensus sequence often found at 
exon-intron boundaries. This is further evidence to suggest that the genomic 
clone p2.8B encodes part of the high affinity neurotensin receptor.
3.10 Future confirmation of the putative mouse neurotensin receptor
The sequence from clone p2.8B suspected to encode the high affinity 
neurotensin receptor could be used as a probe to screen a mouse cDNA library 
in order to isolate the corresponding clones. Sequencing and subsequent 
expression studies of isolated cDNAs would verify the validity of the p2.8 
clone encoding the high affinity receptor. Full length cDNAs could be 
expressed in a cell line that does not normally express the receptor thus 
allowing ligand binding assays to be performed with neurotensin and its 
analogues. Alternatively, cDNAs could be expressed in Xenopus oocytes, 
subsequent electrophysiological measurements could be performed to confirm 
the receptor's functionality in response to neurotensin. Supporting evidence to 
authentic the p2.8B clone could also come from chromosomal localisation of 
this genomic clone. The rat cDNA has previously been used to assign the NTR 
gene to the H region of mouse chromosome 2, Laurent et al., 1994. It would 
be expected that clone p2.8B would also map to this region.
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3.11 Summary
Conditions for the successful screening of a mouse genomic DNA library, with 
a rat NTR cDNA derived probe, were defined by Southern blot analysis. A 
high stringency probing was performed with high stringency washings on 
digested mouse and rat genomic DNAs. This produced hybridising bands on a 
Southern blot with a profile typical of a single copy gene. For mouse genomic 
DNA; EcoRl bands of 9.2 kb and about 20 kb, and BamHl bands of 2.8 kb and
4.5 kb were observed. Therefore, these conditions were used to screen a 
bacteriophage X library, (EMBL3; Balb/c). After tertiary screening, 8  positive 
X clones were isolated. Initial analysis suggested that two of these clones 
contained the 2.8 kb BamHl band, (cedi and cedlO), and the 4.5 kb band, 
(ced5), both band sizes were previously observed with the initial Southern blot 
analysis, (Figure 3.2). The 2.8 kb and the 4.5 kb BamHl bands were subcloned 
and subjected to sequence analysis. The 2.8 kb band contained a potential 
large open reading frame encoding sequence with 84% homology to the first 
890 nucleotides of the rat high affinity NTR cDNA. The sequence homology 
increased to 97% when only the sequence encoding the transmembrane 
domains I-IV was considered. Furthermore, the predicted peptide sequence of 
the isolated mouse clone p2 .8  has a high identity to the human and rat high 
affinity neurotensin receptors, 84% and 79% respectively.
The principle aim of these experiments was to identify 
suitable mouse genomic DNA fragment(s) of the NTR gene for the design of a 
targeting construct. Therefore, the isolation of the 2.8 kb BamHl fragment 
containing homology to the 5* coding sequence of the rat cDNA satisfied this 
criterion. It contained suitable coding sequence that could be specifically 
mutated and presented a sufficiently large piece of homology for the design of 
an insertional type targeting construct similar to that of Hasty et al., 1991a. 
The design of such a construct and the principles behind the gene targeting 
approach employed, are detailed in Chapter 4.
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Chapter 4
A ’Hit and Run* Approach to Targeting the Neurotensin
Receptor gene
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4.1 Introduction
The primary aim of this section of work was to produce a targeting construct 
that could be used to mutate an allele of the NTR gene in embryonic stem (ES) 
cells. The various different approaches considered for targeting the NTR gene 
are detailed in Chapter 1. The most attractive strategy at the time, (the summer 
of 1992), was to generate an integrative construct for the NTR gene and 
employ the two-step recombination procedure successfully used by Hasty et 
a l , 1991a.
The two-step recombination strategy, also known as the 
'Hit and Run' method was chosen in preference to the other approaches for 
several reasons. It was reported by Hasty et a l  1991b, that higher gene 
targeting frequencies were obtained using integrative targeting vectors. In their 
study they observed 5 to 12 fold higher targeting frequencies using integrative 
vectors as opposed to replacement vectors of the same length. This is because 
the vector is linearised within the homologous gene sequence providing 
molecules for recombination with homology at both ends and thus superior to 
molecules with homology only at one end. Therefore, smaller gene fragments 
are required using this method. Furthermore, the two-step system allows the 
creation of site specific mutations within the target gene. Although, the 
original modification to the NTR gene was to create a null mutation, the 
development of the 'Hit and Run' procedure was seen to be invaluable to the 
creation of more specific subtle mutations via a second generation of targeting 
constructs.
The 'Hit and Run' procedure itself, introduces its site 
specific mutation into the target gene by a two step process. The targeting 
construct contains the homologous gene sequence with its engineered mutation. 
This sequence is flanked on either side with a neomycin and a thymidine 
kinase cassettes. This allows the positive selection of integration via 
neomycin, and reversion via selection for the loss of the thymidine kinase 
cassette. The construct is linearised within the region of gene homology, such 
that the first step of the targeting requires the insertion of the targeting vector at 
the gene locus by reciprocal recombination. This integration results in the 
duplication of the gene sequence used in the targeting construct separated by 
the neomycin cassette, the thymidine kinase cassette and the accompanying 
plasmid sequences. The second step of the procedure involves selection for 
resolution of the duplication by a single reciprocal intrachromosomal event, 
referred to as reversion. This reversion results in the removal of the neomycin
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and thymidine kinase cassettes, leaving behind one copy of the gene. Since 
recombination can occur at any position between any two homologous sites of 
the duplication, some of the revertant clones will retain the desired mutation 
and some will be wild type. This procedure is illustrated in Figure 4.1, with the 
desired reversion event shown, (reproduced from Chapter 1 for the readers 
convenience).
PGK W
NEO
Amp
Homologous Gene Sequence
* J
TK
PGK
Endogenous
Gene
Homologous
Recombination
I ntrachromasomal 
Recombination
Mutant
Allele
Figure 4.1 The 'Hit and Run' procedure. The diagram shows an insertional 
vector containing a neomycin cassette (NEO), a thymidine kinase cassette (TK), 
the plasmid p-lactamase gene conferring ampicillin resistance (Amp), 
phosphoglycerate kinase promoter (PGK), and the mutated gene site is 
indicated by an *. The method is a two step recombination process; 
homologous recombination of the vector at the gene locus results in a
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duplication that can be subsequently resolved by intrachromosomal 
recombination. The reversion event has resulted in the mutated sequence being 
retained within the endogenous gene. Refer to section 4.1 for a more detailed 
explanation.
4.2.1 Design of an insertional targeting vector for the NTR gene
The insertional vector for the disruption of the NTR gene was based on the 
p2.8B plasmid containing the coding sequence for the first 242 aa residues of 
the receptor. The strategy was to introduce a linker into the coding sequence 
at the AccI restriction site (GTATAC) at nucleotide position 210-215. The 
linker would introduce a stop codon within the region of the gene encoding the 
first transmembrane domain (TM) of the receptor at aa position 71. However, 
the parental plasmid also contained an AccI site within its polylinker. 
Therefore, the plasmid A ccI  restriction site had to be removed before the 
introduction of the mutagenic linker into the unique AccI site of the gene 
sequence. Finally, the mutated 2.8 kb BamHl fragment was subcloned into the 
BamHl site of the pNT plasmid. This plasmid contains a neomycin and 
thymidine kinase cassettes on either side of the BamHl cloning site. The 
completed construct can then be linearised within the region of homology at 
the unique Nhel site (GCTGTA), at nucleotide position 603-608, (within 
transmembrane domain IV). The completed construct and construction steps 
are summarised in Figure 4.2.
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BamHl
Xhol A go I EcoRI
T7 Promoter Hinc II Eco RV T3 Promoter
III
AccI Nhel
Th e 2 .8  kb  Bam  HI in s e r t  o f  th e p2 .8B p  lasm i d
Deletion of th e  AccI site fro m th ep la  smid by the 
ligation of the t f /nc l l  and Eco RV sites
t
Insertion o f  the  KLF linker in to  the coding sequence  
of the  NTR gen eat  the  AccI site
I
Subcloning of the2 .8  kb BamHl fra gment containing 
the KLF linker into the BamHl site of pNT plasmid
I PGK
NEO
Amp
BamHl % Nhel
NTR 2.8 kb,
PA
TK
PGK
BamHl
-►
Figure 4.2 The strategy for creating an insertional type vector for targeting of 
the mouse NTR gene. The completed vector, (pKLF), is shown linearised at the 
unique Nhel site. The asterisk denotes the linker insertion site. The location of
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sequences encoding the transmembrane domains I-IV; PGK phosphoglycerate 
kinase promoter; PA SV40 polyadenylation site; AMP, b-lactamase gene; NEO, 
neomycin phosphotransferase gene; TK, HSV thymidine kinase gene.
4.2.2 Verification of the genomic 2.8 kb B am H l fragment
Prior to the construction of the targeting vector it was advisable to check that 
the mouse 2.8 kb BamHl fragment was homologous to the the rat sequence. 
This question was addressed by Southern blot analysis of mouse genomic DNA 
using a probe derived from the non coding sequence of the subcloned 2 .8  kb 
BamHl fragment. The 1.5 kb P vm II fragment that was used as a probe is 
diagramatically portrayed in Figure 4.3.
Vector I II III IV Vector
PvuII PvuII
 1—
PvuII
1.5 kt>
Figure 4.3 The 1.5 kb Pvu II probe fragment. The above diagram represents the 
p2.8B plasmid. The presumptive transmembrane domains are represented (I to 
IV) and the relative positions of the PvmII restriction sites are shown.
The high stringency Southern blot analysis suggests that 
the sub-cloned 2.8 kb BamHl mouse fragment is homologous to the genomic 
fragment of the rat NTR gene. The autoradiograph of the Southern blot of the 
various digested genomic mouse and rat DNAs with plasmid controls is shown 
in Figure 4.4. Lane 1 depicts a mouse 9.2 kb EcoRl hybridising band of the 
same size as that previously observed using a probe derived from the rat NTR 
cDNA, (Figure 3.2). Lane 2 contains a 2.8 kb BamHl rat band which gives a 
weak hybridisation signal relative to the expected mouse BamHl band of the 
same size. Presumably this is because of greater sequence divergence between 
intronic sequences of different species. Lane 4 shows a hybridising 1.5 kb 
Pvm II mouse band as expected. Lane 5 contains a hybridising Kpnl band of 
about 9 kb. The control lanes, (6 , 7 and 8 ), of the Bam H l digested p2.8B 
plasmid produced the expected hybridising bands of 2 .8  kb in size.
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Lane 1 2 3 4 5
9 kb
2.8 kb
1.5 kb
Figure 4.4 G enom ic Southern blot analysis o f m ouse and rat D N A s, probed 
with a 1.5 kb P vmII fragm ent derived from  the p2.8B plasm id. 10 jig o f each 
genom ic DNA was digested with the appropriateenzym e, resolved on an 0.7%
agarose  gel, b lo tted  on to a ny lon  m em brane and p ro b ed  w ith  the
aforem entioned 32P labelled  probe. The resulting 3 day au toradiograph  is 
show n above w ith the hybrid ising band sizes ind icated  to the right o f the 
Figure.
Lane 1; 10 |ig  m ouse gD N A /PcoR I 
Lane 2; 10 |ig  rat gD N A /Pam H I 
Lane 3; 10 p.g m ouse gDNA/PvMlI 
Lane 4; 10 |ig  m ouse gDNAJ BamHl 
Lane 5; 10 |ag m ouse gDNAJKpnl 
Lane 6; 5 pg o f plasm id p2.8B/ZtamHI 
Lane 7; 0.5 pg o f plasm id p2.8B/PtfraHI 
Lane 8; 50 fg o f plasm id p2.8B/ZtaraHI
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4.2.3 Deletion of the AccI site from the p2.8B plasmid
Prior to the addition of a mutating linker, it was necessary to remove the 
parental plasmid derived A ccI restriction site from the p2.8B plasmid. 
Removal of the AccI restriction site was achieved by double digestion of the 
p2.8B plasmid with enzymes flanking the AccI site. The p2.8B plasmid was 
double digested with EcoKV  and Hincll enzymes. This resulted in the removal 
of the AccI site. The resulting linearised plasmid was band purified from a 1 % 
LMP agarose gel to remove it from the intervening 20 bp fragments. The 
purified plasmid was then blunt-end ligated overnight and transformed into 
D H 5a cells. The resulting colonies were picked, grown overnight, plasmids 
purified and subjected to AccI restriction digestion. Plasmid with the AccI site 
removed were only linearised on digestion as opposed to producing a 420 bp 
band. Before proceeding to the next cloning step, selected plasmids were 
sequenced to confirm the predicted sequence junction at the site of deletion. 
The sequence of one such plasmid, (p2.8BA"), is presented in Figure 4.5.
Xhol EcoRI PstI Smal BamHl
(XCOCCCTCG AC GTCATC 
GGGGGGGAGC TC( 'AGTAGdT
3A ATTCCTGCAG CCCGGGGGAT CCCTGAGCCG GCA 
TAAGGACGTC GGGCCCCCTA GGGACTCGGG CGT
pBluescript IISK-
polylinker 2.8 kb BamHl
Insert
Figure 4.5 Sequence from the p2.8BA' plasmid polylinker. The sequence 
shown is that of the vector poly linker where the ligation junction between the 
H indi and EcoRV restriction sites are indicated as boxed, (5' gtcatc 3'). The 
start of the 2.8 kb BamHl insert sequence is also shown.
4.2.4 Insertion of the KLF linker into the p2.8BA" plasmid
Insertion of the linker termed KLF into the p2.8BA" plasmid was undertaken in 
order to mutate the coding sequence of the NTR gene. The linker was 
designed such that it would introduce a stop codon into the NTR gene at 
nucleotide position 210-215, i.e. at aa position 71 of the receptor, thus
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d is ru p tin g  th e  g e n e  w ith in  th e  f irs t  tra n sm e m b ra n e  d o m a in . T h e  lin k e r  a lso  
in tro d u c e s  a u n iq u e  Kpnl  re s tr ic tio n  s ite  w h ich  can  b e  u se d  to  fa c i l i ta te  th e  
an a ly s is  o f  p o ten tia lly  ta rg e te d  c lo n es . T h e  K L F  lin k e r  w as m ad e  by  d e s ig n in g  
a s in g le  18 m er o l ig o n u c le o tid e  w h ich  w as  p a rtia lly  c o m p le m e n ta ry  to  itse lf , 
su ch  th a t o n  an n e a lin g  it fo rm e d  a d u p lex  w ith  s tick y  en d s  c o m p a tib le  w ith  a 
cu t A cc I re s tr ic tio n  site.
F irs tly , the  p2 .8B A ~ p la sm id  w as lin e a rised  at its  u n iq u e  
A c c I  s i te  a n d  t r e a te d  w ith  s h r im p  a lk a l in e  p h o s p h a ta s e ,  ( S A P ) , to  
d e p h o s p h o ry la te  its  e n d s  . T h e  K L F  lin k e r  w as  p re p a re d  by  k in a s in g  the  
o l ig o n u c le o tid e  to  p h o sp h o ry la te  the  en d s  o f  the  m o le c u le s . P r io r  to  l ig a tio n , 
the  o lig o n u c le o tid e  w as h e a te d  to  9 5 °C  fo r  5 m in u tes  and  th en  a llo w e d  to  coo l 
to  ro o m  te m p e ra tu re  s lo w ly . T h e  l in k e r  w as  th en  a d d e d  to  th e  l in e a r is e d  
p 2 .8 B A " a t 10 a n d  50  m o la r  e x c e s s  a n d  lig a te d  o v e rn ig h t. T h e  re s u l t in g  
lig a tio n s  w e re  tra n s fo rm e d , c o lo n ie s  p ic k e d , g ro w n  an d  th e  re su ltin g  p u r if ie d  
p la sm id s  an a ly se d  fo r su c ce ss fu l in se rtio n  o f  the  lin k e r by  Kpnl  d ig es tio n . T h e  
n e w  Kpnl  s ite  p ro d u ce s  a 4 6 0  bp  ban d  on  d ig es tio n  i f  th e  p la sm id  c o n ta in s  the  
K L F  lin k e r, (F ig u re  4 .6 ). O n e  in  ev e ry  th re e  p la sm id s  a n a ly se d  c o n ta in e d  the  
lin k e r . T h e  se lec ted  p la sm id s  w e re  su b seq u e n tly  c h e ck e d  fo r  a s in g le  c o rre c t 
in se r tio n  o f  the  K L F  lin k e r  by  d o u b le  s tra n d e d  se q u en c in g  u s in g  a sp e c if ic a lly  
d e s ig n e d  o lig o n u c le o tid e  th a t h y b r id ise d  u p s tre a m  o f  the  in se r tio n  s ite . T h e  
p la sm id  se q u en c e  ac ro ss  th e  s ite  o f  in se rtio n  and  d e ta ils  o f  the  K L F  lin k e r  are  
g iv en  in F ig u re  4 .7
1 2 3 4 5 6 7 8 9 1 0
■— 4 6 0  bp
Figure 4.6 R estriction analysis o f p2.8B  plasm ids contain ing  the K LF linker. 
P lasm ids were d igested  w ith Kpnl  to identify those that contained  the K LF 
linker. Lanes 4, 6 and 8 contain plasm ids with the KLF linker; lanes 1, 2, 3, 5, 7 
and 9 are p2.8 plasm ids cut w ith Kpnl; lane 10 is 1 kb m arker.
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G  - 
T  -
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S to p
C o d o n
Figure 4.7 Sequence o f the KLF linker across the AccI site o f insertion. The 
sequence is from  the single insertion o f a KLF linker into the p 2 .8B A ' plasm id. 
The in-fram e stop codon and Kpnl restriction site that the linker in troduces are 
indicated.
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4.2.5 Subcloning of the 2.8 kb Bam H l fragm ent of the p2.8BA“ plasmid 
into the pNT plasmid
T h e  f in a l s tep  in  th e  c re a tio n  o f  an  in se rtio n a l v ec to r, (p K L F ), w as to  su b c lo n e  
the  2 .8  k b  BamHl  f ra g m e n t fro m  o f  the  p2.8BA ~ p lasm id  in to  the  p N T  p la sm id . 
T h e  p2 .8 B A ~  p la s m id  w as  d ig e s te d  w ith  th e  BamHl  e n z y m e . T h e  re s u l t in g  
d ig e s t w a s  re so lv e d  on  a 1 .2%  L M P  ag a ro se  gel an d  the  2 .8  kb  BamHl  b an d  
w as p u r if ie d . T h is  D N A  fra g m e n t w as th en  lig a ted  in to  the  d e p h o sp h o ry la te d  
BamHl  c u t p N T  p la sm id  a t a  v e c to r  to  in se rt ra tio  o f  1:3 and  1:1. T h e  lig a tio n s  
w ere  th e n  tra n s fo rm e d  in to  D H 5 a  ce lls ; re su ltin g  c o lo n ie s  w ere  p ick e d , g ro w n  
o v e rn ig h t ,  an d  p la s m id s  p u r if ie d  by  the  'o n e  s tep ' m in i-p re p  m e th o d . T h is  
a llo w e d  p la sm id s  to  be  re so lv e d  on  a 1% a g a ro se  gel and su c ce ss fu l su b c lo n e s  
to  b e  is o la te d  on  th e  b a s is  o f  s iz e . H o w e v e r , p re s u m p tiv e  p o s it iv e s  w e re  
s u b je c te d  to  Bam  H I d ig e s tio n  to  c o n firm  the  p re se n c e  o f  th e  2 .8  k b  in se r t. 
F u r th e rm o re , th e  o r ie n ta tio n  o f  th e  in se r t  w as d e te rm in e d  by  Sstl  d ig e s tio n , 
s in c e  th e  in se r t  c o n ta in s  a s in g le  Sstl  s ite  35 bp  fro m  o n e  en d . T h e  p N T  
p la s m id  c o n ta in s  3 Sstl s ite s , p ro d u c in g  tw o  d is tin c tiv e  b a n d in g  p a tte rn s  on  
d ig e s tio n  (a p p ro x im a te  s ize s  o f  e ith e r  4 .4  kb , 2 .8  kb , 1.9 kb  and  1.2 k b  o r 4 .7  
kb , 4 .4  kb , 1.2 k b  an d  60  b p ). F ig u re  4 .8  p re se n ts  an  e x a m p le  o f  su c h  an  
a n a ly s is . In  to ta l, 4  such  p la sm id s  w ere  iso la ted , k n o w n  as p K L F (A , B , C , and  
D ).
Lane 1 2 3 4 5 6 7  8 9
Figure 4.8 R estriction analysis o f pN T plasm ids containing the 2.8 kb BamHl 
fragm ent. BamHl d igestions released  the 2.8 kb inserts from  the pN T
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plasmids. Sstl digestions revealed the orientation of the inserts in the pNT 
plasmids.
Lane 1; clone 1 /BamHl 
Lane 2; clone 2 /BamHl 
Lane 3; clone 3 /BamHl 
Lane 4; clone 4 /BamHl 
Lane 5; 1 kb Marker 
Lane 6; clone 1 /Sstl 
Lane 7; clone 2 ASstl 
Lane 8; clone 3 /SM 
Lane 9; clone 4 ASM
The BamHl digestions in Figure 4.8 reveal two clones containing the 2.8 kb 
insert i.e. clone 1 and clone 3. Both clones have the insert ligated into the pNT 
plasmid in the same orientation as revealed by the Sstl digests. This orientation 
is the same as that presented for the completed plasmid in Figure 4.2. Clone 2 
is the wild type plasmid with no insert. Clone 4 is an unknown contaminant.
4.3 Targeting the NTR gene using the pKLF vector
4.3.1 Transfection and selection of E14 ES cells
The pKLF plasmid was linearised within the region of homology at the Nhel 
site, as detailed in Figure 4.2. The E14 ES cells were expanded to a density of 
5 X 107, and prepared as described in Material and Methods. After 
electroporation the cells were plated onto 6  round plates, ( 1 0  cm in diameter). 
Selection for neomycin resistance was achieved by adding 200 |ig/ml of G418 
to the medium in which they were maintained for the next 14 days. Colonies 
were then big enough to be picked, (at least 1 mm in diameter). One half of 
each colony was picked into a 24 well plate, expanded and frozen down, 
(section 2.5.6), the other half of the colony was harvested for PCR analysis. A 
total of 650 colonies were processed in this manner.
4.3.2 PCR analysis of G418 resistant colonies
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The G418R colonies should not require to be analysed at this stage , but 
expanded and selected with gancyclovir to produce revertant Ganc$ colonies. 
Then the GANCS colonies would be analysed by Southern blot or PCR 
analysis, for the correct reversion event. For the NTR gene targeted with the 
pKLF insertional vector, both possibilities existed for the analysis of ES cell 
clones because, the KLF linker molecule introduces a new K pnl site for 
Southern analysis, and also provides unique sequence for the design of a PCR 
primer pair for a diagnostic PCR. However, the desired reversion event will 
not be detected unless the insertional vector has integrated at the NTR gene 
locus. Therefore, the G418R colonies were screened for the correct insertion of 
the targeting pKLF vector at the NTR gene locus by PCR.
The diagnostic PCR reaction to identify clones containing 
the correct insertional event was performed using the primer pair detailed in 
Figure 4.9. A unique forward primer designed to hybridise to the KLF linker, 
and a reverse primer to the 2.8 kb BamHl insert at a point down stream of the 
Nhel cut site. The reasoning for this experimental design was that this PCR 
reaction could only possibly produce a 900 bp band if the targeting vector had 
correctly inserted to give a duplication, therefore, creating contiguous sequence 
between the ES4 and ES6  primer sites. The majority of the G418R colonies 
should result from random integrants, thus not allowing the production of the 
900 bp PCR band.
NTR 2.8 kb  Bam Hl
BamHl X N tiel Bam H l
ES4 P2 ES6
900 bp  PCR Product
Figure 4.9 Primers for the PCR analysis of G418R ES colonies. Primer positions 
are shown relative to the NTR 2.8 kb BamHl fragment of the pKLF vector and 
its Nhel cut site. The 3' positions of the primers are indicated by arrow heads. 
PCR analysis of G418R colonies was performed using the ES4 primer, (5' ctg 
gtg acc get gta tga ggt a 3'), and the ES6 primer, (5' etc tcc ata tgt tgc tea gta t 
3'). The 32P end labelled P2 primer, (5' get age cat atg gca ctg atg a 3'), was 
used as a probe in the Southern analysis of the PCR products.
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T h e  D N A s o f  th e  G 4 1 8 R c o lo n ie s  w e re  a n a ly s e d  in  
b a tc h e s  o f  12 p o o le d  c o lo n ie s  /P C R  rea c tio n . P o s itiv e  P C R  rea c tio n s  w o u ld  be 
fo llo w e d  by  P C R /s ib -se le c tio n  to  id en tify  in d iv id u a l p o s itiv e  c lo n es , (K im  an d  
S m ith ie s , 1988). T h e  resu lts  o f  one  su ch  P C R  sc reen  are  sh o w n  in F ig u re  4 .1 0 . 
I t  w o u ld  a p p e a r  th a t  so m e  o f  the  P C R  re a c tio n s  h a v e  in  fa c t  p ro d u c e d  the  
d ia g n o s tic  9 0 0  b p  b a n d  as w e ll as som e  b an d s  o f  u n e x p e c te d  s izes. T h e re fo re , 
th e  g e l w as  S o u th e rn  b lo tte d  and  p ro b e d  w ith  a 32P e n d  la b e lle d  p rim e r, (P 2 ), 
th a t  h y b r id ise s  in te rn a lly  to  the  900  bp  b a n d  to a u th e n tic a te  the  900  b p  b a n d , 
d e ta ile d  in  F ig u re  4 .1 0 .
9 0 0  bp
1 2 3 4  5 6 7 8  9 1 0 1 1 1 2
Figure 4 .10 The PCR analysis o f batches o f 12 G 418R colonies, (top panel), 
and the Sou thern  analysis o f the PC R  reactions, (low er panel). T he PC R 
analysis o f the pooled clones, using prim ers ES4 and ES6, was perform ed on 
100 ng o f  D N A  denatured at 95°C for 10 m inutes. 35 cycles were perform ed at; 
94°C for 30 s, 57°C for 1 minute and extended at 72°C for 1.5 m inutes. 10 |l l  of 
each reaction were resolved on a 1.2% agarose gel. The gel was transferred to a 
nylon m em brane and probed with the 32P labelled  P2 prim er, (low er panel). 
The expected 0.9 kb band is indicated on the right o f each picture. Lanes 1 and
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12 are 1 kb m arker, lanes 2 to 11 are the PCR reaction products for pooled  
colonies A to J.
T h e  re s u l t  w as  s o m e w h a t u n e x p e c te d  in  th a t 4 , (p o ss ib ly  5), o f  th e  10 p o o ls  
p ro d u c e d  h y b rid is in g  b an d s  o f  the  e x p e c te d  9 0 0  bp ban d , (lanes 5, 7 , 9 an d  10), 
an d  a  n u m b e r  o f  sm a lle r  h y b rid is in g  b a n d s  w ere  p re se n t in  m an y  o f  the  lan es . 
O n e  o f  the  p o s itiv e  p o o ls  w as e x p a n d ed , a llo w in g  D N A  to be iso la te d  fro m  10 
o f  th e  12 c lo n e s  fo r  P C R  an a ly s is , ( f ig u re  4 .1 1 ). T h is  re su lte d  in  3 p o te n tia lly  
p o s i t iv e  c lo n e s  b e in g  id e n tif ie d . T h is  r e s u l t  w o u ld  in d ic a te  a  ta rg e tin g  
f re q u e n c y  o f  a p p ro x im a te ly  1 in  10 ta rg e te d  c o lo n ie s . S u ch  a h ig h  ta rg e tin g  
f re q u e n c y  w as  n o t a n tic ip a te d  a n d  w as  p re su m e d  to  be  th e  r e s u l t  o f  fa ls e  
p o s itiv e s  w h ich  are  d isc u sse d  la ter. N e v e rth e le ss , the  P C R  resu lts  in d ic a te  the  
p o te n tia l p re se n c e  o f  p o s itiv e  c o lo n ie s  fo r the  in te g ra tio n  o f  the  p K L F  v ec to r.
1 2 3 4 5 6 7 8 9  10 12
— 900 bp
1 2 3 4 5 6 7 8 9  10 12
— 9 0 0  bp
Figure 4.11 The PCR and Southern blot analysis o f individual clones from  pool 
D o f G 418R colonies, (lane 5 o f F igure 4.10). The PCR reaction and Southern 
blot conditions are the sam e as those detailed in F igure 4.10. Lane 1 is 1 kb 
m arker; lanes 2 to 12 are the PCR and Southern blot results for clones D1 to 
D l l .  The expected diagnostic PCR band o f 0.9 kb is apparently present in lanes 
3, 5 and 10.
114
Chapter 4
4.3.3 PCR analysis and selection of gancyclovir resistant colonies
The integration of the pKLF insertional vector creates a duplication within the 
NTR gene which does not necessarily disrupt the gene. Therefore, selection 
for the reversion event was undertaken to produce revertant ES colonies 
containing a disrupted NTR allele. The G418R colonies were expanded to a 
density of 1.5 X 106 cells/colony, and selected in gancyclovir for 10 days. 
Then the GancR colonies, 150 in total, were picked and analysed in pools of 12 
clones as described before. The DNA from each pool was analysed for the 
presence of a revertant clone carrying the desired mutation i.e. retention of the 
KLF linker at the AccI site of the NTR gene, by PCR. The PCR strategy is 
such that the primers selected, (ESI and ES2), will only permit amplification 
when the correct gene targeting/reversion event has occured. The ES 1 primer 
is unique to the construct with its 3' end complimentary to the KLF linker. The 
ES2 primer is gene specific but hybridises upstream of the region of homology 
used in the targeting construct. Details of the primers used are shown in Figure 
4.12.
NTR 2.8 kb  Bam Hl
EcoRI Bam H l %
N h e l
Bam Hl
ES2 p i  ESI
— * ------------------------------------r- 420 b p  PCR product
Figure 4.12 The primers for the PCR analysis of GancR colonies. The positions 
of the primers are shown relative to the 2.8 kb BamHl fragment of the pKLF 
vector. The ESI primer, (5' aca aaa agt gcc agg tat gag gta c 3'), is unique for 
the vector site at the KLF linker. The ES2 primer, (5' a gga gat ccc aga etc tga 
agg aga 3'), site is 5' to the region of homology used in the targeting construct. 
The 32P end labelled PI primer, (5' get age cat atg gca ctg atg a 3'), was used as 
a probe in the Southern analysis of the PCR products.
115
Chapter 4
T h e  p ro d u c ts  o f  the  P C R  re a c tio n s  w e re  ru n  on  a 1 .4%  a g a ro se  gel, w h e re  no 
v is ib le  b a n d s  w e re  o b s e rv e d  o f  th e  c o rre c t  s iz e , w ith  th e  e x c e p tio n  o f  th e  
p o s itiv e  co n tro l, (F ig u re  4 .1 3 ). T h e  g e l w as S o u th e rn  b lo tted  and  p ro b e d  w ith  
an  in te rn a lly  h y b rid is in g  p r im e r  ( P I ) ;  an  e x a m p le  o f  a  ty p ica l b lo t is sh o w n  in 
F ig u re  4 .1 3 . T h e  o n ly  v is ib le  h y b r id is in g  b an d  is th a t o f  the  p o s itiv e  c o n tro l. 
T h is  re su lt w as ty p ica l fo r  all th e  G a n c R c o lo n ie s  an a ly se d , d e m o n s tra tin g  th a t 
n o  r e v e r ta n t  c o lo n ie s  c o n ta in in g  th e  m u ta g e n ic  K L F  lin k e r  a t th e  d e s ire d  
lo ca tio n  w ere  iso la ted .
Lane 1 2 3 4 5 6 7 8 9  11
Lane 1 2 3 4 5 6 7 8 9  11
Figure 4.13 The PCR analysis o f batches o f 12 G ancR colonies, (top panel), and 
Southern blot analysis o f the PCR reactions, (low er panel). The PCR analysis 
of the pooled colonies, using prim ers E S I ana ES2, was perform ed on a 100 ng 
of D N A  denatured at 95°C for 10 min. 35 cycles were perform ed at; 94°C  for 
30 s, 62°C for 1 m inute and ex tended  at 72°C for 1 m inute. 10 ml o f each
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reaction was resolved on a 1.4% agarose gel. The DNAs were transferred to 
a nylon membrane and probed with a 32P end-labelled primer PI, (details 
provided in Figure 4.12), the resulting autoradiograph is represented in the 
lower panel. Lanes 1 and 11 are 1 kb marker, lanes 2 to 8 are 12 clone pools (A 
to H), lane 9 is a positive control PCR of 100 ng of mouse DNA amplified with 
primers ESI and P2 which produces an 830 bp band which contains the PI 
primer probe site, lane 10 is a negative control PCR of 100 ng mouse DNA 
amplified with the ES 1 and ES2 primers.
4.3.4 Discussion of the results for the PCR analysis of G418R and GancR 
ES colonies
A number of positive PCR results were observed for G418R colonies, yet no 
positive PCR results were observed in the analysis of the revertant GancR 
colonies. The projected number of G418R colonies, containing the pKLF 
insertional vector integrated as desired at the NTR locus, was higher than 
expected at possibly 1 targeted integration for every 10 G418R colonies. It was 
probably the case that a number of false positives were observed. Several 
explanations can be given to explain these results, some of which are presented 
below.
When employing any PCR screening regime for the 
analysis of ES colonies, false positives are always a potential problem, since 
the picking of a positive colony from the culture plate results in the dispersion 
of cells from that colony throughout the plate. Thus subsequent colonies 
picked may be contaminated with these ’positive cells', resulting in positive 
PCR results for negative colonies.
Another source of false positives could come from the 
'end extension repair' of the pKLF vector prior to genome integration. This 
phenomenon was first reported by Adair et al., 1989 and further studied by 
Aratani et a l , 1992. They suggest that the incoming targeting vector has its 
region of homology extended by some sort of repair mechanism mediated by 
homologous recombination. One proposed model for this end extension repair 
involves the pairing of one end of the homologous vector sequence with the 
target locus, and subsequent extension of the vector sequence from the 3' end 
of the molecule with the 5' end of the vector molecule being repaired by the 
enzymes responsible for DNA synthesis of the lagging strand. This would 
result in the formation of a Holliday junction between the vector and the target
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locus. Following branch migration of the Holliday junction, resolution of the 
junction would result in an extended vector molecule that could then integrate 
randomly into the genome, ( model A is presented in Figure 4.14). The other 
proposed mechanism for end extension repair, model B, is also presented in 
Figure 4.14. This mechanism requires a DNA replication fork to pass through 
the target locus, opening the duplex DNA. The action of endonucleases and 
exonucleases could create single stranded tails within the replicating duplex. 
These molecules could then pair with the incoming single stranded vector ends. 
Following, gap repair and the action of nucleases, the production of end 
extended vector molecule and a repaired target locus could result.
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Tar get ing Vector
M O D E L  A
5' ,
Gene
Locus
/ZX
5 ' --------
5 '
, /  X
A  3'
i
5 '
A 3'
A 3'
A 3'
M O D E L  B
5 '
AJ f
J l----------Z
\n------ r
A  3 '
A  3 '
A  3 '
A 3'
A 3 ’
Figure 4.14 Two possible models for end extension repair. Refer to the text for 
a description of models A and B. The diagrams were adapted from Aratani et 
a l, 1992.
Regardless of the mechanism of end extension repair the Aratani et al., 1992 
study, produced 58 potentially targeted colonies with various targeting vectors. 
However, only half of these were the result of gene integration at the aprt gene 
locus under study. PCR and Southern analysis confirmed that the false 
positives were the result of the phenonomen known as 'end extension repair' of 
the incoming vector followed by random genome integration.
Another possibility for the production of false positive 
PCRs could be by a process known as 'PHLOP', polymerase halt mediated 
linkage of primers, (Fronham et al., 1990). It has been suggested that the 
initial rounds of a PCR reaction can give rise to 'extended primers' as a result of 
truncated linear amplification from a primer target site within the genome. The 
resulting longer primer molecules could subsequently hybridise to another site 
within the genome that contained extensive homology, especially to the 3' end 
of the molecule. If this second site was situated at an amplifiable distance from
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one of the original primer sites, then exponential amplification of intervening 
sequence could occur, generating false positive PCR bands. Thus 'PHLOP', 
must be considered as a serious source of contamination in PCR analysis of the 
G418R colonies. This was principally because of the potential for the 
generation of those 'extended primer' molecules. Each G418R clone contains 
the chromosomally integrated vector, albeit randomly integrated. However, the 
unique ES4 primer, designed to hybridise to the KLF linker, would have been 
able to do so for every G418R clone. The first rounds of a PCR reaction could 
produce 'extended primer' molecules if the Taq polymerase stalled within the 
region of NTR homology. These molecules would then have sequence 
homology at their 3' ends to the NTR gene. If the sequence extension of the 3' 
end is long enough, then molecules of sufficient homology will be produced 
that could hybridise to the endogenous NTR gene. The ES6  primer which 
hybridises upstream of the Nhel site is gene specific and not vector specific. 
Thus the ES6  primer in combination with 'extended primers' could potentially 
produce target molecules that could be exponentially amplified in subsequent 
rounds of PCR, by the ES4 and ES6  primers, resulting in the production of the 
900 bp band and false positives. Fronham et al., 1990, note that, these 
artifacts are generally produced after 30 rounds or more of PCR, and especially 
when the DNA template is isolated from a cell pool of transfectants.
Furthermore, it must be noted that the success of this 
PCR analysis relies on separating the 2 primer sites, (ES4 and ES6 ), by 
linearisation of the Nhel vector site. Linearisation of the molecule followed by 
random integration of the vector molecule, should result in two juxtaposed 
primer sites that are not capable of producing the amplifiable 900 bp band. 
However, if the vector re-ligates prior to integration then the vector sites may 
no longer be separated when the vector integrates. Thus, a re-ligated vector 
that integrates without disruption of the intervening sequence between the ES4 
and ES6  primer sites, would provide a suitable target sequence for the 
production of 900 bp molecules and false positive PCR results. A possible 
solution to this problem would have been to use a primer downstream of ES6 , 
lying outwith the region of the gene that is duplicated. However, this would 
require the reliable amplification of a PCR product in excess of 2.4 kb.
Therefore, in this experiment a number of sources by 
which false positive PCR reactions could be produced must be taken into 
consideration. However, some of the 650 G418R colonies may be the result of 
the correct integration of the pKLF vector. Thus the colonies were expanded 
and selected using gancyclovir for the reversion event to produce GancR
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colonies containing the mutating KLF linker at the NTR gene locus. The PCR 
analysis of the 150 GancR colonies did not result in the detection of any desired 
colonies. This could be explained, in part, by the explanations given for false 
positive PCR results. However, if colonies carrying the duplication of the NTR 
gene existed, they may not have been expanded to high enough density prior to 
gancyclovir selection for the desired reversion event to be produced. When 
this selection was undertaken only two published examples existed of 
successful reversion events (Hasty et al., 1991a). The hprt gene duplication 
reverted at a rate of 4.3 x 10~6 per cell generation with two of the fifteen HAT1, 
colonies retaining the desired mutation. The reversion rate for the Hox-2.6  
gene duplication was at a rate of 3.9 X 10‘ 3 per cell generation. This is a 1000- 
fold difference between these 2  genes, which the authors suggest could be a 
function of the recombinational efficiencies of the two gene loci. I proceeded 
with expanding the cells to a density of 1.5 X106 cells per colony prior to 
selecting for the reversion event without any knowledge of at what frequency a 
targeted NTR gene may revert. Thus the cells may not have been expanded to 
a great enough density to recover the desired reversion event.
Moreover, the design of the insertional type vector pKLF 
was unknowingly further compromised by the position of the mutation relative 
to the double strand break in the vector, as revealed in a recent publication by 
Hasty et a l , 1995. This study investigated the frequency with which the ends 
of insertion vectors undergo gene conversion and if the reaction has a 
preference for conversion to vector or chromosomal sequence. A number of 
insertion vectors for the aprt locus carrying a mutation within the gene 
homology were linearised at various distances from the mutation and the 
frequency of gene conversion measured. It was observed that the frequency 
with which the mutation was lost in favour of chromosomal sequence on 
homologous integration was inversely proportional to the distance between the 
vector mutation and the double strand break. Loss of chromosomal sequence 
in preference to vector sequence was a low frequency event. One particular 
insertion vector was linearised at 0.427 kb from the mutation and underwent 
gene conversion to chromosomal sequence at 40% of all homologous 
integrations. Extrapolation to the pKLF insertion vector in this study, predicts 
that at least 40% of correctly targeted clones would have lost the mutagenic 
linker sequence by gene conversion. In conclusion, this particular vector 
construction may have produced targeted clones but, due to the design of the 
vector and/or duplication reversion rates, it was unlikely to give the desired 
revertant clones at a practical frequency.
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4.4 Sum m ary
An insertional type vector for targeting the neurotensin receptor gene (NTR) by 
the 'Hit and Run' approach was made using the homologous 2.8 kb BamHl 
genomic fragment. This BamHl fragment was engineered such that a 
mutagenic KLF linker was introduced at the AccI site and the homologous gene 
sequence was flanked on either side by a neomycin and a thymidine kinase 
cassette. Insertion of this linker created an in-frame stop codon and introduced 
Kpnl restriction sequence into the region of the gene encoding the first 
transmembrane domain of the receptor. The linker served two purposes, firstly 
to create a null mutation of the gene and secondly to provide a unique sequence 
for the identification of targeted clones by a PCR or Southern blot strategy. 
The gene targeting approach, a two step recombinational procedure known as 
'Hit and Run', was attempted. The first step of producing a targeted duplication 
of the NTR gene may have been achieved. However, the PCR analysis 
appeared to be complicated by false positive PCR results, since an unusually 
high targeting frequency of possibly 1 in 1 0  clones was suggested by the data. 
The second step of selecting for revertant colonies did not yield any of the 
desired revertant colonies. This may be a result of vector design and/or not 
expanding the colonies to a high enough density prior to gancyclovir selection 
for reversion. The results and conditions of the targeting experiment are 
summarised in Figure 4.15
ES cell 
line
Electroporation
settings
No. of cells and 
amount of vector
Transformation
frequency
Targeting
frequency
No. of revertant 
targeted clones
E14 500 |IF, 250 V 5 X 107 cells 
25 |ig DNA
1.3 X 10-5 1/10* 0 from 150 
resistant colonies
Figure 4.15 Summary of the results from the 'Hit and Run' targeting experiment 
of Chapter 4. *Targeting frequency as determined by PCR analysis, see section 
4.3.4 for a discussion on false positives.
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Chapter 5
Construction of a Replacement Vector for Targeting the 
Neurotensin Receptor Gene.
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5.1 Introduction
The lack of success in generating a targeted mutation of the NTR gene with the 
pKLF vector, led to the re-evaluation of the 'Hit and Run' procedure as a 
method for producing a null mutation of the gene. Principal concerns 
surrounded the general applicability of this procedure, such as the rate of 
reversion of the 'average' gene locus. Furthermore, the actual design of the 
targeting construct (pKLF), with its relatively small amount of gene homology 
and position of the mutation within that homology, may have compromised the 
vector's ability to generate the desired mutation. Moreover, data concerning 
the use of isogenic versus non isogenic DNA, overall length of homology, the 
selective utilities of insertional and replacement vectors, became available with 
respect to their influence on targeting frequencies of the Hprt gene (Deng, et 
al., 1992a). For these reasons a replacement construct, utilising the positive 
negative selection (PNS) strategy (Thomas, and Capecchi, 1987), was designed 
to target the NTR gene.
The first step in construction of the replacement vector 
was the isolation of isogenic mouse genomic fragments from a 1 library derived 
from DNA of the mouse 129J strain. Subcloning of a suitably large fragment 
of the NTR gene and restriction map analysis followed. Vector design required 
the introduction of a neomycin cassette to produce a mutation and provide 
positive selection of vector integration into ES cells. Secondly, a thymidine 
kinase cassette was added to provide negative selection against random 
integrants and hence enrich for targeted events. A PCR screening procedure 
was designed to detect targeted clones. However, to ensure the success of such 
a screen a control vector was also made. This vector was based on the 
replacement vector with additional 5' gene sequence, to that of the replacement 
construct. Thus the control vector contained homologous sequence that would 
only be encountered if the targeting vector correctly targeted the NTR gene. 
This control vector allowed the evaluation of sets of PCR primers designed to 
detect homologous recombinants as a result of gene targeting with the 
replacement vector.
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5.2 Subcloning of the 9.2 kb E coR l fragment of the NTR gene from a 129J 
mouse genomic library
5.2.1 Screening of a bacteriophage X Dash 129 J mouse genomic library
The strategy for screening the X Dash 129J mouse genomic library was 
essentially identical to that for the isolation of X clones from X EMBL3 Balb/c 
mouse genomic library described in Chapter 3. The probe used was the same 
as the 32p labelled 1.4 kb Smal derived fragment of the rat cDNA previously 
used, (Figure 2.1). Prehybridisation and hybridisation of the library filters was 
performed exactly as before with the same 50% formamide based buffer. The 
only exception was that the library was plated onto 40 (10 cm X 10 cm) plates 
at a density of 25000 p.f.u./plate. Therefore a total number of 1 000 000 
plaques were screened.
5.2.2 Results of the library screen
j
i|
Initial screening of the library resulted in the identification of 18 putative 
positive X clones. After secondary and tertiary rounds of screening and 
! purification, a total of 16 X clones were isolated. Figure 5.2 represents the
i
| autoradiographs from primary and secondary rounds of the library screen.
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A
C
B
D
Figure 5.1 Prim ary and secondary screening o f putative positives from  the X 
D ash 129 J library. Panels A and B are autoradiographs o f a set o f rep lica  
filte rs from  the prim ary screen; the arrow s ind ica te  the positions o f  tw o 
presum ptive positive clones. Panels C and D are the autoradiographs from  the 
secondary screening o f a positive clone. The probe and hybridisation conditions 
are those detailed in Chapter 3, (section 3.2).
5.2.3 Identification of a genomic 9.2 kb £coRI fragm ent
T h e  g e n o m ic  S o u th e rn  b lo t a n a ly s is  fro m  C h a p te r  3, F ig u re  3 .2 , in d ic a te d  a 
h y b r id is in g  9 .2  k b  £ c o R I  b a n d  to  the  5 ' d e r iv e d  p ro b e  o f  th e  ra t c D N A . 
R e fe re n c e  to  the  su b se q u e n t 5' p ro b in g s  o f  the  X c lo n e s  F ig u re  3 .5  in d ic a te s  
th a t  th e  2 .8  kb  BamHl  fra g m en t o f  the  N T R  gen e  is lo c a te d  w ith in  the  9 .2  k b
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Eco R I fra g m e n t. T h e  2 .8  kb  BamHl  f ra g m e n t re fe rre d  to  w as th a t su b c lo n e d  
(p 2 .8 B ) and  u sed  fo r  the  c o n s tru c tio n  o f  a 'H it and  R un ' ty p e  v ec to r. S in c e  the
9 .2  k b  Eco  R I f ra g m e n t  c o n ta in s  a 5 ' p o r tio n  o f  th e  N T R  g e n e , e n c o d in g  
tra n s m e m b ra n e  d o m a in s  I to  IV , th is  w as c o n s id e re d  a su ita b le  f ra g m e n t o f  
g e n e  h o m o lo g y  fo r  the  c o n s tru c tio n  o f  a  re p la c e m e n t v ec to r . T h e  im m e d ia te  
g o a l w as to  id e n tify  su ch  X c lo n e s  c o n ta in in g  the  9 .2  k b  EcoRl  an d  su b c lo n e  
su c h  a fra g m e n t. T w o  su ch  X c lo n e s  w e re  iso la te d . F ig u re  5 .2  in d ic a te s  th e  
p re s e n c e  o f  th e  9 .2  k b  E coR l  an d  2 .8  k b  BamHl  b a n d s ; th e  9 .2  k b  b a n d  o f  
c lo n e  T 1 2  w as  su b c lo n ed .
9.2 kb 
2.8 kb
9.2 kb
2.8 kb
Figure 5.2 Restriction digestion and Southern analysis o f X clones T1 and T12. 
The d igestions w ere reso lved  on an 0.7%  agarose gel and transferred  to a 
nylon m em brane. The probe used was the 32p labelled 1.4 kb Smal fragm ent 
derived from  the rat cD N A . The hybridisations were perform ed as described 
in C hapter 3.
L a n es  1 an d  8 are  1 k b  m ark e r
lane  2:; c lo n e  T1 /BamHl  (d eg rad ed )
lane  3:; c lo n e  T1 /EcoRl
lane  4:; c lo n e  T1 /EcoRl  an d  BamHl
lane  5:; c lo n e  T 1 2  /BamHl
lane  6;i c lo n e  T 1 2  /EcoRl
lane  7;1 c lo n e  T 1 2  /EcoRl  and  BamHl
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Both clones T1 and T12 contain the 9.2 kb EcoRl fragment that hybridises to 
the rat NTR cDNA. This mouse genomic fragment contains the 2.8 kb BamHl 
fragment as revealed by the double digestions; lanes 4 and 7.
5.2.4 Subcloning and restriction mapping of the 9.2 kb E coR l fragment
The 9.2 kb EcoRl fragment from the X T12 clone was subcloned in plasmid 
pGem 7Zf. The EcoRl cut vector was dephosphorylated using shrimp alkaline 
phosphatase (SAP), extracted with phenol chloroform twice, precipitated with 
ethanol and resuspended in dH2 0 . The X DNA was EcoRl digested, 
precipitated with ethanol, resuspended in dH2 0 . Ligations were performed 
overnight and subsequently transformed into DH5a. The white recombinant 
colonies were analysed by the 'one step' mini prep DNA method, (Chapter 2, 
section 2.3.10). This resulted in the identification of subclones for the 9.2 kb 
EcoRl fragment as well as the 5' and 3' flanking EcoRl fragments, (4.8 kb and
1.2 kb), from the T12 clone.
The 9.2 kb EcoRl subclone, (p9.2EiG7), was confirmed 
by restriction enzyme analysis. Restriction digests were performed with rare 
cutting enzymes and those enzymes known to infrequently cut the 2 .8  kb 
BamHl fragment. The data generated in this analysis are summarised in Figure
5.3.
1 kb
Scale i------------ 1
E B N  N B K B  B X  E
2.8 kb Bam HIM---------------------------►
Figure 5.3 A restriction map of the 9.2 kb EcoRl fragment. The position of the 
previously characterised 2.8 kb BamHl fragment is indicated, as are the relative 
positions of the sequence encoding transmembrane domains by the black boxes. 
E, EcoRl\ B, BamHl; N, Ncol\ K, Kpril; Bg, BglH; X, Xbal.
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5.3 Construction of a replacement type targeting vector for the NTR gene.
5.3.1 The strategy for construction of the replacement vector
The replacement vector was generated by deleting part of the coding sequence 
contained within the 9.2 kb E coR l  NTR gene fragment, by inserting a 
neomycin cassette at the N col deletion site and placing a thymidine kinase 
cassette 3' of the large arm of gene homology. Creation of this construct 
required several cloning steps which are summarised by the flow chart 
presented in Figure 5.4. Essentially the neomycin and thymidine kinase 
cassettes were derived from the pNT plasmid, and sequentially introduced into 
the 9.2 kb EcoRl gene fragment. However, insertion of the neomycin cassette 
was via a Sail site introduced by the insertion of a linker at the Ncol deletion 
site. This extra linker step was necessary due to the presence of an Xhol site in 
the gene fragment. Finally, linearisation of this vector (p2.8EiNeoTk)
| produced a construct with two arms of homology, 1.3 kb and 6.4 kb, that was 
! used to target the NTR gene in ES cells.
i
it
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Subcloned the 9.2 kb EcoRl fragment of the NTR gene 
into the pGem7fZ plasmid.
Created the p9.2EiG7 plasmid
Deletion of the Ncol fragment ffomthe p9.2EiG7 plasmid.
This 1.5 kb Ncol fragment encodes aa residues 207 to 242 
of the gene. Ligation of a linker into this site introduced a 
unique Sail site.
Created the P9.2EiL plasmid.
--------------------------------------  Subcloned the end- filled
XbaVXhol Neo cassette 
fragment of the pNT 
plasmid into pBS SKII.
Subcloned the 1.75 kb Xhol fragment from the pNeo 
plasmid into the unique Sail site of the p9.2EiL plasmid. 
Created the p9.2EiNeo plasmid.
Subcloned the EcoRl 
/Hindlll thymidine kinase 
cassette fragment into the 
pGem9Zf plasmid.
Subcloned the the 9.45 kb EcoRl fragment from the 
p9.2EiNeo plasmid into the EcoRl site of the pTk 
plasmid.
Created the p9.2EiNeoTk plasmid.
Linearisation of the p9.2EiNeoTk plasmid at the unique 
Sail site created the replacement type construct for gene 
targeting in ES cells.
Figure 5.4 Construction of a replacement type vector. The various cloning steps 
and manipulations involved in creating the replacement type construct used for 
targeting of the NTR gene in ES cells.
130
Chapter 5
5.3.2 Deletion of the N c o l  fragment from the 9.2 kb E coR l NTR gene 
fragment and addition of a Sa il linker
Deletion of the Ncol fragment creates a mutation within the 9.2 kb EcoRl NTR 
gene fragment. This deletion step was followed by the addition of a linker, 
which created a unique Sail restriction site, into which a neomycin cassette was 
subcloned. Deletion of the Ncol 1.5 kb fragment removed part of the gene 
encoding aa residues 207 to 242; the remainder of the fragment was intronic.
The p2.9EiG7 plasmid was digested with N co l and 
resolved on a 1 % agarose gel from which the deleted plasmid was band 
purified to separate it from the 1.5 kb Ncol fragment. The deleted plasmid was 
then ligated overnight with the Sail linker, (5' cat ggc teg age 3’). However, no 
linker containing plasmids were isolated. Therefore, the deleted plasmid was 
dephosphorylated using the SAP enzyme. The partially self-complementary 
oligonucleotide used to make the linker with Ncol sticky ends, was 
phosphorylated with the T4 DNA kinase enzyme prior to its use. The 
phosphorylated oligonucleotide was heated to 95 °C for 10 minutes and allowed 
to anneal slowly to room temperature prior to the ligation. The deleted plasmid 
and linker were ligated overnight at vector to linker molar ratios of 1 :1 0  and 
1 :1 0 0 .
Successfully transformed ligations were analysed by 
restriction digestion of the plasmids. EcoRl/SaH digestions were performed; 
the EcoRl enzyme frees the 7.7 kb, (9.2 - 1.5), insert from the 3 kb plasmid, 
and the Sail enzyme cuts the insert in two, if the linker is present, to produce
1.3 kb and a 6.4 kb fragments. The desired modified plasmid, (p9.2EiL), was 
eventually obtained as is detailed in Figure 5.5. The Ncol digestion linearised 
the plasmid due to the conservation of the Ncol sites after linker insertion, (lane 
3). The Sail digestion also linearises the vector due to the presence of the Sail 
linker's restriction site, (lane 4). The Sall/EcoRl digestion produces the 
expected restriction pattern of 3 kb, 1.3 kb and 6.4 kb fragments for the 
modified plasmid, (p9.2EiL).
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7.7 kb 
3 kb 
1.3 kb
Figure 5.5 Restriction analysis o f the p9.2EiL  plasm id. The p9.2EiL  plasm id 
was digested w ith the appropriate enzym es, to detect the presence o f the Sail 
linker, and the reactions were resolved on a 1% agarose gel. Lane 1 is 1 kb 
m arker; lane 2, uncut p9.2E iL  plasm id; lane 3, p9.2EiL  /Ncol; lane 4, p9.2E iL  
/Sail', lane 5, p9.2EiL /Sail and EcoRl.
5.3.3. Insertion of the neomycin cassette into the p9.2EiL plasmid
T h is  s tag e  o f  th e  c o n s tru c tio n  in v o lv e d  tw o  sep ara te  su b c lo n in g  step s. F irs tly , 
th e  n e o m y c in  c a sse tte  fro m  the  p N T  p la sm id  w as su b c lo n e d  in to  the  p B S  SK  
11“ p la sm id . T h is  a llo w ed  the  n e o m y c in  c a sse tte  to  be re tr ie v e d  fro m  th e  p N e o  
p la s m id  b y  Xhol d ig e s tio n . T h e  Xhol e x c ise d  n e o m y c in  c a s s e t te  w a s  th en  
su b c lo n e d  in to  th e  c o m p a tib le  Sail s ite  o f  the  p 9 .2 E iL  p la sm id .
T h e  p N T  p la sm id  w as d ig es te d  w ith  th e  Xhol  an d  Xbal 
e n z y m e s  to  re le a se  th e  n e o m y c in  c a sse tte . T h e  1.75 kb  n e o m y c in  f ra g m e n t  
w a s  th en  b a n d  p u r if ie d  by  re so lu tio n  on  a 1% L M P  a g a ro se  g e l. T h e  p u r if ie d  
b a n d  w as th en  e n d -f ille d  u s in g  th e  K len o w  en zy m e . T h is  f ra g m e n t w as  th en  
b lu n t-e n d  lig a te d  in to  the  d e p h o sp h o ry la te d  B S S K  11“ p la s m id , l in e a r is e d  a t 
th e  Hincll  site . W h ite  re c o m b in a n t co lo n ie s  w ere  in itia lly  a n a ly se d  by  a g a ro se  
g e l e le c tro p h o re s is  o n  th e  b a s is  o f  s u p e rc o ile d  p la s m id  s iz e . H o w e v e r , 
c o n f irm a tio n  o f  th e  su b c lo n in g  w as  a c h ie v e d  by  Xhol re s tr ic tio n  d ig e s tio n , 
w h ic h  re le a s e s  th e  n e o m y c in  c a s s e tte . T h is  w as  p o s s ib le  as  th e  1.7 k b  
n e o m y c in  f ra g m e n t w as f la n k e d  by  tw o  Xhol s ites: one  s ite  w a s  re c o n s titu te d  
on  in se r tio n  in to  o f  the  n e o m y c in  ca sse tte  in to  the  p la sm id  a n d  the  o th e r  w as
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p ro v id e d  by  th e  f la n k in g  p o ly lin k e r  seq u en ce  at the  Hincll/Xbal ju n c tio n . T h is  
su b c lo n e  w as  k n o w n  as p N eo .
T h e  n e o m y c in  c a sse tte  w a s  re c o v e re d  fro m  th e  p N e o  
p la sm id  by  Xhol  d ig e s tio n  an d  b a n d  p u rif ic a tio n  on  a 1 .2%  L M P  a g a ro se  gel. 
T h e  1.7 k b  Xhol f ra g m e n t w as th en  su b c lo n ed  in to  the  Sail s ite  o f  the  p 9 .2 E iL  
p la s m id . T h e  r e c o m b in a n t  p la s m id s  w e re  id e n t if ie d  by  Ncol r e s t r ic t io n  
d ig e s tio n . P la sm id s  c o n ta in in g  th e  n e o m y c in  c a s s e tte  p ro d u c e d  tw o  o th e r  
b a n d s  as o p p o s e d  to  th e  p a re n ta l  p la sm id . T h is  is b e c a u s e  th e  n e o m y c in  
c a sse tte  c o n ta in s  an  in te rn a l Ncol  s ite  an d  th e  Sail l in k e r  p ro v id e s  tw o  Ncol 
s ites  f la n k in g  th e  n e o m y c in  c a sse tte . R es tric tio n  an a ly s is  o f  so m e  o f  the  c lo n es  
re c o v e re d  fro m  th is  lig a tio n  e x p e rim e n t are  p resen ted  in F ig u re  5 .6 .
1 2 3 4 5 6 7
— 10.5 kb
.5 kb
------1.1 kb
—
6 5 0  bp
Figure 5.6 R estric tion  analysis o f potential clones con tain ing  the neom ycin  
cassette. A ll cand idate  clones were digested w ith the Ncol enzym e and the 
reactions resolved on a 1.2% agarose gel. Lane 1 is 1 kb m arker; lanes 2, 3, and 
5 are p lasm ids contain ing the neom ycin fragm ent; lanes 4 and 6 are the p9.2Ei 
plasm id; lane 7 is the p9.2EiL  plasm id.
T h e  N col  a n a ly s is  o f  th e  re c o v e re d  p la s m id s  fro m  th e  
t ra n s fo rm a tio n  c o n s is te d  o f  th re e  ty p es  as i l lu s tra te d  in  F ig u re  5 .6 . T h e  
o r ig in a l  p la s m id , (p 9 .2 E i) ,  c o n ta in in g  th e  9 .2  k b  E coR l  m o u se  g e n o m ic  
fra g m e n t w as  d e te c te d ; lan e s  4  an d  6. Ncol d ig es tio n  o f  th is  p la sm id  re le a se d  
th e  g e n o m ic  1.5 k b  f ra g m e n t o f  th e  N T R  g ene , w h ic h  sh o u ld  n o t b e  p re se n t. 
T h e  se c o n d  p la s m id  ty p e  w as  p 9 .2 E iL , w h ic h  has  its  1.5 k b  Ncol  f ra g m e n t 
rem o v e d  an d  re p la c e d  w ith  th e  Sail linker; lane  7. T h e re fo re , on  d ig e s tio n  w ith  
Ncol th is p la sm id  w as  lin e a rise d , re le a s in g  the  Sail lin k er. L a s tly , the  d e s ire d  
p la sm id  c o n s tru c t w as  iso la te d  c o n ta in in g  the n e o m y c in  c a sse tte  su b c lo n e d  in to  
th e  Sail s ite  o f  th e  Sail  l in k e r . D ig e s tio n  o f  th is p la sm id  w ith  Ncol r e su lts  in  
the  re le a se  o f  th e  n e o m y c in  c a sse tte  as tw o frag m en ts , (1.1 k b  an d  6 5 0  b p ), due
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to an internal Ncol site. One of these clones, termed p9.2EiNeo, was used for 
the final stage of the construction i.e. addition of the thymidine kinase cassette.
Finally, the orientation of the neomycin cassette relative 
to the NTR gene fragment was determined by B glll digestion. This was 
possible as the neomycin cassette contains a Bglll restriction site within the 
polyadenylation sequence, 150 nt from the end. Thus a distinct banding pattern 
would be generated depending on the orientation of the cassette relative to the 
two B glll sites of the gene fragment. As presented in the diagram of Figure 
5.7, a B glll digestion would yield fragments of 1.3 kb, 6.55 kb and 4.6 kb, 
(forward orientation). The reverse orientation would result in Bglll fragments 
of 1.3 kb, 5.1 kb and 6.05 kb.
1 kb
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Figure 5.7 A restriction map of the 9.2 kb NTR gene fragment, detailing the 
position of the Bglll restriction site in the neomycin cassette relative to the Bglll 
sites of the gene fragment. The neomycin cassette was cloned into the gene 
fragment via the insertion of a Sail linker. The original 9.2 kb EcoRl gene 
fragment is shown with black stripes indicating the position of the sequences 
encoding the transmembrane domains I-IV and a neomycin cassette insertion. 
PGK, phosphoglycerate kinase promoter; PA, SV40 polyadenylation site; Neo, 
neomycin phosphotransferase gene;E, EcoRl', B, BamHl; N, Ncol; Bg, Bglll; X, 
Xbal and K, Kpnl.
This Bglll restriction analysis was necessary as the orientation of the neomycin 
cassette was crucial to the design of PCR primers for the analysis of ES 
colonies. Furthermore, the relative position of the B glll site allowed the 
accurate prediction of B glll fragment sizes for the Southern blot analysis of
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ta rg e te d  ES c lo n e s . F ig u re  5 .8  p re se n ts  such  an a n a ly s is  fo r  the  p 9 .2 E iN e o  
p la sm id  (lan e  2), w ith  the  Bglll d ig es tio n  rev e a lin g  a b a n d in g  p a tte rn  in d ic a tiv e  
o f  th e  n e o m y c in  c a sse tte  o r ie n ta te d  in  th e  fo rw a rd  d ire c tio n  as d isp la y e d  in  
F ig u re  5.7.
10. 7 kb 
6.55 kb 
4.6 kb
—  1.3 kb
Figure 5.8 Bglll restriction analysis o f the p9.2EiN eo plasm id. The restriction  
digest was reso lved  on a 1% agarose gel. Lane 1 is 1 kb m arker, lane 2 is 
p9.2EiN eo digested with Bglll, lane 3 is p9.2Ei digested with Bglll.
5.3.4 Addition of the thymidine kinase cassette
T h e  f in a l s ta g e  o f  th e  re p la c e m e n t v e c to r  c o n s tru c tio n  in v o lv e d  tw o  c lo n in g  
s tep s. T h e  th y m id in e  k in ase  c a sse tte  w as su b c lo n ed  from  the  p N T  p la sm id  in to  
th e  p G e m 9  v e c to r , g e n e ra tin g  the  p T K  p la sm id . T h e  g e n e  f ra g m e n t w ith  th e  
n e o m y c in  c a ss e tte  w as  su b se q u e n tly  su b c lo n e d  fro m  th e  p 9 .2 E iN e o  p la s m id  
in to  th e  p T K  p lasm id .
T h e  E coR l/H in d ll l  2 .7  k b  f ra g m e n t ,  c o n ta in in g  th e  
th y m id in e  k in a s e  c a s s e t te  f ro m  th e  p N T  p la s m id , w as  s u b c lo n e d  in to  th e  
p G e m 9  p la sm id . T h e  £ c o R I / / /m d I I I  d o u b le  d ig es tio n  o f  the  p N T  p la sm id  w as  
re s o lv e d  on  a 1 % a g a ro se  ge l, w h e re  th e  2 .7  k b  f ra g m e n t w as b a n d  p u r if ie d . 
T h e  p u r if ie d  f ra g m e n t w as  sub  c lo n e d  in to  the  EcoRl/Hindlll  d ig es te d  p G e m 9  
p la s m id , a t v e c to r  to  in se r t  ra tio s  o f  1:1 an d  1:3. W h ite  c o lo n ie s  f ro m  th e  
tra n s fo rm a tio n  o f  the  D H 5 a  c e lls  w e re  g ro w n  o v e rn ig h t an d  the  re c o m b in a n t  
p la sm id s  p u r if ie d . C o n fo rm a tio n  o f  the  th y m id in e  k in ase  c a sse tte  s u b c lo n in g  
su c ce ss , w as  c o n firm e d  by  EcoRl/Hindlll re s tr ic tio n  d ig es tio n . T h e  o r ie n ta tio n  
o f  th e  c a s s e t te  w a s  d ic ta te d  by  th is  d ire c tio n a l  c lo n in g  s te p . O n e  su c h  
su b c lo n e , te rm e d  p T K , w as  u se d  fo r th e  f in a l s te p  o f  th e  re p la c e m e n t v e c to r  
c o n s tru c tio n .
1 2 3
J 1 1
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The pTK plasmid was linearised at its EcoRl restriction 
site. The band purified EcoRl fragment from the p9.2EiNeo plasmid and the 
linearised pTK plasmid were ligated overnight. The desired recombinant 
plasmid was isolated on the basis of supercoiled plasmid size using the ’one 
step' plasmid miniprep procedure. Finally, the orientation of the 9.4 kb EcoRl 
fragment of the construct was determined by Sstl digestion. If inserted as 
desired, an Sstl restriction fragment profile of 6.85 kb, 4.59 kb, 3.05 kb and 
two bands of approximately 280 bp. would be produced, as opposed to the 
reverse orientation of 5.8 kb, 4.59 kb, 3.05 kb, 1.33 kb and a 280 bp band. 
Therefore, lane 5 of Figure 5.9 shows the digestion profile of a clone with the 
desired insert orientation. This clone, p9.2EiNeoTK, represents the completed 
replacement construct used to target the NTR gene in ES cells.
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6.85 kb 
4.59 kb 
3.05 kb
-  280 bp
Figure 5.9 Restriction analysis o f clones containing the 9.45 kb EcoRl fragm ent 
o f the p9.2EiN eo plasm id subcloned into the EcoRl restriction site o f the pTK  
plasm id. Sstl digestion o f these p lasm ids allowed the orientation o f the 9.4 kb 
insert relative to the pTK plasm id to be deduced. P lasm ids were digested with 
Sstl and the reactions resolved on a 1.2% agarose gel. Lane 1 is 1 kb m arker, 
lane 2 is clone 1, lane 3 is clone 2 lane 4 is blank, lane 5 is clone 3, lane 6 is 
clone 4. The band sizes on the right o f the gel picture refer to clone 3 o f lane 5. 
The restriction map of clone 3, designated p9.2EiN eoTK , is displayed below  the 
gel p icture. Sstl d igestion o f c lone 3 produces the predicted  fragm ent sizes 
deduced from  the restriction map, i.e. 6.85 kb, 4 .59 kb 3.05 kb and 2 bands o f 
about 280 bp. The original 9.2 kb EcoRl gene fragm ent is show n w ith black 
stripes indicating the position o f the sequence encoding transm em brane dom ains 
I-IV , a neom ycin  cassette  insertion  and is flanked by the thym idine kinase 
cassette. PGK, phosphoglycerate kinase prom oter; PA, SV 40 polyadenylation 
site; N E O , neom ycin phosphotransferase  gene; TK , HSV  thym id ine kinase 
gene; E, E coR l; B, BamHl; N, Ncol; Bg, Bglll; K, Kpnl; X, Xbal and S, Sstl. 
T he w avy line at both ends o f the construct represents the pG em 9 plasm id  
sequences (2.9 kb), with an Sstl restriction site that is not positioned to scale due 
to its proxim ity to the insert DNA.
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5.4 A control replacement vector for the development of a diagnostic PCR 
screen
5.4.1 Construction of a control replacement construct
A control construct was made to test the feasibility of the PCR screen designed 
to detect targeted ES clones. This construct consists of an additional 175 bp of 
5' flanking sequence upstream of the 9.2 kb EcoRl fragment of the NTR gene 
used for the replacement construct.
The subcloned 4.8 kb EcoRl fragment from the T12 lambda clone, (this chapter 
section 5.2.4), contained the 5' flanking DNA of the 9.2 kb EcoRl fragment. 
Partial mapping of this subclone identified a suitable Xhol fragment that was 
used to construct the control vector. A summary of the mapping data and the 
650 bp Xhol fragment used for the control vector construction are outlined in 
Figure 5.10.
1 k b
Scale i-------------- 1
E E B
xm
6 5 0  bp
N B
Figure 5.10 Partial restriction maps of the 9.2 kb and 4.8 kb EcoRl fragments 
subcloned from lambda T12. The relative position of the sequence encoding the 
transmembrane domains are indicated as black stripes within the 9.2 kb ZTcoRI 
fragment. The 650 bp Xhol fragment used for the construction of the control 
vector has been highlighted. E, EcoRl’, B, BamHl; N, Ncol; Bg, Bglll; X, Xhol 
and K, Kpnl.
An outline of the strategy used to construct the control vector is presented in 
Figure 5.11 The first step requires the subcloning of the 650 bp Xhol fragment 
from the T12 X clone. The T12 X clone was digested with the Xhol enzyme, 
resolved on a 1.4% LMP agarose gel and the 650 bp fragment band purified.
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This fragment was then ligated into the Xhol linearised pBS SK IT vector, at 
vector to insert ratios of 1:1 and 1:3. The resulting recombinant plasmids were 
purified and assayed for the presence of the insert DNA by Xhol restriction 
digestion. Furthermore, the orientation of the insert DNA was determined by 
EcoRl digestion. The correct orientation produces a 475 bp band as opposed to 
a 175 bp band when digested with EcoRl. A successfully ligated plasmid was 
isolated and named pX650.
The pX650 plasmid was subjected to double-stranded 
DNA sequencing. This sequence information was used to design primers for 
the diagnostic PCR screen described in section 5.8 of this chapter. It also 
confirmed the mapping data generated for the T12 X clone, as the sequence was 
in agreement with that produced from the 5' end of the 9.2 kb EcoRl fragment. 
The second stage of the construction involved the subcloning of the 9.45 kb 
E coR l fragment of the 9.2EiNeo plasmid into the EcoRl digested pX650 
plasmid. Digestion of the pX650 plasmid with the EcoRl enzyme releases a 
475 bp fragment of the NTR gene. However, this portion of the gene already 
exists at the terminal end of the 9.45 kb EcoRl fragment. Therefore, only the 
remaining unique 175 bp DNA of the pX650 plasmid will be added to the 9.45 
kb EcoRl fragment when it is ligated into the EcoRl digested pX650 plasmid.
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Subclone the 650bp Xhol fragment from the 
T12 X clone into the Xhol site of pSK II 
vector creating the pX650 plasmid.
Purify the 9.45 ZscoRI fragment from 
Delete the 475 bp Xhol/EcoKl fragment the 9.2EiNeo plasmid
from the pX650 plasmid
Ligate the 9.4 5kb EcoRl fragment into the deleted 
pX650 plasmid.
Creates the p9.2EiNeoC plasmid containing an extra 175 
bp of 5' flanking sequence of the NTR gene.
Figure 5.11 A flow diagram summarising the various manipulations 
involved in the creation of the p9.2EiNeoC control vector.
The pX650 plasmid was digested with the EcoRl enzyme 
and the vector band with its 175 bp of insert was purified from a 1% LMP 
agarose gel. The 9.45 kb fragment from the p9.2EiNeo plasmid was purified 
by similar means. The XhoUEcoRl digested plasmid DNA and the 9.45 kb 
DNA fragment were ligated overnight at vector to insert ratios of 1:1 and 1:3. 
Recombinant plasmids were initially isolated on the basis of the size of their of 
supercoiled plasmids using the one step plasmid preparation procedure. 
Candidate clones were analysed by restriction digestion to determine if the 
insert was subcloned in the correct orientation. Digestion of the intended 
construct with the Xhol enzyme should produce the reconstructed 650 bp Xhol 
fragment. The analysis of one such clone, p9.2EiNeoC is depicted in Figure 
5.12.
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Figure 5.12 R estriction analysis o f the p9.2EiN eoC control plasm id. Restriction 
analysis o f this clone confirm s the reconstruction o f the 650 bp Xhol fragm ent. 
Lanes 1 and 2 are 1 kb m arker; lane 3 is p9.2EiN eoC digested with E coR l, lane 
4 is p9.2E iN eoC  digested with Xhol.
5.4.2 Design and testing of nested prim ers for the PCR analysis of ES Cell 
clones
F o r th e  s u c c e s s fu l  iso la tio n  o f  ta rg e te d  E S  ce ll c lo n e s  u s in g  a P C R  sc re e n  it 
w as  a d v is a b le  to  te s t  th e  f id e l i ty  o f  th e  P C R  re a c tio n . T h is  re q u ire d  th e  
a n a ly s is  o f  se ts  o f  P C R  p rim e rs , (22  m e rs  to  25 m ers), on  th e  co n tro l p la sm id . 
In itia lly  it w as  h o p e d  th a t th e  d e v e lo p m e n t o f  a s im p le  P C R  sc re e n  in v o lv in g  
on ly  o n e  se t o f  p r im e rs  w o u ld  p ro v id e  a re lia b le  sc reen . H o w e v e r  th is  w as no t 
a c h ie v e d . In s te a d , a  tw o  step  P C R  p ro c e d u re  w as u se d  k n o w n  as n e s te d  P C R . 
T h e  in it ia l  P C R  re a c tio n  w a s  p e rfo rm e d  u s in g  p r im e rs  F5 a n d  B 4 , (F ig u re  
5 .1 3 ) , an d  1 /40  o f  th is  re a c tio n  w as  u se d  as the  te m p la te  fo r  a  s e c o n d  P C R  
re a c tio n  u s in g  p r im e rs  F8 an d  B 1. T h e  F8 an d  F5 p rim e rs  are  d e riv e d  fro m  the  
a d d itio n a l Xhol/EcoRl  175 b p  o f  N T R  g e n e  seq u en ce . T h e  B1 and  B 4  p rim e rs  
a re  th e  'u n iq u e ' p r im e rs  d e r iv e d  f ro m  th e  P G K  p ro m o te r  o f  th e  n e o m y c in  
c a s s e tte . T h e  F 8 /B 1  p r im e r  p a ir  a re  in te rn a l  in  lo c a tio n  to  th e  f ir s t  se t o f  
p r im e rs  w ith  re s p e c t  to  the  c o n tro l p la sm id  te m p la te ; see  F ig u re  5 .1 3 . T h e  
ra t io n a le  fo r  th is  is  th a t th e  f ir s t  P C R  re a c tio n  w o u ld  e n ric h  fo r  th e  ta rg e t
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molecules, if any existed; the second reaction would then amplify the target 
molecules in preference to any spurious molecules produced by the first PCR 
reaction.
1 kb
Sc al e i-------------- 1
X E  XB N N B K
M— ii . . . J — i--------M------1I  I  I  I  PGK | N e o  PA I
Bg
„  1.9 kb
F5 ---------------------------------------  B4 1st Ro und P CR
Pg  K65kb---------------- B 1  2ndR o  und PC R
Figure 5.13 The nested primer pair used for the PCR analysis of ES cells. The 
restriction map depicted is of the 5' end of the control vector. The expected 
PCR product sizes for the primer pairs are indicated. Primers; F5 (5* taa ggg age 
tga aga egg eta egg 3'), F8 (5' gat cgt gaa aga aag ate gtg ctg 3'), B1 (5' ctg act 
agg gga gga gta gaa ggt g 3'), B4 (5' cca ttt gtc acg tcc tgc acg ac 3'). Black 
stripes indicate the sequence position encoding the transmembrane domains I- 
IV; PGK, phosphoglycerate kinase promoter; PA, SV40 polyadenylation site; 
NEO, neomycin phosphotransferase gene; E, EcoRl; B, BamHl; N, Ncol; Bg, 
Bglll; K, Kpnl and X, X hol.
The sensitivity of this nested PCR screen was tested by using these conditions 
to amplify the desired band from varying amounts of control plasmid (template 
target molecules), mixed with genomic DNA. The genomic DNA provides a 
competitive background against which the primers must seek out and 
preferentially hybridise/amplify the target molecules for the reaction to be 
successful.
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T h e  se n s itiv ity  o f  the  re a c tio n  w as te s ted  on  300  ng  o f  g e n o m ic  m o u se  
D N A  s u p p le m e n te d  w ith  s e r ia lly  d e c re a s in g  a m o u n ts  o f  c o n tro l p la s m id  , 
p 9 .2 E iN e o C . Q u a n tit ie s  o f  p la s m id  p ro v id in g  3 .3  X  105 ta rg e t m o le c u le s , 
(e q u iv a le n t to  th e  n u m b e r  o f  ta rg e t m o le c u le s  o f  a s in g le  co p y  g en e  in  1 p g  o f  
g D N A ), ran g in g  to  q u a n titie s  p ro v id in g  in  th eo ry  s in g le  co p y  n u m b e r  o f  ta rg e t 
m o le c u le s  w e re  u se d . T h e  re su lts  o f  th e  n e s te d  P C R  sc re e n  a re  p re s e n te d  in  
F ig u re  5 .14 .
1 2 3 4 5 6 7 8 9 10 11 12 13
Figure 5.14 N ested PCR on serial dilutions o f the control plasm id. E ach  clone 
was subjected to 25 cycles o f 94°C for 30s, 55°C for 30s and 72°C for 2 min 10s 
w ith prim ers B4 and F5. 1/10 o f each reaction was then used as a tem plate for a 
subsequent reaction o f 30 cycles at 94°C for 30's, 52°C for 2 min 10s w ith the F8 
and B1 prim er pair. 10 pi o f each nested PCR reaction was then reso lved  on a 
1.2% agarose gel. Lane 1 and 13 are 1 kb m arker,
lane 2: tem plate D N A  was 250 ng m ouse gD N A  + 40 pg o f control plasm id 
lane 3: tem plate DN A was 250 ng m ouse gDN A + 4 pg o f control plasm id 
lane 4: tem plate D N A  was 250 ng m ouse gD N A  + 400 fg o f control plasm id 
lane 5: tem plate D N A  was 250 ng m ouse gDN A + 40 fg o f control plasm id 
lane 6: tem plate D N A  was 250 ng m ouse gD N A  + 4 fg o f control plasm id 
lane 7: tem plate D N A  was 250 ng m ouse gD N A  + 0.4 fg o f control plasm id 
lane 8: tem plate D N A  was 250 ng m ouse gDN A + 0.04 fg o f control plasm id 
lane 9: tem plate DN A was 250 ng m ouse gD N A  + 0.4 fg o f control plasm id 
lane 10: tem plate DNA was 250 ng m ouse gDN A -ve control 
lane 11: tem plate D N A  was 250 ng m ouse gDN A -ve control 
lane 12: tem plate DN A was 4 pg o f control plasm id +ve control
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These results indicate that this PCR screen was capable of amplifying the 
desired product band of 1.65 kb from as little as 0.4 fg of control plasmid 
DNA, p9.2EiNeoC. This translates to a theoretical copy number of about 33 
target molecules.
5.4.3 Transfection and selection of E14 ES cells with the control vector.
Transfection of E14 cells was undertaken to evaluate the PCR analysis of ES 
clones. Isolated G418R clones were analysed using the nested PCR screen 
outlined in the previous section.
E14 ES cells were grown to an approximate density of 5 
X 107/175 cm2 plate. The cells were prepared for electroporation and 
electroporated with 40 jug of the control plasmid p9.2EiNeoC linearised at its 
Sail site. The cells were then allowed to recover for 24 hours prior to G418 
selection, which continued for 14 days. Then, 20 of the 1000 G418R colonies 
produced were subjected to DNA isolation and PCR analysis. The results of 
the nested PCR analysis are presented in Figure 5.15. As indicated only 6  of 
the 10 clones analysed produced the major PCR product of the expected 1.65 
kb. The other 4 clones that did not give rise to the expected band are thought 
to be genuine PCR results for these clones, and not failed PCR reactions. 
Repeating the nested PCR analysis for these 4 clones and other clones, (data 
not shown), produced similar results. A probable explanation is that the 
terminal NTR gene sequences were lost from the control vector during 
electroporation and genome integration. Loss of the gene sequences from the 
vector dictates loss of the F 8 and F5 primer sites, therefore no randomly 
integrated vector sequence would produce the desired template for the 
production of the 1.65 kb PCR fragment. Furthermore, one of these clones was 
selected to further test the sensitivity of this PCR approach. The DNA from 
clone 9 was serially diluted and used as template for the nested PCR analysis. 
No loss of signal was detected when only 1/32 of the same DNA was used as a 
template, (data not shown). A comparable level of sensitivity was achieved 
when using the control plasmid as a template for the nested PCR, as little as 0.4 
fg of plasmid (about 33 target molecules) was detectable. Thus the results 
indicate that the nested PCR regime previously outlined was sufficiently 
sensitive to be used as a screen for targeted ES cell clones.
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Figure 5.15 N ested PCR analysis o f G 4 1 8 ^  colonies. 1/10 o f the DNA sam ple 
from  each clone was subjected to 25 cycles o f 94°C for 30s, 55°C for 30s and 
72°C for 2 min 10s with prim ers B4 and F5. A tenth o f the PCR reaction was 
then used as a tem plate for a subsequent reaction o f 30 cycles at 94°C for 30's, 
52°C for 30s and 72°C for 2 min 10s with the F8 and B1 prim er pair. 10 |il o f 
each nested PCR reaction was then resolved on a 1.2% agarose gel. Lane 1 is 1 
kb m arker, lanes 2 to 10 are the PCR reactions o f clones 1 to 9 respectively.
5.5 Sum m ary
A  re p la c e m e n t v e c to r , (p 9 .2 E iN e o T k ,) , w as c o n s tru c te d  to  ta rg e t th e  N T R  
g e n e  u t i l is in g  th e  p o s it iv e  n e g a tiv e  s e le c tio n  s tra te g y . T h is  v e c to r  w a s  
a s se m b le d  u s in g  a g e n o m ic  9 .2  kb  E c o R l N T R  g e n e  fra g m e n t su b c lo n e d  fro m  
the  129J m o u se  lib ra ry . A n  in te rn a l 1.5 kb  Ncol fra g m en t w as d e le ted  fro m  the
9 .2  k b  E coRl  f ra g m e n t, c re a tin g  a d e le tio n  w h ic h  re m o v e d  g e n e  s e q u e n c e s  
e n c o d in g  aa  re s id u e s  207 to  242. T h e  n eo m y cin  casse tte  fro m  the  p N T  p la sm id  
w as  su b c lo n e d  fro m  the  the  p N e o  p la sm id  in to  the  Sail lin k e r  p lac e d  b e tw e e n  
the  Ncol re s tr ic tio n  s ite s  o f  the  p 9 .2 E i p lasm id . T h e  fra g m en t w as th en  f la n k e d  
by  the  ad d itio n  o f  the  th y m id in e  k in ase  casse tte , ag a in  su b c lo n e d  fro m  the  p N T  
p la sm id . L in e a r is a tio n  o f  the  v e c to r  a t the  u n iq u e  Sail s ite  o f  th e  p o ly lin k e r  
p ro d u c e s  a re p la c e m e n t c o n stru c t w ith  tw o  arm s o f  h o m o lo g y , (1 .3  kb  a n d  6 .4  
k b ) . T h u s  a c o n s tru c t  s a tis fy in g  th e  g u id e lin e s  su g g e s te d  b y  D e n g  et. a l . , 
1992a, w as p ro d u ce d .
In  ad d itio n , a  co n tro l c o n s tru c t w as g e n e ra te d  to  e v a lu a te  
th e  P C R  p r im e rs  th a t m ay  be  u se d  fo r  the  s c re e n in g  o f  ta rg e te d  ES c lo n e s .
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This vector consisted of the same 9.2 kb EcoRl gene fragment engineered with 
the neomycin cassette, plus an additional 175 bp of gene sequence flanking the 
short arm of homology. This construct was then used to transfect E14 ES cells 
and generate G418R colonies for the assessment of the PCR screen. The nested 
PCR analysis devised, successfully amplified the predicted 1.65 kb DNA 
fragment from the majority of colonies analysed. Furthermore, this screen was 
able to amplify the 1.65 kb product from as little as 0.4 fg of plasmid, 
(approximately 33 target molecules). Thus a reliable PCR screen was 
generated which would allow the identification of ES clones targeted with the 
p9.2EiNeoTK replacement vector.
Chapter 6
Chapter 6
Targeted Mutagenesis of the Neurotensin Receptor Gene in ES
Cells.
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6.1 Introduction
Targeted disruption of the NTR gene in ES cells was achieved using the 
replacement construct p9.2EiNeoTk, and employing the positive negative 
selection strategy outlined in Figure 6.1, (Thomas and Capecchi, 1987). This 
approach allows selection to be applied simultaneously for an integrative event 
and against random integrants. The targeted ES clones were to be initially 
detected by the nested PCR analysis developed in Chapter 5. Confirmation of 
targeted clones was achieved by expanding individual clones for Southern blot 
analysis. The strategy was to generate as many targeted sub lines as possible 
from different ES cell lines; E14, R l, CGR8 and CGR8 .8 . The targeted ES cell 
lines would then be used to generate chimaeric mice via blastocyst injection 
and reimplantation into pseudo-pregnant mice.
Neo
5 6
Replacement
Vector
X X
I
Gene
Locus
6 7
OR
Targeted
Integration
Random
Integration
Neo TK
Figure 6.1 The targeted integration and random insertion of a replacement 
vector as observed in the positive negative selection strategy of gene targeting. 
The replacement construct consists of exons 2, 3, 5 and 6  with exon 2 being 
replaced by a neomycin cassette. The region of gene homology is flanked on 
one side by a thymidine kinase cassette. Targeted integration of the vector by 
homologous recombination would result in the replacement of exon 4 with a
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neom ycin cassette at the gene locus, but no integration o f the thymidine kinase 
cassette. However, random integration o f the vector into the genom e, w ould  
generally result in the thymidine kinase cassette also being incorporated into the 
genom e. Thus, integrants can be selected for with G418 due to the neom ycin  
cassette, i.e. positive selection. Enrichment for targeted integrations can be 
achieved using gancyclovir to select against the presence o f  the thym idine  
kinase cassette, i.e. negative selection.
6.2 Transfection and selection of E14 ES cells with replacement construct;
PCR results
The first ES cell line used for transfection was the E l 4 cell line; Handy side et 
al., 1989. This cell line was derived from the 129/Ola substrain of the 129/J 
mouse strain, Lyon and Searle, 1989. This is a feeder independent line that 
was maintained on BRL conditioned medium. The initial strategy for the 
detection of targeted clones was a nested PCR analysis of batched clones; for 
this genomic DNAs from G418R GancR colonies were isolated in batches of 12 
and subjected to the sensitive PCR regime developed in Chapter 5 section 5.6. 
Positive batches of 12 clones could then be expanded and re-analysed by 
individual PCRs or by Southern blot analysis to identify targeted clones.
E14 ES cells, passage 22, were harvested and prepared 
for transfection by electroporation. 40 pg of the p9.2EiNeoTK was linearised 
with the Sail enzyme and resuspended in 800 pi of 1 X PBS with 4.9 X 10^ ES 
cells. After electroporation the cells were plated onto 5 round plates, 10 cm in 
diameter. All plates received G418 after a 24 hour recovery period. However, 
only 4 of the 5 plates received gancyclovir; the fifth plate served as a control 
for the enrichment of targeted clones using gancyclovir. From the 4 plates to 
which G418 and gancyclovir were added, a total of 220 G418R GancR colonies 
were recovered. The fifth plate produced a total of 224 G418R colonies. This 
translates to an apparent enrichment of almost 4-fold for targeted clones over 
random integrants.
The G418R GancR colonies were picked into and 
expanded in 24 well plates. Batches of 12 colonies were pooled for PCR 
analysis, with one half of each colony used to seed a well of a 24 well plate. 
The cells of the 24 well plates were grown to near confluence and stored in situ 
at -70°C until required. The DNA was isolated from the batches of clones and 
subjected to the nested PCR analysis outlined in Chapter 5. The results of this 
PCR analysis are presented in Figure 6.2.
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Figure 6.2 N ested PCR analysis o f the batched G 418R G ancR colonies. 1/10 o f 
the D N A  sam ple from  each clone w as subjected to 25 cycles o f 94°C for 30 s, 
55°C for 30 s and 72°C for 2 min 10 s w ith prim ers B4 and F5. A second round 
o f PCR was perform ed on 1/10 o f the previous PCR reaction for 30 cycles at 
94°C for 30 s, 52°C for 30 s and 72°C  for 2 min 10 s. D etails o f the prim ers 
used are presented in F igure 5.14. 10 pi o f each nested PCR reaction was then 
resolved on a 1.2% agarose gel. Lanes 1, 12, 17 and 22 are 1 kb m arker; lane 2 
is the negative control (PCR results for 100 ng tem plate o f m ouse genom ic 
DNA); lanes 3 to 11 are batches A to I respectively; lanes 13 to 16 are batches J 
to M ; lanes 14 15 and 16 are batches N, O and P; lane 22 is a positive control 
using DNA from  a clone generated during the control transfection, (section 5.7).
T h e  P C R  re su lts  su g g e s te d  th a t 10 o f  the  16 b a tch es  a n a ly se d  c o n ta in  at lea s t 1 
ta rg e te d  c lo n e . T h is  tra n s la te s  to  a  m in im u m  o f  10 p o s itiv e  c lo n e s  in  192, i.e. 
a n  ap p ro x im a te  ta rg e tin g  fre q u e n c y  o f  1 in  19. T h is  w as an e n c o u ra g in g ly  h ig h
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targeting frequency, and batches of clones were expanded for individual 
analysis.
6.3 Southern blot analysis of E14 G418R GancR colonies
The positive results from the PCR analysis on the batches of clones suggested a 
high targeting frequency of 1 in 19 targeted to non-targeted clones. Individual 
targeted clones were then studied by Southern blot analysis. Although it was 
possible in theory to identify positive pools by individual PCRs, this was not 
done. Apprehension about false positives PCR results and the ultimate need to 
verify potentially targeted clones by Southern blot analysis, dictated the 
following analysis.
Southern blot analysis was performed using the 3 kb 
BgBl-Xhol fragment derived from the p4.8Ei plasmid. This fragment maps 5' 
to the gene fragment used for construction of the replacement vector. Probing 
genomic Southern blots with this fragment results in the detection of the 10.45 
kb restriction fragment of the NTR gene. However, if the gene is targeted with 
the p9.2EiNeoTK construct, then a new Bglll restriction site is introduced into 
the gene via the neomycin cassette. For such targeted clones a 5.95 kb band 
was observed on Southern analysis. Details of the 3 kb BgBl-Xhol probe 
fragment, its relationship to the replacement vector and sizes of the predicted 
Bglll restriction fragments are presented in Figure 6.3
Southern blot analysis was performed on the 220 G418R 
GancR colonies. The cells were retrieved from -70°C storage, expanded, 
DNAs isolated for Bglll restriction digestion, the subsequent gel was Southern 
blotted to nylon membrane and probed using the labelled 3 kb Bglll-Xhol 
fragment. A total of 5 targeted clones were identified, 4 of which are presented 
in Figure 6.4.
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Figure 6.3 Details of the DNA probe fragment used for Southern blot screening 
of G418R GancR clones. Restriction maps for the targeting construct, 
p9.2EiNeoTK, and the NTR gene locus are shown. The sizes of the bands 
expected from Bglll digested targetedand non targeted alleles are indicated. The 
Bglll-Xhol fragment used as a probe is indicated by the black box. The original
9.2 kb EcoRl gene fragment is shown with black stripes indicating the position 
of the transmembrane domains I-IV, a neomycin cassette insertion and flanked 
by a thymidine kinase cassette. PGK, phosphoglycerate kinase promoter; PA, 
SV40 polyadenylation site; Neo, neomycin phosphotransferase gene; TK, HSV 
thymidine kinase gene; E, EcoRl; B, BamHl; N, Ncol; Bg, Bglll; X, Xhol and 
K, Kpnl.
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Figure 6.4 Southern blot analysis o f G 418R G ancR E14 ES cell colonies. 5- 
15 jig DNA o f individual clones was digested with Bglll enzym e, resolved on 
0.7%  agarose gels and subsequently  transferred  to nylon m em branes. The 
32p labelled BglU-Xhol probe was prepared by the random  prim ing m ethod, 
(M aterial and M ethods; section 2.4.18), and hybridised in a 50%  form am ide 
based  bu ffer at 2-3 X 10^ dpm /m l. The resu lting  au to rad iog raphs are 
presented in panels A and B. Panel A: lanes 1,2,3,4 and 6 are non-targeted 
clones since only the w ild type allele o f 10.45 kb was present; lane 5 is a 
targeted clone (E14A), wild type allele o f 10.45 kb and m utant allele o f  5.95 
kb. Panel B: lanes 1, 4, 6, 7 and 8 are non-targeted clones contain ing  only 
the w ild type allele o f 10.45 kb; lanes 2, 3 and 5 are targeted clones, (E14B , 
E14C and E14D respectively).
6.4 Transfection and selection of R1 ES cells; Southern blot results
T h e  R1 E S  ce ll line , (N agy , et al. , 1993), w as  tra n sfe c te d  w ith  the  re p la c e m e n t 
c o n s tru c t,  (p 9 .2 E iN e o T K ). T h is  1 29 /J  d e riv e d  c e ll lin e  w a s  c h o se n  fo r  its  
a b il i ty  to  g e n e ra te  c h im a e r ic  m ic e  b y  a g g re g a tio n  as w e ll as by  b la s to c y s t  
in je c tio n , (W o o d , et al. , 1993). T h e  R1 ES ce ll line  w as m a in ta in e d  on  a  fe e d e r  
in d e p e n d e n t sy stem  w ith  g ro w th  m ed iu m  su p p le m e n te d  w ith  L IF .
T h e  R1 E S  c e lls  w e re  t ra n s fe c te d  a n d  s e le c te d  in  a  
s im ila r  m a n n e r  to th a t d e sc rib ed  fo r  the  E 1 4  ce ll line . B rie f ly , 4 0  p g  o f  Sail
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lin e a rise d  p 9 .2 E iN e o T K  p la sm id  w as m ix ed  w ith  a p p ro x im a te ly  5 X  10^ ce lls  
a n d  e le c tro p o ra te d . T h e  c e lls  w e re  p la te d  o n to  5 p la te s  w ith  th e  m e d iu m  
su p p le m e n te d  w ith  200  fig /m l G 4 1 8  a fte r  a 24 h o u r  re c o v e ry  p e rio d ; 4  o f  the  
p la te s  a lso  re c e iv e d  g a n c y c lo v ir  @ 1 X  10~6 M . G 4 1 8 ^  G a n c ^  c o lo n ie s  w e re  
re a d y  to  p ic k  a f te r  12-14  d a y s  o f  s e le c tio n , o f  w h ic h  168 c o lo n ie s  w e re  
re c o v e re d . T h e  f if th  p la te  w h ic h  o n ly  re c e iv e d  G 4 1 8 , p ro d u c e d  161 c o lo n ie s . 
T h is  tra n s la te s  to  an  en ric h m e n t fa c to r  o f  ab o u t 4  fo ld  fo r  th is  ex p e rim e n t.
T he  G 4 1 8 R G a n c R co lo n ie s  w ere  p ick e d  and  e x p a n d e d  in 
24  w e ll p la te s . W h e n  n e a r  c o n flu e n t, 80  % o f  th e  c e lls  w e re  h a rv e s te d  fo r  
D N A  iso la tio n  an d  S o u th e rn  a n a ly s is . T h e  re m a in d e r  o f  the  ce lls  w e re  g ro w n  
to  n e a r  c o n f lu e n c e  and  s to re d  a t -7 0 °C  u n til req u ired . N e s te d  P C R  a n a ly s is  
w a s  n o t p e r fo rm e d  on  th ese  c lo n e s  as th e  p re v io u s  e x p e r im e n t p re d ic te d  a 
ta rg e tin g  f re q u e n c y  o f  ab o u t 1 in  4 0  c lo n es , w h ich  w as su itab ly  h igh  to  p ro c e e d  
w ith  S o u th e rn  a n a ly se s  o f  th ese  c lo n e s . T h e  a p p ro a c h  u sed  w as  id e n tic a l to 
th a t d e sc r ib e d  in  th e  p rev io u s  sec tio n  an d  re su lte d  in  a to ta l o f  4  ta rg e te d  sub  
lin es  b e in g  iso la te d . A gain , a c o m p a ra b le  ta rg e tin g  fre q u e n c y  o f  ab o u t 1 in  40  
co lo n ie s  w as o b se rv e d . T he  resu lts  a re  p rese n ted  in  F ig u re  6 .5 .
B
10.45 kb 
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154
Chapter 6
C  D
1 2 3 4 5 6  1 2 3 4 5 6
Figure 6.5 Southern blot analysis o f G 418R G ancR colonies o f the R1 ES cell 
transfec tion . 5-15 p g  DN A o f ind iv idual clones was d igested  w ith  Bglll 
enzym e, resolved on 0.7%  agarose gels and subsequently  transferred  to nylon 
m em branes. The 32P labelled BgBl-Xhol probe was prepared by the random  
prim ing m ethod, (M aterial and M ethods; section 2.4.18), and hybrid ised in a 
50%  fo rm am id e  based  b u ffe r  at 2-3 X 106 dpm /m l. T he re su ltin g  
autoradiographs are presented in panels A, B, C and D. Presence o f the 5.95 kb 
fragm ent denotes a targeted allele as observed for; panel A lane 3, panel B lane 
2, panel C lane 4 and panel D lane 5. These are targeted clones R l.A  to R l.D  
respectively. All other lanes only display the wild type allele o f 10.45 kb.
6.5 Transfection and selection of CGR 8  ES cells; Southern blot results
T h e  C G R 8  E S  c e ll lin e  w as  a lso  d e r iv e d  fro m  th e  1 2 9 /O la  m o u se  s tra in , 
(M o u n tfo rd  et a l ,  1994). T h is  is a h ig h ly  g e rm lin e  tra n s m is s ib le  c e ll lin e , 
a p p ro x im a te ly  30  %  o f  g e n e  tra p  g e n e ra te d  ES c e ll l in e s  w e re  g e rm  lin e  
t ra n s m is s ib le , (p e rs o n a l c o m m u n ic a t io n , D r. W . C . S k a rn e s , th e  B B S R C  
C e n tre  fo r  G e n o m e  R e s e a rc h , U n iv e rs i ty  o f  E d in b u rg h , S c o tla n d ) . T h e  
t ra n s fe c tio n  a n d  se le c tio n  o f  the  C G R 8  ce ll lin e  w as e s se n tia lly  th e  sam e  as 
th a t  fo r  E 1 4  a n d  R1 c e ll l in e s  e x c e p t  a m e th o d  o f  e le c tro p o ra t io n  w ith  
p a ra m e te rs  d e fin e d  by D r. W . C . S k a rn e s  w as u sed , as d e sc r ib e d  in  M a te ria l 
an d  M e th o d s , (se c tio n  2 .5 .9 ).
A p p ro x im a te ly  1 X  108 ES ce lls  w ere  e le c tro p o ra te d  w ith  
150  p g  o f  Sail  l in e a r is e d  p 9 .2 E iN e o T K  p la sm id . G 4 1 8  a n d  g a n c y c lo v ir
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s e le c tio n  w e re  as b e fo re  e x c e p t a to ta l o f  20 p la te s  w e re  u se d  w ith  o n e  p la te  
o n ly  re c e iv in g  G 4 1 8 , the  c o n tro l fo r  g a n c y c lo v ir  e n ric h m e n t. A  to ta l o f  38 
G 4 1 8 R G a n c R c o lo n ie s  w e re  p ic k e d  fro m  the  o th e r  19 p la te s  w ith  6 c o lo n ie s  
re m a in in g  on  th e  'G 4 1 8  o n ly ' p la te . T h is  su g g e s ts  an  e n r ic h m e n t f a c to r  o f  
a b o u t 3 fo ld . T h e  e le c tro p o ra tio n  o f  th ese  c e lls  w a s  a b n o rm a l, as a tim e  
c o n s ta n t o f  0 .3  m s w as re c o rd e d  as o p p o se d  to  0.1 m s, (D r. W . C . S k a rn e s , 
p e rso n a l c o m m u n ic a tio n ) . N e v e r th e le ss , the  38 G 4 1 8 R G a n c R c o lo n ie s  w e re  
p ro c e s s e d  fo r  S o u th e rn  a n a ly s is  as p re v io u s ly  d e sc r ib e d , and  th e  re s u l ts  a re  
p re se n te d  in  F ig u re  6.6.
T h e  re su lts  fro m  the  S o u th e rn  an a ly s is  re v e a le d  o n ly  on e  
c lo n e  ta rg e te d  in  the  ex p e c te d  m an n e r, c lo n e  C G R 8 .A  (lane  4 ). H o w e v er, lane  
2 c o n ta in s  an u n e x p e c te d  b an d  o f  ab o u t 3.5 kb  in  s ize  w h ich , m ay  be  th e  re su lt 
o f  a  ta rg e tin g  e v e n t a c c o m p a n ie d  by  a re a r ra n g e m e n t a t th is  a lle le  c a u s in g  a 
d e le tio n . F u rth e rm o re , the  in te n s ity  o f  th is band  is n o t e q u iv a le n t to  th a t 10.45 
k b  b a n d  o f  the  w ild  type  a lle le . T h e re fo re , on ly  a p o rtio n  o f  th e  ce lls  fro m  th is 
c lo n e  n o w  c o n ta in  th is  ta rg e te d  b u t re a rra n g e d  a lle le . F o r  th e se  re a s o n s  the  
c lo n e  w as d isc a rd ed  from  fu rth e r  an a ly sis .
10 . 45  kb
5 . 95  kb 
2.5 kb
F igure  6.6 Southern  b lo t analysis o f G 418R G ancR co lon ies from  C G R 8 
transfection. 5-15 mg o f D N A  from  individual clones w asdigested w ith  Bglll 
enzym e, resolved on 0.7%  agarose gels and subsequently transferred  to nylon 
m em branes. The 32P labelled BgRl-Xhol probe was prepared by the random  
prim ing m ethod , (M aterial and M ethods; section 2.4.18), and hybrid ised in a 
50%  fo rm am id e  based  b u ffe r  at 2-3 X 10^ dpm /m l. T he re su ltin g
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autoradiograph is shown with band sizes. Lanes 1 and 3 are apparently em pty; 
lane 2 contains a targeted but rearranged clone; lane 4 shows a banding pattern 
ind icative o f a targeted clone (CG R 8.A ); lane 5 d isplays the 10.45 kb band 
observed for the wild type allele.
6 .6  C haracterisation of the CGR8 .A ES cell line
O c c a s io n a lly  ta rg e te d  ES ce ll lin es  ca rry  a ra n d o m  in te g ra tio n  o f  the  ta rg e tin g  
co n s tru c t. F o r  th is  rea so n  it is g o o d  ro u tin e  p rac tic e  to  c h e ck  ta rg e te d  ES lines 
p r io r  to  b la s to c y s t  in je c tio n . F u r th e rm o re , c o n tin u e d  p a s sa g e  o f  E S  c e lls  in  
c u ltu re  c a n  ty p ic a lly  re s u lt  in  a b n o rm a l c h ro m o so m e  n u m b e rs . T h e re fo re  
m e ta p h a s e  s p re a d s  w e re  p re p a re d  f ro m  th e  C G R 8 .A  lin e  to  d e te rm in e  
c h ro m o so m e  n um ber.
S o u th e rn  b lo t  a n a ly s is  o f  th e  C G R 8 .A  lin e  w as  p e rfo rm e d  u s in g  a 
p ro b e  d e riv e d  fro m  the  c o d in g  re g io n  o f  the  th y m id in e  k in a se  c a sse tte . A n 
in te rn a l 9 0 0  bp  Pstl  f ra g m e n t d e riv e d  fro m  the  H S V  th y m id in e  k in a se  g e n e  
( p T K )  w as  u sed  as p ro b e  to  id en tify  the  p re se n c e  o f  such  se q u en ces  in  ta rg e ted  
an d  n o n  ta rg e te d  ES ce ll c lo n e s ; F ig u re  6 .7  d isp la y s  the  re s u lts  o f  su ch  an 
an a ly s is .
g  1 2 3 4 5 6 7 8  910  12 14
Figure 6.7 Southern blot analysis o f the CG R8.A  clone with a thym idine kinase 
derived probe. 5-15 mg of DN A from  individual clones was digested w ith Bglll 
enzym e, resolved on 0.7%  agarose gels and subsequently transferred  to nylon 
m em branes. The 32P labelled  probe, (a Pstl 900 bp fragm ent derived from
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pTK ), was prepared by the random  prim ing m ethod , (M aterial and M ethods; 
section 2.4.18), and hybridised in a 50% form am ide based buffer at 2-3 X 106 
dpm /m l. The resulting autoradiograph is shown with band sizes. Panel A lane 2 
contains a 1.4 kb hybridising band from  a non-targeted clone. Panel B lane 5 
contains DNA from  the targeted CG R8.A clone; lanes 1 and 14 are 1 kb m arker 
lanes both displaying a hybridising 1.6 kb plasm id derived band; the rem aining 
lanes are o f non-targeted ES clones.
T h e  ta rg e te d  C G R 8 .A  line  do es  n o t ca rry  an in te g ra te d  co p y  o f  th e  th y m id in e  
k in ase  casse tte , as su g g ested  by  the  lac k  o f  a h y b rid is in g  b an d  in  lan e  5 p a n e l B 
o f  F ig u re  6 .7 .
T h e  p o ss ib ili ty  o f  an a b e rra n t c h ro m o so m e  n u m b e r  fo r  th is  lin e  w as  
a d d re s se d  by  c o u n tin g  m ito tic  sp re a d s . A  to ta l o f  50  sp re a d s  w e re  e x a m in e d  
w ith  a s tro n g  m o d u la r  d is tr ib u tio n  o f  40  c h ro m o so m e s  b e in g  o b se rv e d . F ig u re  
6 .8  r e p re s e n ts  a ty p ic a l  m e ta p h a s e  sp re a d  f ro m  th e  C G R 8 .A  c e ll  l in e , 
d isp la y in g  the  no rm al m o u se  c h ro m o so m e  co m p le m e n t o f  40.
Figure 6.8 M etaphase spread from  the CGR8.A  ES cell line.
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6.7 Transfection and selection of CGR8.8 ES cells; Southern blot results
The CGR8 .8  ES cell line was derived from the CGR8 cell line by Dr. W. C. 
Skarnes of the BBSRC Centre for Genome Research, University of Edinburgh, 
Scotland. This cell line has a higher germline transmission rate than the 
parental strain; approaching nearly 70% of gene trap generated cell lines were 
germline transmissible.
Transfection and selection of the CGR8 .8  cell line was 
performed as described for the CGR8  cell line. On this occasion the observed 
time constant was as expected, i.e. 0.1 ms. The number of G418R GancR 
colonies from the 19 plates totalled approximately 2,700. The plate that 
received no gancyclovir produced approximately 480 colonies, which 
translates to about a 3-fold enrichment using gancyclovir selection. The 
number of G418R GancR colonies produced was too many to be processed by 
one person. Therefore, a total of 192 were picked and expanded for Southern 
analysis. Of the 182 colonies successfully analysed only 2 were apparently 
targeted, (Figure 6.9). This calculates as a targeting frequency of about 1 clone 
in 90.
The targeting frequency for the CGR8 .8  ES cell line is 
lower than that previously observed for the E l4 and R1 cell lines of 1 in 40 
clones. Moreover, the enrichment produced by the gancyclovir selection was 
less than previously observed with an apparent drop from 4 to 3-fold. It is not 
possible to attach any statistical significance to these results since a number of 
other variable factors could have contributed to the differences observed, other 
than solely being a property of the CGR8 .8  line.
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Figure 6.9 Southern analysis o f G 418R G ancR colonies from  the transfection o f 
C G R 8.8 ES cells. 5-15 jig o f D N A  from  individual clones was d igested w ith 
Bglll enzym e, reso lved  on 0.7%  agarose gels and subsequently  transferred  to 
nylon m em branes. The 32P labelled  Bglll-Xhol probe was prepared  by the 
random  prim ing m ethod, (M aterial and M ethods; section 2.4.18), and hybridised 
in a 50%  fo rm am ide based  b u ffe r at 2-3 X 106 dpm /m l. The resu ltin g  
autoradiographs are shown with band sizes indicated in panel A and B. L ane 3 
o f each autoradiograph represents a targeted clone as indicated by the presence 
o f the 5.95 kb band, (clones C G R 8.8A  and CG R8.8B ). All o ther lanes contain 
non-targeted clones.
6 .8  Sum m ary
T ra n s fe c t io n  o f  th e  E 1 4  E S  c e ll l in e  w ith  th e  p 9 .2 E iN e o T K  r e p la c e m e n t  
c o n s tru c t  p ro d u c e d  a ta rg e tin g  f re q u e n c y  o f  a b o u t 1 in  4 0  ta rg e te d  to  n o n - 
ta rg e te d  c lo n e s  u s in g  th e  p o s it iv e  n e g a tiv e  se le c tio n  s tra te g y . A  g a n c y c lo v ir  
e n r ic h m e n t fac to r  o f  4 -fo ld  w as  o b se rv e d . T h is  re a so n a b le  ta rg e tin g  fre q u e n c y  
re s u l te d  in  th e  su b se q u e n t o m is s io n  o f  th e  n e s te d  P C R  sc re e n in g  s tra te g y  fo r  
ta rg e te d  c lo n e s  d e v e lo p e d  in  C h a p te r  5. T h e  P C R  a p p ro a c h  w as  a lso  d ro p p e d  
b e c a u s e  fa lse  p o s itiv e  re su lts  w e re  b e in g  p ro d u ce d . T h e  in itia l P C R  sc re e n  o f  
th e  E 1 4  G 4 1 8 R G a n c R c lo n e s  su g g e s te d  a ta rg e tin g  f re q u e n c y  o f  a b o u t 1 in  19, 
b u t  th is  w a s  e v id e n tly  n o t th e  c a se  as r e v e a le d  b y  th e  S o u th e rn  a n a ly s is .  
P o s s ib le  e x p la n a tio n s  fo r  fa ls e  p o s it iv e  P C R  re s u lts  h a v e  p re v io u s ly  b e e n  
p re s e n te d  in  C h a p te r  4 ; s e c tio n  4 .3 .4 . T ra n s fe c tio n  o f  th e  R1 E S  c e ll  lin e
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resulted in a similar targeting frequency of 1 in 40 with a gancyclovir 
enrichment factor of 4-fold. The results of transfection of the CGR8 ES cell 
line produced fewer G418R GancR colonies than expected due to some 
unknown error believed to have occurred during the preparation of the cells for 
the electroporation procedure. The results obtained from targeting the CGR8 .8  
ES cell line produced a lower targeting frequency of only about 1 in 90, and a 
lower gancyclovir enrichment factor of about 3-fold. These transfection 
experiments were performed using different electroporation conditions and in 
different laboratory environments. Therefore, direct comparison of targeting 
or enrichment frequencies between the cell lines would be invalid. In 
summary, the total numbers of targeted sub-lines produced for the NTR gene 
were: 5 from the E 14 ES cell line, 4 from the R1 ES cell line, 1 from the CGR8 
ES cell line and 2 from the CGR8 .8  ES cell line, see Figure 6.10.
ES cell 
line
Electroporation
settings
No. of cells and 
amount of vector
Transformation
frequency
Enrichment
factor
Targeting
frequency
No. of
targeted
clones
E14 500 pF, 250 V 5 X 107 cells 
25 pg DNA
2.2 X 10‘5 4 1/40 5
R1 500 pF, 250 V 5 X 107 cells 
25 pg DNA
1.6 X 10'5 4 1/40 4
CGR8 3 |iF, 800 V 1 X 108 cells 
150 pg DNA
1.2 X 10'6 4 1/40 1
CGR8.8 3pF, 800 V 1 X 108 cells 
150 pg DNA
9.6 X 10'5 3 1/90 2
Figure 6.10 Summary of the conditions and results from the ES cell 
transfection experiments of Chapter 6.
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Chapter 7
Production of Transgenic Mice
I
j
162
Chapter 7
7.1 Introduction
Chimaeric embryos can be produced by either blastocyst injection, 
(Papaioannou and Johnson, 1993), or by aggregation of morula stage embryos 
with the targeted ES cell lines, (Wood et a l , 1993). The chimaeric mice 
reported in this chapter were generated by blastocyst injection performed by 
Dr. W. C. Skarnes of the Centre for Genome Research, University of 
Edinburgh, Scotland. The E14 targeted ES cell lines were not microinjected 
into blastocysts as 4 of them were lost due to bacterial contamination of the 
tissue culture facilities; the fifth line did not recovery from temporary -70°C 
storage. However, the four targeted RI ES cell lines and the targeted CGR8 ES 
cell line were successfully microinjected into blastocysts, to produce chimaeric 
mice.
7.2 Results of blastocyst injection for the targeted R l ES cell sublines
The four targeted ES cell lines RI.A-D were injected into 3.5 day C57BL/6J 
derived blastocysts. The RI.A and RI.B cell lines were injected into 16 
blastocysts, and the embryos were mixed prior to transplanting into two 
pseudopregnant females. None of the resulting offspring displayed any coat 
colour chimaerism. Cell lines RI.C and RI.D were injected into 17 blastocysts 
and transferred to two pseudopregnant females who produced 11 offspring. 9  
of the mice were weakly chimaeric, (10-15% agouti coat colour; see Figure 
7.1), the other two were not. Breeding of these chimaeric mice did not produce 
any germline transmission of the null NTR allele, as observed by the lack of 
offspring with agouti coat colour.
7.3 Results of blastocyst injection for the targeted CGR8 ES cell subline
The targeted CGR8 .A cell line was microinjected into 12 blastocysts, resulting 
in the production of 3 male offspring with 80% to 90% chimaerism; see Figure
7.2. The 3 strongly chimaeric males were mated with C57BL/6 females to test 
for germline transmission. However, all these males proved to probably be 
sterile, as no progeny were produced with several different females.
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A
Figure 7.1 R1 derived chim aeric mice. Photographs A and B show a m ale 
m ouse that was typically representative o f the w eakly chim aeric m ice produced 
by injection o f targeted R l.C  and R l.B  cell lines, (129/SvJ), into C 57B L/6 
blastocysts. The agouti coat colour, w hich covered approxim ately 10 to 15% 
o f the m ouse, was the ES cell derived fraction o f the m ouse as opposed to the 
blastocyst derived black coat colour.
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A
Figure 7.2 CGR8 derived chim aeric mouse. Photographs A and B show one of 
the m ale derived offspring from  injection o f the targeted C G R8.A  cell line, 
(129/O la), into C57BL/B derived blastocysts. The 80-90%  agouti coat colour 
represents the ES cell derived portion o f the m ouse, as opposed to the black coat 
colour o f the blastocyst.
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7.4 Summary
The production of chimaeric mice was successfully achieved for the targeted 
Rl.A , R l.B  ES and CGR8 .A ES cell lines. The level of chimaerism achieved 
using the R1 ES cell lines was estimated at about 10-15%, based on coat 
colour, for the 9 offspring. Coat colour chimaerism is a good indication of the 
level to which an ES cell line has contributed to the germline. Therefore, the 
likelihood of germline transmission of the null NTR allele was not high using 
these chimaeric mice; not surprisingly germline transmission was not obtained. 
However, the targeted CGR8 .A ES cell line produced 3 strongly chimaeric 
male mice displaying 80-90% agouti coat colour derived from the ES cell line. 
Unexpectedly, these mice did not achieve germline transmission of the targeted 
allele; possible reasons for this lack of transmission are presented in the 
Discussion, (Chapter 8 ; section 8.2.3). Finally, the targeted cell lines generated 
from the CGR8 .8  ES cell line await blastocyst injection at the time of thesis 
submission.
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Chapter 8
In Situ Hybridisation of the Neurotensin Receptor in the
embryonic mouse
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8.1 Introduction
The overall aim of this project was to investigate the function of the NT 
transmission system within the adult CNS of the mouse using an unconditional 
gene 'knock out' strategy. However, if NT has an alternative role during 
development of the CNS, for example as a trophic factor, then mutation of the 
receptor could result in developmental abnormalities of the CNS that may 
confuse or limit this approach's ability to unravel the function of the NT system 
within the adult brain. The following in situ hybridisation study was designed 
to look at the expression of the NTR receptor mRNA within the developing 
mouse embryo. Previous studies have indicated a post-natal developmental 
pattern of expression for NTR that differs from the expression observed in the 
adult rodent brain, Sato et al., 1992, which suggests that neurotensin may have 
a distinct function within the developing brain.
It must be noted that the work presented within this 
chapter was produced with the help and supervision of Dr. M. Sutherland from 
Vanderbilt University, U.S.A.
8.2 In  situ hybridisation of sagittal mouse embryo sections
A series of mid-sagittal embryo sections taken from days 13.5, 15.5 and 17.5 
embryos, were hybridised with an anti-sense 35S labelled oligonucleotide 
probe, (Chapter 2 sections 2.4.31 and 2.4.32), for the mouse neurotensin 
receptor. The sequence for the probe was derived from clone p2.8 (Chapter 3 
figure 3.11), from nucleotide position 262 to 306,( 5'- cag tgc tct gca ggc tct 
gca gcg act tct tcc gcg eta gag tga 3'). The following Figures 8.1, 8.2, 8.3 and
8.4 present the results of such an analysis. Figures 8.2, 8.3 and 8.4 also include 
histological sections detailing the expected anatomical development of mid- 
sagittal sections taken from similar time points, (adapted from Kaufman, 
1992).
Figure 8.1 details the results for the hybridisation of the 
mouse probe derived from the putative mouse NTR sequence of Chapter 2. As 
expected, specific hybridisation is observed to m id-brain structures 
corresponding to the location of the substantia nigra and the ventral tegmental 
areas panel A. A number of negative controls were performed, whereby the 
same probe, but with a 50 molar excess of unlabeled probe, was hybridised to 
adjacent sections from the mouse mid-brain; no specific hybridisation was 
observed. The series of sagittal embryo sections first produced a weak signal
168
Chapter 8
h y b rid is in g  to  a d ev e lo p in g  s tru c tu re  o f  the  m o u se  fo reb ra in  a t day  13.5, F ig u re
8 .2 . T h e  h y b rid isa tio n  s ig n a l b e c o m e s  s tro n g e r a t d ay s  15.5 an d  17.5, a n d  the  
se c tio n s  d isp lay  a m o re  d e fin ite  h y b rid isa tio n  s ig n a l p o ss ib ly  c o rre sp o n d in g  to  
th e  d e v e lo p in g  n eo co rtex , F ig u re s  8.3 an d  8.4.
A
Figure 8. 1 M id-coronal section from  the adult m ouse brain. Panel A details the 
hybridisation o f the 35S labelled probe (5'- cag tgc tct gca ggc tct gca gcg act tct 
tcc gcg eta gag tga 3') to an area o f the brain that corresponds to the substania- 
n igra and the ventral tegm ental area  o f the m ouse m id-brain . S, substan tia  
nigra; V, ventral tegm ental area.
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A
H
Figure  8.2 Sagittal section from  a 13.5 day m ouse em bryo. Panel A  is a 
h isto logical section o f the m ouse em bryo from  approxim ately  the sam e tim e 
po in t o f developm en t and is a m id-section  sag itta l slice that is ro u g h ly  
equivalent to that o f Panel B. The low er panel details the specific hybrid isation 
observed with a N TR specific probe derived from  clone p2.8, (5 - cag tgc tct gca
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ggc tct gca gcg act tct tcc gcg eta  gag tga 3'). A rrow  ind ica tes specific  
hybridisation; F, forebrain; M, m idbrain; Hr ,heart; L, liver.
A
B
F igure  8.3 Sagittal section from  a 15.5 day m ouse em bryo. Panel A is a 
h isto logical section o f the m ouse em bryo from  approxim ately  the sam e tim e 
p o in t o f developm ent and is a m id -section  sag itta l slice  that is rough ly  
equivalent to that o f Panel B. The low er panel details the specific hybridisation 
observed with a NTR specific probe derived from  clone p2.8, (5'- cag tgc tct gca 
ggc tct gca gcg act tct tcc gcg eta gag tga 3'). The arrow  indicates specific
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hybridisation; N, N eopallial cortex; M , m idbrain; H, hindbrain; Hr, heart; L, 
liver.
A
F igure 8.4 Sagittal section from  a 17.5 day m ouse em bryo. Panel A is a 
h isto logical section o f the m ouse em bryo from  approxim ately  the sam e tim e 
poin t o f  developm ent and is a m id -sec tion  sag itta l slice  that is roughly
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equivalent to that of Panel B. The lower panel details the specific hybridisation 
observed with a NTR specific probe derived from clone p2.8, (5'- cag tgc tct gca 
ggc tct gca gcg act tct tcc gcg eta gag tga 3'). The arrow indicates specific 
hybridisaton; F, forebrain; S, striatum; T, thalamus; Hr, heart; L, liver.
9.3 Summary
The above hybridisation results indicate the probe derived from clone p2.8B 
hybridised to specific mid-brain structures, Figure 8.1 panel A. Neurotensin 
receptors are known to be expressed highly within the ventral tegmental and 
the substantia nigra brain structures located within the mid-brain of the mouse. 
Therefore, a specific predicted pattern of expression was observed for the 
probe derived from the genomic sequence of the putative mouse NTR in 
agreement with published results for the NTR of the rat, (Szigethy and 
Beaudet, 1989). However, further hybridisation experiments would be 
desirable to confirm the location of the hybridising brain structures. Adjacent 
sections could be simultaneously probed with either the NTR specific probe or 
a dopamine neuron specific probe such as one directed against mRNA of the 
tyrosine hydroxylase gene. Moreover, the in situ hybridisation analysis of 
embryo sections suggested that the NTR mRNA expression is first detected 
within the forebrain of the 13.5 day embryo, and within an undefined structure 
of the 15.5 day and 17.5 day developing mouse brain, (possibly the neocortex). 
The results of this in situ study extends the observations of Sato et al., 1992, 
who have detailed extensive expression of NTR in the day 7, day 14 and day 
21 of the postnatal rat. They observed expression over the neocortex and the 
limbic cortex at a time when neuronal pathways and connections are being 
made, which suggests that NT may have a trophic role within the developing 
CNS distinct from its function in the adult brain.
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9.1 Introduction
After a brief review of the experimental achievements presented here, this 
discussion will briefly consider the immediate future work that needs to be 
undertaken for the further characterisation of the mouse NTR gene. The 
progress that has been made in generating 'knock out' mice for the receptor will 
be reviewed. The possible reasons for the lack of germline transmission, as 
yet, will be considered. Furthermore, if the replacement strategy described in 
Chapter 5 for the generation of a null mutation of the NTR in mice is not 
feasible due to the lack of germline transmission, then alternative strategies that 
may be employed will be discussed. In the light of recent technological 
developments a number of more precise receptor mutations could be 
engineered to ask more specific questions of receptor function in neurotensin 
transmission in the adult CNS. Therefore, some of the possible avenues of 
NTR analysis will be presented in the context of present technology.
9.2 Summary of experimental achievements
9.2.1 Characterisation of the NTR gene
High stringency library screening, using the heterologous rat cDNA identified 
a number of clones (8 X BALB/c clones and 16 X 129J clones), containing 
genomic sequence of the mouse NTR gene. Further restriction and sequence 
analysis revealed a 2.8 kb BamHl fragment encoding a large exonic fragment 
for the first 242 aa residues of the receptor. The mouse sequence was 97% 
identical to the rat cDNA, for the sequence encoding the putative 
transmembranes I to IV. Furthermore, 5' and 3' probings of the restricted X 
clones with defined fragments of the rat cDNA revealed a set of overlapping 
clones encompassing the coding sequence of the gene. However, further 
analysis is necessary to reveal the complete genomic structure of the gene.
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9.2.2 Developmental expression of the NTR gene
In addition, a developmental in situ analysis of the mouse NTR mRNA has 
been initiated. Embryonic slices from day 13.5 and every day until day 17.5 of 
gestation have been probed with a 45 mer antisense oligonucleotide designed 
from the sequence encoding aa residues 87 to 102 of the mouse receptor. 
Initial data indicates transient expression in, as yet, unidentified brain 
structures in the developing cortex, which is clearly evident from day 15.5 to 
day 17.5 of gestation. No published data presently exists on the expression of 
the NTR in the mouse embryonic CNS. However, Sato et al., 1992, studied the 
expression of the NTR mRNA in the rat at postnatal day 0, 7, 14 and 21. They 
classified the NTR mRNA expression pattern into 3 types. The most striking 
was type I expression where the entire neocortex and most of the limbic cortex 
exhibited a high level of mRNA expression during the first postnatal week, 
which decreased greatly thereafter. These results in conjunction with my own 
observations, Chapter 8, suggest a trophic role of neurotensin in the 
development of the CNS, separate from its neurotransmitter role in the adult. 
If such a developmental role exists for neurotensin, then the strategy employed 
to mutate the receptor may cause developmental defects that obscure the 
analysis of the neurotensin function within the adult brain. Therefore, a simple 
'knockout' approach may not be appropriate and more sophisticated conditional 
knockout strategies, (such as those detailed in sections 9.3.3 and thereafter) , 
may be needed to unravel the neurotransmitter role of NT in the adult CNS 
from the presumed trophic role within the developing CNS.
9.2.3 Generation of a null mutation using the p9.2EiNeoTK replacement 
vector
The principal aim of this project was to generate null mutant mice for the 
neurotensin receptor, in order to analyse NT transmission. Significant progress 
has been made, in that a replacement type construct utilising the positive 
negative selection strategy has been used to target the NTR gene in several ES 
cell lines. This was achieved with a reasonable targeting frequency of 1 in 40 
targeted to non-targeted clones for the E l4, RI and CGR8 ES cell lines. 
Although, one targeting experiment with the CGR8.8 cell line produced a 
targeting frequency of 1 in 90. Of these targeted cell lines, 3 sub-lines have 
been used to successfully create chimaeric mice but unfortunately germline 
transmission has not yet been achieved. However, two targeted sub-lines, (CIO
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and K12), of the highly germline transmissible CGR8.8 ES line await 
blastocyst injection at the time of thesis submission.
9.2.4 Possible reasons for the observed lack of germline transmission and 
chimaeric male sterility
The targeted ES cell lines generated may not be able to 
generate ’knock out' mice for a number of reasons. An obvious explanation for 
the lack of germ line transmission is that the targeted ES cell lines, did not 
contribute to the germline of the chimaeric mice generated. This is probably 
the case for the weakly chimaeric mice generated from the targeted RI ES sub­
lines. However, this explanation does not satisfactorily explain the apparent 
sterility of the 3 strongly chimaeric male mice generated from the CGR8.A ES 
cell line. A more likely explanation is that the targeted ES cell line, (CGR8.A) 
had a second copy of the replacement vector integrated randomly in the 
genome. If the thymidine kinase gene was present within the ES cell line, then 
this would prevent germline transmission as expression of the thymidine kinase 
gene in male gonads causes sterility. However Southern blot analysis of the ES 
cell line with a thymidine kinase specific probe proved negative, Chapter 6 
section 6.6. Therefore, it is unlikely that the presence of a random copy of the 
targeting vector is the cause of the apparent sterility. A common cause of the 
lack of germline transmission can be karyotipic abnormalities. Increased or 
decreased numbers of chromosomes are often observed for ES cell lines of 
increased passage. This possibility was addressed by looking at metaphase 
spreads from the CGR8.8 subline, but the normal complement of 40 
chromosomes was present. Nonetheless, this analysis does not rule out smaller 
genome re-arrangements contributing to the failure of this line to transmit to 
the next generation.
Another possible explanation is that the heterozygous 
null mutation of NTR caused the death and readsorption of the developing 
embryos, therefore the apparent sterility and lack of germline transmission. 
This phenomenon, commonly known as haploid insufficiency, results when the 
heterozygous form of the mutant gene causes insufficient production of the 
gene product for normal development. This is an interesting possibility when 
speculating on the nature of the mutant receptor produced by the replacement 
construct. The construct mutates the NTR gene by introducing a neomycin 
cassette within the gene sequence coding for the fourth transmembrane 
domain. This mutation may result in the expression of a truncated receptor that
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still has affinity for neurotensin. Although the proposed binding site for 
neurotensin is within the 3rd extracellular loop, residues of the first 
extracellular loop and transmembrane III have been shown to be important for 
NT binding to its receptor, see Chapter 1 section 1.3.3. Such a mutant receptor 
could cause a dominant mutation of the neurotensin transmission system if its 
affinity was sufficient to bind NT but the truncated receptor was unable to 
transmit the signal. Thus creating a dominant mutation that had deficit in NT 
transmission. This may at first seem an unlikely explanation, since the strongly 
chimaeric male mice were (on limited observation) apparently normal. Unless 
the lack of neurotensin transmission is specifically crucial to the correct 
development of the germline. Thus creating the distinct possibility that the 
lack of germline transmission is probably due to the abnormal development of 
the germline itself, resulting in sterility of the highly chimaeric mice. This 
scenario becomes even more intriguing by the knowledge that NT mRNA is 
known to be expressed in the testes, ( Dobner et al., 1993).
9.3 Future perspectives
9.3.1 Targeted ES cell subline testing
The immediate future direction will be to generate more targeted CGR8.8 ES 
cell lines using the replacement construct (p9.2EiNeoTK), for the production of 
chimaeric mice and hopefully germline transmission. This is required because 
it is possible that the apparent observed sterility is due to a property of the 
particular targeted ES cell subline, (CGR8.A), and independent of the NTR 
mutation introduced by the replacement vector.
9.3.2 Chimaeric analysis of a null NTR mutation
If germline transmission proved to be a problem using multiple ES cell lines 
targeted with the NTR replacement vector, then one possible solution would be 
chimaeric analysis. Typically, ES clones in which both alleles of the gene have 
been mutated are used to generate highly chimaeric mice. This can be done by 
targeting the remaining wild type allele in the heterozygous ES cell line, 
(Mortensen et al., 1991). Alternatively, the heterozygous ES cell line can be 
selected at elevated drug, (G418), concentrations above the threshold of the
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resistance produced by one copy of the gene, (Mortensen et a l, 1992). 
Injection of the homozygous mutant cell lines would be into blastocysts 
derived from gene trap lines that ubiquitously express the lacZ  gene. This 
allows the tissues derived from the ES cell line or the embryo to be 
distinguished at the single cell level.
The chimaeric analysis offers one approach to the 
possible problem of not being able to generate viable mice with the null 
mutation of the neurotensin receptor. However a number of technological 
advances in the gene targeting field offer a range of other strategies to 
overcome this difficulty. Furthermore, it is now possible to generate null 
mutations in a more defined spatial and temporal manner. There have also 
been improvements for the strategies that create subtle mutations within a gene. 
These developments and their possible applications to the analysis of 
neurotensin receptor function will be considered in the following sections.
9.3.3 Conditional Cre-loxP mediated recombination
It may not be possible to generate adult mice with a null mutation of the NTR 
gene using the replacement strategy outlined in this study for reasons 
previously presented. Furthermore, a number of studies have highlighted the 
possible role of neurotensin in early development. Detailed analysis of 
neurotensin mRNA expression in the human and rat foetal colon, observed 
varying patterns of expression during gestation but not in the adult, (Evers et 
al., 1994). Other studies have also recorded developmental expression of the 
NTR gene in the postnatal rat, (Sato et al., 1992). Both of these studies suggest 
that neurotensin may have a trophic role during mammalian development. 
Therefore, to analyse the function of the NTR in the adult mouse CNS by gene 
targeting, other conditional mutational strategies may have to be employed. 
One such approach that can create conditional gene 'knock outs' is the C re-taP  
system. This technique can be used to precisely knockout the expression of a 
gene in one particular cell type as demonstrated by Gu et al., (1994). They 
successfully deleted the promoter and the first exon of the DNA polymerase (3 
gene only in T-cells of mice. This system is based on the Cre-ZoxP 
recombination system of bacteriophage PI. The Cre recombinase lines up 2 
loxP sites that are in direct repeat orientation, and performs site specific 
recombination, excising the intervening DNA and leaving behind a loxP site. 
Therefore, by controlling the expression of the Cre recombinase such that it is
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compartmentalised in a cell type specific and/or a developmentally specific 
manner a conditional mutation of a target gene can be achieved. This system 
requires the production of 2 transgenic strains of mice; one carrying the target 
gene flanked by loxP sites, the other with a Cre expressing transgene under 
specific temporal and spatial promoter control. Such a strategy is outlined in 
Figure 9.1.
The C re-toP  system is not the only scheme capable of 
creating a tissue specific mutation. The FLP enzyme from yeast has the 
potential to manipulate genes in a similar manner, by deleting DNA fragments 
flanked by frt sequences, (Fiering et al., 1993). This system was recently 
shown to efficiently mediate site specific recombination in transgenic mice, 
(Dymecki, 1996). From the point of view of the neurotensin receptor's 
possible trophic role in development, a complete null mutation may not be 
possible. Therefore, confining the mutation of the receptor to the adult CNS 
may alleviate this problem. Using the C re -teP  strategy, conditional mutation 
of the receptor may be achievable by confining the expression of Cre 
recombinase to the adult CNS using a neuron specific promoter that is 
expressed exclusively in differentiated adult neurons. A complete neuronal 
deletion of the receptor would be obtainable by a breeding program that 
combined the Cre expressing transgenic line with a transgenic line bearing a 
NTR gene flanked by loxP sites.
Although the approach is apparently straight forward, 
problems may be encountered in defining a suitably functional portion of the 
desired promoter for the construction of the cre transgene. However, a strategy 
that targeted the cre transgene to the endogenous NTR gene locus, such that the 
cre gene was now under the transcriptional control of the NTR promoter, 
would alleviate such a problem. However, this approach would knockout the 
NTR in all tissues and would not be suitable if haploid insufficiency prevents 
germline transmission. The chromosomal position of the integrated cre 
transgene may result in unpredictable patterns of expression, but individual cre 
expressing lines can be tested. Moreover, if the transgene is only expressed 
transiently during development, then the cre recombinase may not have 
sufficient time to excise all DNA fragments flanked by loxP sites. This may 
explain why only an estimated 40% of T-cells were homozygous for the 
desired deletion of the DNA polymerase-b gene in the Gu et al., 1994 study. 
However it must be noted they used the wild type version of the cre 
recombinase gene. A subsequent publication by Hennet et al., (1995), 
involved the use of a modified Cre recombinase gene with additional kozak
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translational consensus and nuclear localisation signals. They apparently 
achieved complete Cre-/ax;P mediated recombination in T-cells to create a 
deletion of a polypeptide N-acetylgalactosaminyl-transferase gene. More 
recently a report described the efficient expression and action of a cre 
transgene at the one-cell zygote stage of embryonic development, (Lasko et al., 
1996). This was achieved using a cre transgene under the control of the 
adenovirus Ella promoter. Therefore, the choice of promoter, for cre transgene 
expression, is crucial to the success of developing a strategy for the conditional 
mutation of the NTR gene.
Genomic
Locus
Targeting Vector
N e o
TK
32
Targeted Locus
Cre Recombinase
Expression
Cassette
Inter-crossing of the Two 
Transgenic Lines Results in 
Temporal and Spatial 
Cre-LoxP Mediated 
Recombination
Deleted Locus
Figure 9.1 Cell specific deletion of exon 2 using the Cre/loxP mediated 
recombination system. The target gene consists of 4 exons represented by the 
black boxes, thin lines introns. The replacement construct consists of: exons 2 
and 3; a neomycin cassette (Neo); a thymidine kinase cassette (TK); 2 loxP sites 
represented by open triangles, one of which is intronic the other 3' of Neo. The
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targeted locus integrates the loxP sites and Neo intronically, such that they do 
not interfere with gene expression. A second transgenic strain is generated, 
expressing the Cre recombinase transgene (Cre) under control of a cell specific 
promoter (P). A breeding program involving the 2 mouse strains and 
subsequent expression of the Cre recombinase results in the deletion of exon 2 
from the target locus only in those cell types expressing the Cre recombinase.
9.3.4 Temporal control of gene expression
A number of groups have been working towards defining systems that would 
allow the deactivation of genes in specific cell types. Bujard and Gossen, 
1992, modified the cis and trans control elements of the E.coli transposon Tn 
10 tetracycline resistance operon. The transcription of the operon genes is 
negatively regulated such that in the absence of the antibiotic, the tetracycline 
resistance repressor (tetR) binds to the operator sequences of the promoter. In 
the presence of the antibiotic the genes of the operon become transcriptionally 
active because the tetracycline binds to the tetR and presents binding to the 
operator sequences. However, this system was modified such that tetracycline 
turns genes off instead of on. This was achieved by combining the tetR gene 
with HSV c-terminal domain of the VP16 gene, thus creating a hybrid activator 
protein. This hybrid transactivator (tTA) can bind to and activate mammalian 
genes that have promoters fused to tetracycline operator (tetO) sequences but 
only in the absence of tetracycline. This system has been shown to work in 
mice using the reporter genes b-galactosidase and luciferase under the 
transcriptional control of the m inim al prom oter from the human 
cytomegalovirus fused to tetO sequences. In the Furth et a l., 1994, study 
several transgenic lines were generated with the reporter constructs described 
above and also expressing the hybrid transactivator (tTA). Expression of the 
reporter genes was achieved at several chromosomal loci using this system, 
demonstrating that the tTA could gain access to the bacterial promoter 
elements packaged into chromatin. Inhibition of the reporter constructs was 
achieved by applying tetracycline, which prevents the transactivator from 
binding to the tetO sequences. Basal gene activity was not observed when b- 
galactosidase activity was assayed. However, measurable levels of luciferase 
activity were occasionally observed in some tissues. They concluded that basal 
gene activity is apparently a function of the minimal promoter and the 
chromosomal location of the transgene. Removal of the tetracycline resulted in 
the induction of the reporter genes as expected. Therefore, this system offers
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the potential to turn genes on and off at will, by the presence or absence of 
tetracycline.
The tem poral control of gene expression using 
tetracycline, the hybrid transactivator and the tetO sequences could possibly be 
used to perturb the neurotensin transmission system in the mouse. One 
scenario would involve the neurotensin receptor transgene (cDNA) under 
control of the hybrid transactivator tTA. These transgenes would have to be 
introduced into a null NTR background, (refer to Figure 9.2).
Targeted NTR gene Neo
Hybrid transactivator gene 
(tTA)
The tTA gene product
Expression of NTR 
cDNA transgene
tetR | Vpl6
I
I
tetO
"NTR cDNA
Addition of tetracycline
No expression of NTR cDNA 
transgene
NTR cDNA
tetO
Figure 9.2 Temporal control of the NTR gene expression using the tetracycline 
system. This strategy requires the expression of the NTR cDNA transgene 
under transcriptional control of the hybrid transactivator (tTA). These 
transgenes are introduced into a null NTR background. The endogenous NTR 
gene has been targeted with a replacement construct that introduces a disrupting 
neomycin cassette into exon 2 of the gene. The hybrid transactivator gene 
consists of the tetracycline repressor gene (tetR) fused to the HSVc-terminal 
domain of the VP 16 gene (VP 16). The gene is controlled by the adenovirus 
Ella promoter (P). The product of the hybrid transactivator, (represented by the
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black circle joined to the black triangle), binds to the tetracycline operator 
sequences, (tetO), of the cDNA promoter and activates transcription. The above 
scenario is achieved in the absence of tetracycline, which prevents the hybrid 
transactivator protein from binding to the tetO sequences. The NTR gene is 
down regulated by the addition of tetracycline. Arrows above genes indicates 
transcriptional expression.
One difficulty would be in creating a minimal promoter with tetO control 
sequences that would permit the correct neuronal expression of the receptor. If 
possible administration of tetracycline would down regulate the expression of 
the receptor. However there would be a lag period before the receptor would 
be removed from neuronal membranes. Normal neurotensin transmission has 
shown that the receptor becomes internalised on binding of the ligand and 
hence is removed from the cell surface, (Charby et a l, 1993). However, it is 
not clear whether this is the case for all neurotensin receptors. Furthermore, 
basal activity from the minimal promoter may provide sufficient expression of 
the NTR transgene such that no observable disruption of the neurotensin 
system is achieved. Some of the problems associated with the minimal 
promoter and the site of integration of the transgene can be evaluated using the 
bi-directional promoter developed by Baron et al., 1995. This promoter co- 
regulates the expression of two transcriptional units from the centrally located 
tetO sequences flanked by two minimal promoters. As before this b i­
directional promoter is responsive to the hybrid transactivator tTA, which in 
turn is negatively regulated by tetracycline. Since two genes can be co­
regulated by this promoter, a reporter gene such as b-galactosidase could be 
included with the NTR gene on the other side. Therefore, a gene such as NTR 
could be monitored via the expression of a reporter gene and permit the 
evaluation of particular transgenes in mice. Furthermore, a sensitive reporter 
gene such as luciferase could be used to assay for basal gene expression from 
the minimal promoter in the presence of tetracycline. Nonetheless, tetracycline 
mediated inhibition of the NTR expression is possible in theory using this 
system.
The strategy outlined above for temporal control of the 
NTR gene is elaborate, technically demanding and involves a number of 
uncertainties. Another system offering temporal gene control is based upon the 
Drosophila melanogaster ecdysone hormone and its receptor. Ecdysone 
mediates its effects through the functional ecdysone receptor, which is a 
heterodimer of the ecdysone receptor (EcR) and the product of the ultraspiracle 
gene, (USP). Modification of this system has achieved inducible gene
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expression within the mouse, (No et al., 1996). In order to create an efficient 
inducible system for mammalian genes, No and co-workers made several 
modifications to the original system. They replaced EcR's natural partner with 
its mammalian homologue, namely the retinoid X receptor (RXR). A 34-fold 
increase in induction was achieved using this heterodimeric pair. However, a 
212-fold increase was achieved by creating a fusion protein of the EcR with the 
VP16 activation domain fused to the N-terminal truncated version of the EcR, 
creating VpEcR. In addition, the ecdysone responsive promoter was modified 
by inserting Spl consensus binding sites between the minimal promoter and 
the ecdysone response elements, (EcREs), to increase transriptional activity. 
Furthermore, the binding specificity of VpEcR was changed to preclude 
activation by endogenous frasenoids on synthetic promoters containing EcRE 
elements. This required the mutation of 3 aa residues of the VpEcR within the 
P box of the DNA binding domain, such that the altered receptor mimicked the 
DNA binding specificity of the glucocorticoid receptor. This hybrid receptor 
named VgEcR is responsive to a hybrid response element termed E/GRE. This 
element is a hybrid between the glucocorticoid response element (GRE) and 
that of the type two nuclear receptors such as RXR. When this system was 
tested in cell lines, maximum induction levels were observed of 20000-fold 
after 20 hours of exposure to the ecdysone agonist muristerone A. 
Comparisons were made between the ecdysone and tetracycline systems using 
transient transfections. The basal activity of the ecdysone responsive promoter 
was shown to be 20-fold lower than that of the tetracycline repressor promoter 
and 500-fold lower than the tetracycline transactivator promoter.
It would appear that the ecdysone system offers several 
advantages over the tetracycline system, such as higher inducible transcription 
rates and lower basal activity of the promoters. Besides, the lipophilic 
qualities of ecdysteroid compounds permits rapid penetration to all tissue types 
including the brain. Also, the short half life of such compounds will allow 
precise potent inductions and facilitate rapid clearance from tissues. Therefore, 
this system should be a more controllable than the tetracycline system. 
Furthermore, these compounds are not known to be toxic or affect mammalian 
physiology. This system presents a strategy for the efficient temporal 
induction of a gene in transgenic mice with responsive promoter elements that 
exhibit low basal activity. One of the more obvious uses for temporal gene 
induction would be ablation experiments using the diphtheria toxin A gene 
under control of the ecdysone responsive promoter (E/GRE). The ablation 
could be spatially regulated by restricting the expression of the synthetic
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receptor (Vp EcR) to specific cell types by placing it under the control of a 
tissue specific promoter.
With respect to analysing the NTR gene, there exists the 
possibility of using this system in conjunction with the Cre-/oxP strategy for 
creating temporally and spatially specific mutations. For example, the receptor 
could be induced to mutate only in the adult brain thus avoiding any problems 
associated with expression of a mutant receptor during development. This 
would require a number of transgenes to be developed and introduced into the 
mouse germ line as well as targeted modification of the endogenous NTR gene. 
Firstly the NTR gene would have to be targeted by homologous recombination 
in ES cells to generate a segment of the gene flanked by loxP sites. The 
induction of the cre recombinase transgene could be placed under the control 
of the modified ecdysone responsive promoter. Therefore, induction of Cre 
recombinase and hence mutation of the NTR gene would be dependent upon 
the administration of an ecdysone agonist. The advantage of this strategy to 
the original approach, outlined in previous section 9.3.2, is that the NTR 
mutation could be created at many different developmental stages using the 
same transgenic mouse line. The system could be further modified by 
restricting the expression of the ecdysone heterodimeric receptor to neuronal 
cells or a subset of neuronal cells by placing the retinoid X receptor transgene 
under specific neuronal promoter control. This would create a system for 
analysing NTR function in the CNS with respect to the developing brain and 
the adult neurotensin transmission pathways.
The ability to mutate a gene in such a temporal and 
spatial manner offers numerous possibilities for investigation. However this 
ability to interfere with neurotensin transmission in the CNS in a temporal and 
spatial manner is particularly exciting considering the body of evidence 
implicating the neurotensin transmission in the mesolimbic system with an 
involvement in the pathology of schizophrenia, (Chapter 1; section 1.4), since 
the disease is increasingly thought to have some developmental defect in its 
etiology. Therefore, to perturb the neurotensin system at a particular time point 
of development may be more informative of the effect such a NTR mutation on 
mouse development and behaviour.
9.3.5 Creation of subtle mutations within the neurotensin receptor
186
Chapter 9
Three approaches for introducing subtle mutations into any gene have been 
reported recently. They will be briefly described and the potential mutations 
that one might want to introduce into the NTR gene will be considered.
The first of these techniques is similar to the tag and 
exchange strategy, (Askew et a l , 1993; refer to Chapter 1: section 1.16), and 
involves two sequential replacement events. Stacey et al., 1994, refer to their 
approach as a double replacement strategy which they used to replace the 
mouse a-lactalbumin gene with its human homologue. However, the general 
principles of the technique are applicable to introducing specific subtle 
mutations into any mouse gene. A replacement vector of the target gene is 
constructed using the Hprt selectable marker inserted within exonic sequence. 
The gene targeting and selection was performed using a hprt-deficient ES cell 
line. This cell line exploits the ability to select for and against the hprt marker 
gene. Therefore, unlike the tag and exchange method only one selectable 
marker is introduced into the target locus after the first replacement event, 
although the replacement can carry the thymidine kinase cassette as a negative 
selectable marker for enrichment of homologous integrants. This cell line can 
then be re-targeted with a second replacement vector bearing the desired gene 
mutation. This vector does not contain a positive disrupting selectable marker, 
since positive selection is achieved by selection for the loss of the hprt gene at 
the target locus.
Superficially, this double replacement method appears to 
be the same as the tag and exchange method but, it offers a number of 
advantages. Firstly, the thymidine kinase cassette is not integrated into the 
target locus as a selectable marker for the second replacement step or exchange 
step. Instead, thymidine kinase is used as a negative selection marker in the 
traditional manner for a replacement vector designed for the positive negative 
selection regime. With the tag and exchange approach the thymidine kinase 
gene becomes integrated into the 'tagged' locus but this is not the case for the 
double replacement strategy. Therefore, the added advantage of using the ES 
cell line from the first replacement event to generate a null mutation for the 
gene of interest exists. This also allows for testing the totipotency of targeted 
ES cell lines prior to further manipulations of the second replacement step. 
Thymidine kinase gene expression in male gonads causes sterility, thus 
precluding the use or testing of the ES cell lines generated in the first step of 
the tag and exchange method. However, both techniques permit the design of 
numerous replacement type constructs to introduce various mutations into the 
target locus in the second step of their procedures.
187
Chapter 9
The next approach to introducing desired specific 
mutations into a given gene combines components of the 'tag and exchange' 
and the 'hit and run' strategies. A replacement type construct is generated 
carrying neomycin and thymidine kinase cassettes internal to a duplicated 
portion of the target gene. The subtle mutation is carried on one arm of gene 
homology but does not form part of the duplicated gene sequence, see Figure
9.3. Therefore, the first step involves the targeting of the desired gene with the 
replacement type vector. This creates a duplication at the target locus which is 
resolved in the second step by applying negative selection against the 
integrated thymidine kinase cassette. The resolution is by intrachromosomal 
recombination between the duplicated portion of the gene.
Genomic
Locus
Replacement Type Vector
Targeted Locus
Intrachromosomal
Recombination
Site Specific 
Mutation of 
Target Locus
-| Neo | TK |-
Figure 9.3 A two step replacement/excision technique for introducing subtle 
mutations into any gene locus. The 4 exons of thegene are represented with 
black boxes; the thin lines are the intronic sequences. The replacement type 
vector consists of exons 2 and 3 with exon 3 and its flanking intronic sequences 
being duplicated; the fused selection cassette, (Neo and TK), inserted between
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the duplicated gene homology which is clearly highlighted by the underlining 
arrows. The asterisk denotes thesite specific mutation with in exon 2. The first 
step of the procedure involves targeting the locus with the replacement type 
vector. The targeted locus undergoes negative selection against the presence of 
the thymidine kinase cassette in order to select for excision of the duplicated 
sequence by intrachromosomal recombination. Such a reaction should result in 
the locus retaining the site-specific mutation.
This replacement/excision technique was developed by Horie et al., 1995, 
using the F9 mouse cell line. The major advantage of this method over the hit 
and run procedure is that the subtle mutation is more likely to be retained at the 
chromosomal locus after the excision event, as the mutation is not part of the 
duplicated gene homology. Horie and co-workers observed excision 
frequencies as high as 84% for a targeted locus. However, another targeted 
clone only produced GancR colonies with a 7% frequency of producing the 
desired excision. This was not due to loss of the desired mutation but a result 
of inactivation of the thymidine kinase due to methylation of the EcoKl site 
within the promoter of the thymidine kinase cassette (Tasseron-de Jong et al., 
1989). Nonetheless, this strategy introduces a new technique for generating 
subtle mutations at any loci within the mouse genome.
The first technique of a double replacement strategy 
would appear to be the most attractive of the two techniques primarily because 
the thymidine kinase cassette is used in the replacement construct for the 
enrichment of targeted clones in the first step. Furthermore, the targeted cell 
line can be used to generate a null mutation for the target gene in mice, which 
would also test the totipotency of the cell line prior to further manipulations. 
However it must also be noted that the Cre-/oxP offers great potential for the 
creation of subtle mutations within the NTR gene. Such a strategy involves a 
gene targeting event using a replacement vector that places the positively 
selectable marker within the intronic sequence of the gene flanked by loxP 
sites. The site specific mutation is contained within an arm of homology of the 
vector. Application of cre recombinase can be in vitro, at the ES cell stage, or 
in vivo; mating of the homozygous mutant mouse line carrying the ZaxP-Neo- 
loxP cassette with a transgenic line expressing Cre early in development will 
result in the deletion of the Neo cassette from the gene locus, leaving behind an 
intronic loxP site and the site specific mutation, (refer to Figure 9.4). Recently 
the feasibility of such a strategy was demonstrated by Lasko et al., 1996. They 
created a Cre expressing transgenic line in which the adenovirus Ella promoter 
directs expression of the cre transgene. This transgene has the ability to delete
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DNA, flanked by loxP sites, at the zygote stage of mouse development. 
Therefore, if the Cre recombinase correctly excises the intervening DNA at this 
stage of development, then all tissue types will acquire the desired mutation. 
This approach has the added advantage of not requiring extended tissue culture 
of the targeted ES cells, in order to expose them to Cre recombinase, prior to 
blastocyst injection and also saves on the labour of screening for the desired 
mutation.
Genomic
Locus
Targeting Vector
Neo
TK |
Targeted Locus Neo *
Cre Recombinase 
Expression Cassette
P | Cre
Breeding of the Two Transgenic Lines 
Results in Temporal and Spatial Cre-LoxP 
Mediated Recombination
Deleted Locus
Figure 9.4 Site-specific mutation of a gene using the Cre-/oxP mediated 
recombination system. The target gene consists of 4 exons represented by the 
black boxes, thin lines introns. The replacement construct consists of: exons 2 
and 3; a neomycin cassette (Neo); a thymidine kinase cassette (TK); 2 loxP sites 
represented by open triangles, both of which are intronic 3' and 5' of Neo. The 
targeted locus integrates the loxP sites and Neo intronically, such that they do 
not interfere with gene expression. A second transgenic strain is generated, 
expressing the Cre recombinase transgene (Cre) under control of a cell specific 
promoter (P). A breeding program involving the 2 mouse strains and
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subsequent expression of the Cre recombinase results in the deletion of exon 2 
from the target locus only in those cell types expressing the Cre recombinase.
Therefore, alternative procedures exist for the generation of subtle mutations 
within the neurotensin receptor. One particularly interesting function of the 
NTRs has been the observation that on binding their ligand, the receptor 
neurotensin complex becomes internalised and subsequently undergoes 
retrograde axonal transport. Upon reaching the cell bodies an increased 
expression of the tyrosine hydroxylase enzyme was observed. However, the 
functional significance of such a process is not known. This has been 
demonstrated within the rat brain for the NTRs associated with the 
dopaminergic neurons of the nigrostriatal pathway, (Castel et al.. 1994). The 
NTRs have been shown to be primarily located on the pre-synaptic membranes 
of these neurons and the cell bodies within the substantia nigra pars compacta. 
The high density of NTRs associated with the nigrostriatal pathway makes this 
a desirable system, not only for the functional analysis of this receptor but, the 
general functional study of the phenomenon of neuropeptide axonal transport 
in the CNS.
The creation of informative mutations, with respect to the 
analysis of retrograde axonal transport, has been aided by mutational studies of 
the receptor in cell culture systems. Charby et al., 1995, performed site 
directed mutagenesis of the cDNA encoding the NTR. The various constructs 
were transiently transfected into mammalian COS7 cells and assayed for their 
ability to internalise iodinated neurotensin. To summarise, they identified two 
aa residues (Thr-422 and Tyr-424) which when point mutated to Gly virtually 
abolished the receptor's ability to internalise the labelled neurotensin.
Therefore it would be desirable to generate a transgenic 
mouse expressing a mutant NTR gene with altered Thr-422 and Tyr-424 aa 
residues in a similar manner to Chanbry and his colleagues. This could be 
achieved by employing one of the gene targeting techniques previously 
presented. However, it may be more informative to create such a mutation in 
the adult CNS so as not to complicate the analysis. In theory, the available 
technology exists to create such a mutation in the mouse. One possibility 
would be to 'switch off the endogenous NTR gene using the Cre-/axP system 
or by using the tetracycline system, in conjunction with 'switching on' a mutant 
cDNA NTR transgene which is responsive to ecdysone agonist, or 
constitutively expressing the mutant cDNA transgene. The following scenario 
represents a strategy for manipulation of the expression of the NTR gene and
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also serves the purpose of elucidating the possibilities that now exist with the 
present transgenic mouse technologies.
Disruption of the NTR gene could be regulated in a 
spatial and temporal manner. The endogenous NTR gene could be engineered 
such that loxP sequences flank the first exon. Mutation of the NTR gene in the 
mouse would require the expression of the Cre recombinase gene. Typically 
the spatial and temporal control of the mutation is derived from the cell 
specific promoter driving the Cre recombinase expression. However, the Cre 
transgene could be placed under the transcriptional control of the ecdysone 
responsive promoter (E/GRE). Therefore, use of an ecdysone agonist will 
induce the expression of Cre recombinase and delete the first exon of the 
endogenous NTR gene. Similarly, a transgene expressing the mutant NTR 
cDNA, for aa residues Thr-422 and Tyr-424, could be under the inducible 
expression of the E/GRE promoter. A further two transgenes would have to be 
introduced into the mouse germline, namely the components of the synthetic 
heterodimeric ecdysone receptor i.e. the VpEcR gene and the RXR gene. To 
introduce spatial control to this system one or both of the transgenes for the 
ecdysone receptor could be placed under control of a dopaminergic expressing 
promoter such as that from the tyrosine hydroxylase gene or the dopamine 
transporter gene. To recap, presuming sufficient inducible expression and low 
basal activity of the Cre recombinase transgene and the mutant NTR cDNA 
transgene, in conjunction with sufficient tissue specific expression of the 
ecdysone receptors, it should be possible to create an ecdysone spatially and 
temporally regulated system for the analysis of a mutant NTR with respect to 
its ability to internalise within the mouse CNS. An added advantage of the 
system outlined, is that administration of an ecdysone agonist at any particular 
time point of development should activate the desired mutant receptor gene and 
simultaneously 'knock out' the endogenous NTR gene in the CNS, (Figure 9.5).
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Endogenous NTR gene 
Cre transgene
-PZ1-E M  1
E/GRE Cre recombinase
NTR cDNA transgene E/GRE NTR cDNA
Transgenes expressing the 
heterodimeric ecdysone 
receptor
Endogenous NTR gene
TH
Addition of ecdysone agonist
1
-0 = 1- ^
Cre transgene E/GRE Cre recombinase
NTR cDNA Transgene E/GRE NTR cDNA
Transgenes expressing the 
heterodimeric ecdysone 
receptor
TH VpEcR — TH" RXR
Figure 9.5 Temporal and spatial mutation of the NTR gene and expression of a 
NTR cDNA with a site specific mutation of the aa residues implicated in 
retrograde axonal transport of NT in the CNS. This strategy involves the 
expression of several transgenes within a mouse line which is homozygous for 
the engineered NTR gene. The transgene is placed under the transcriptional 
control of the ecdysone responsive promoter, (E/GRE), as is the NTR cDNA 
bearing the site specific mutation of aa residues 422 and 424, represented by the 
asterisk. Two other transgenes would be introduced into the mouse germline for 
the expression of the heterodimeric ecdysone receptor; the retinoid X receptor 
gene, (RXR) ; the synthetic component of the ecdysone receptor, (VpEcR). 
These receptor genes are under the transcriptional control of the tyrosine 
hydroxylase promoter, (TH). Addition of an ecdysone agonist activates the
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expression of Cre recombinase, which in turn promotes the site specific 
recombination of the loxP sites and deletes exon 1 of the NTR gene, the 
expression of the NTR cDNA transgene is also switched on. Transcriptional 
expression is represented by arrowed lines above the genes.
Another interesting mutation of the NTR, would be a 
deletion within the 3rd intracellular loop of the receptor, (Yamada et al., 1994). 
Deletion of aa residues 270-296, apparently abolished the receptors ability to 
stimulate polyphosphoinositide hydrolysis but, did not reduce its ability to 
stimulate cAMP formation when assayed in CHO-K1 cell line. This mutation 
did not affect the binding affinity of neurotensin to the mutant receptor 
compared to the wild-type receptor. The present mouse technology would 
allow the expression and analysis of this receptor in vivo and the functional 
significance of this secondary messenger pathway to neurotensin transmission 
to be evaluated.
9.3.6 Summary of perspectives
The previous sections of this discussion highlighted methods that could be used 
for the creation of precise specific and temporal mutation of the NTR to 
manipulate NT transmission within the adult CNS for a number of reasons. 
For example, the NTR gene knock out may not be capable of germline 
transmission due to sterility caused by haploid insufficiency. Therefore, 
homozygous mutant mice may not be produced using any simple knockout 
approach detailed in this thesis. Secondly, my own observations have recorded 
the expression of the neurotensin receptor within the embryonic CNS. Early 
transient postnatal expression of the receptor has also been detailed within the 
developing rat brain long before a neuronal network is established, Sato, et a l, 
1992. Taken together, these data suggest that the neurotensin system plays an 
important trophic role in the CNS distinct from its neurotransmitter like role in 
the adult. However, analogy with the DA system emphasises the point that 
expression of mRNA does not imply function. DA production and DA 
receptor expression have been observed in the developing mouse embryo, (day 
10 and day 15). Therefore, it was surprising that targeted mutation of the 
tyrosine hydroxylase gene produced phenotypically DA"/DA" mice which 
developed a normal dopaminergic neuronal network. Although these mice 
were hypoactive and stopped feeding shortly after birth, this phenotype could
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be rescued by administration of the drug L-DOPA, such that nearly normal 
growth was achieved. Nevertheless, if the null mutation of NTR does not 
cause sterility, lethality or severe developmental abnormalities it is still 
desirable to analyse the NT transmission of the adult CNS independently of a 
complex mutant background caused by abnormal developmental trophic effects 
or abnormal intestinal function(s).
The effects of a NTR null mutation within the adult CNS 
may be many fold. NT has been observed to elicit antinociceptive qualities on 
central administration into the PAG brain structure. Therefore, the lack of NT 
transmission may perhaps cause an increase in sensitivity to painful stimuli or 
fail to down regulate pain perception under the appropriate physiological 
conditions such as fear. NT application to the cholinergic neurons to the basal 
forebrain (NBM) is excitatory and causes cortical arousal. The NTR'/NTR" 
mouse may have an impairment in this process that may manifest itself as an 
attention deficit. Furthermore, this brain structure has been implicated in the 
processing of learning and memory. A number of behavioural tests could be 
employed to address the question of learning and memory impairment in 
mutant mice. Other effects such as hypothermia enhanced ethanol and 
barbiturate sedation have been observed on central injection of NT. 
Presumably the administration of NT to mice which are neuronally NTR" 
/NTR" will no longer elicit such effects. This is a somewhat contentious 
conclusion as it implies that there is only one type of NTR. Some 
pharmacological and electrophysiological data exists suggesting that the 
hypothermia and antinociceptive effects are mediated by a low affinity NTR 
subtype. NTR binding study analysis of NTR"/NTR" mice will answer the 
question of multiple NTR subtypes, since labelled NT should not elicit a 
binding profile within the neurotensinergic systems if only one receptor 
subtype exists.
There is also doubt concerning the mechanism by which 
NT interacts with the DA in the nigrostriatal pathway. Most data points to an 
antagonistic function of the activated NTR on D2 receptor transduction, such 
that an increased Di receptor-mediated DA transmission is favoured. 
However, one hypothesis proposes that the mode of action is of NT forming a 
complex with DA, and in this way preventing DA from binding to D2 
receptors, (Adachi et al., 1990). If so, the NTR7NTR" mice on application of 
NT should still elicit this NTR independent action and presumably an increase 
in GABAergic activity in the striatum will be observed.
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The effective lack of NT transmission on the nigrostriatal 
pathway may have implications for the regulation and coordination of 
movement. If indeed the main neuromodulatory action of NT is to antagonise 
the action of D2 receptor transduction, increase presynaptic DA release, 
mediate Di receptor DA transmission then lack of a NT transmission system 
could conceivably down regulate Di receptor mediated transmission, (Xu et al., 
1995). In light of this, the null mutation of the Di receptor may hold some 
clues to the lack of NT transmission. The Di receptor 'knock out' mice display 
hyperactive locomotor activity and decreased levels of dynorphin in the 
striatum. This is not to say that the lack of the NTR would display any 
obviously similar behavioural phenotype, but perhaps will significantly down 
regulate levels of dynorphin due to down regulated DA transmission to elicit 
milder but observable behavioural phenotype. In fact, the modulatory effects 
from the lack of NT transmission on dopaminergic systems, and other neuronal 
systems, may cause subtle local changes such as alteration in levels of gene 
expression, levels of other neuropeptides or alter the reactive state of DA 
receptors. Therefore, a multidisciplinary analysis of NTR"/NTR“ mice using 
molecular, biochemical, electrophysiological and pharmacological will be 
necessary to accurately reveal the phenotypic effects of a null NTR mutation.
Lastly, and of particular interest, is the potential role NT 
transmission plays in the antipsychotic action of neuroleptic drugs. The action 
of the atypical neuroleptics appears to be mediated through the mesolimbic 
system, causing an increase in NT content primarily within the N.Acc. The 
lack of NT transmission system within the dopaminergic neurons will probably 
lead to a down regulation of Di receptor mediated transmission. The effects on 
the postsynaptic neurons may result in reduced transmission of the GABA 
neurons. However, as stated before fine analysis of the dopaminergic circuitry 
and those pathways that it innervates will be necessary to realise the 
phenotypic effects. The treatment of NTR"/NTR_ mice with neuroleptic drugs 
will probably result in increased levels of NT expression in the N.Acc. 
However, without an animal model to assay the behavioural effects of 
neuroleptics it will not be possible to comment on the possible function NT 
transmission has on mediating their effects. Latent inhibition of a conditioned 
emotional response has been proposed as a quantitative measure of selective 
attention. This involves brain functions related to schizophrenia and targets of 
therapeutic drugs. Latent inhibition is poteniated on the administration of 
neuroleptics. However, co-administration of neuroleptics with the NT 
antagonist SR48692 abolished the observed increase in latent inhibition in a
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dose dependent manner. These results suggest that the NT system is required 
to elicit the latent inhibition response. Therefore, it will be interesting to 
determine if the same inhibitory response of latent inhibition is observed for 
NTR"/NTR" mice on neuroleptic treatment. If latent inhibition is not 
poteniated on the administration of neuroleptics to NTR"/NTR' mice then this 
will provide further evidence for the involvement of NT transmission in the 
neuroleptic response.
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